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ABSTRACT 
 
Fluorine-18 (
18
F) is the most frequently used radionuclide in positron emission 
tomography (PET). This is, in part, due to the fact that fluorine is the element that is 
prevalent in organic molecules as well as easy to introduce directly into a molecule of 
interest. In addition, the labelling of biomolecules; such as, oligonucleotide, peptides, 
and proteins with radioisotopes for use in PET imaging is an increasingly important 
research aspect due to the use of these biomolecules in medical diagnostic or therapeutic 
applications. Unfortunately, the direct fluorination of peptides and proteins is difficult 
since harsh reaction conditions (high temperatures, acidic or basic conditions) that are 
required to get high radiochemical yields may destroy those biomolecules. To solve this 
problem, peptides and proteins are generally radiolabelled through a suitable prosthetic 
group under mild conditions. 
This dissertation focuses on the synthesis and properties of novel organoboranes 
designed for 
18
F fluoride anion capture for PET application. With the goal of developing 
new boron-based radiotracer, a series of ortho-phenylene phosphino-boranes and 
carbene-borane adducts were synthesized and studied. This general strategy of attaching 
cationic moiety close to trifluoroborates leads to a B-F bond stabilization in aqueous 
environment. Gratifyingly, these compounds can be radiolabeled via direct 
18
F-
19
F 
isotopic exchange reactions. With these results in hands, the radiolabeled 
organoborane/biomolecule conjugates have been synthesized and evaluated in vivo to 
use as potential PET probes. In addition to trifluoroborate species, we have also prepared 
 iii 
 
a new class of fluorescent dyes called triazaborolopyridiniums and investigated their 
capability as PET/fluorescence dual modality probes.            
In a more fundamental aspect of the some of the ideas presented above, we have 
also decided to explore the synthesis and properties of ambiphilic molecules featuring 
adjacent phosphine and methylium groups. The structures and isomerization processes of 
these compounds are also described in this dissertation. 
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1 
CHAPTER I 
INTRODUCTION TO BORON-BASED RADIOTRACERS FOR POSITRON 
EMISSION TOMOGRAPHY 
1.1 Introduction 
Positron emission tomography (PET) has become a popular imaging technique 
that provides in vivo information on the distribution of radiolabeled biomolecules. This 
technique, which relies on the coincident detection of two 180° high-energy photons that 
are released simultaneously upon positron-electron annihilation, requires the 
incorporation of a positron-emitting atom into the biomolecule under study.
1,2
 Fluorine-
18 has become one of the most popular radionuclides used in PET because of the 
characteristics of its nuclear decay and its relative ease of preparation by irradiation of 
[
18
O]-water.
3
 However, with a half-life of 110 minutes, the incorporation of [
18
F]-
fluorine into biomolecules needs to be carried out in a swift and efficient manner to 
minimize any loss of activity. As an added complication, the irradiation of [
18
O]-water
produces aqueous solutions of [
18
F]-fluoride ions whose reactivity is dampened by
hydration. Because of these obstacles, further growth in the field of 
18
F PET imaging
hinges on the development of fast and reliable radiofluorination protocols that can be 
implemented in aqueous solutions. 
An approach that is gaining increasing visibility is based on the use of 
trifluoroborate derivatives, highly fluorophilic boron compounds that are referred to as 
fluoride captors. The hydrolysis of aryltrifluoroborates has been previously 
 2 
 
investigated.
4
 Although the mechanism of fluoride dissociation involves multiple steps 
(Figure 1), it has been demonstrated that dissociation of the first fluoride anion is a rate-
determining step. In turn, the kinetics of such reactions can be properly treated by a 
simple first-order rate law (rate = kobs[ArBF3]). 
 
 
Figure 1. Kinetic scheme for ArBF3 hydrolysis. 
 
In this chapter, I will provide the relevant background information regarding 
boron-based radiotracers. Three different topics will be presented, including 1) boron-
based radiotracers featuring electron-withdrawing groups, 2) boron-based dyes for 
PET/fluorescence dual modality imaging, and 3) the influence of the cationic moiety on 
the Lewis acid of the boron atom and its application in the construction of boron-based 
radiotracers.   
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1.2 Boron-based radiotracers featuring electron-withdrawing groups 
The effects of substituents on the stability of aryltrifluoroborate in aqueous 
solution were first studied by Perrin and coworkers.
4
 In their work, they found that 
electron-donating substituents, e.g., methoxy groups, accelerate the rate of 
aryltrifluoroborate hydrolysis, whereas electron-withdrawing substituents, e.g., fluoro 
groups, slow it down. With this concept in hand, the Perrin group used 2,4,6-trifluoro-3-
carboxy phenyl boronic ester (1) and 2,6-difluoro-4-carboxy phenyl boronic ester (2) as 
prosthetic groups to capture [
18
F]-fluoride anions in aqueous solution. Compound 1 was 
conjugated with fluorescent boron-dipyrromethene (BODIPY) dye
5
, which would allow 
for the visualization of sub-nanomole quantities of radiolabeled aryltrifluoroborate on a 
TLC plate, whereas compound 2 was connected to amino-linked biotin
6
 to for potential 
streptavidine labeling (Figure 2). Both conjugated compounds (3 and 4) can be 
transformed into aryltrifluoroborate derivatives (5 and 6) by treatment with KHF2 in 
acidic conditions. The radioactive species 5 and 6 can be prepared by the reaction of 
[
18
F]-fluoride anion with arylboronate ester derivatives 3 and 4 using [
19
F]-KHF2 as a 
carrier. The kinetic stability of [
18
F]-5 and [
18
F]-6 was investigated by their relative 
autoradiographic density on the TLC plate. The rate constants (kobs) for the 
defluorination of [
18
F]-5 and [
18
F]-6 calculated from the first-order rate equation are 1.2 
± 0.4 x 10
-4
 min
-1
 and 2.8 ± 0.9 x 10
-4
 min
-1
, respectively (kobs of K[PhBF3] = 0.0245 
min
-1
). These results indicate that the electron-withdrawing nature of the fluorine atoms 
on the benzene ring in 5 and 6 may help stabilize the trifluoroborate moiety in aqueous 
solution.  
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Figure 2. Scheme showing the synthesis of 5 and 6. 
 
 To prove that fluoro-substituted phenyl boronic ester can be used as a prosthetic 
group for PET imaging and that its corresponding aryltrifluoroborate is stable in vivo, 
Perrin and coworkers prepared a new biotinylated arylboronic ester (7) via an amide 
coupling reaction between 1 and biotinylated piperazine to test its in vivo stability.
7
 The 
[
18
F]-biotinylated aryltrifluoroborate 8 can be prepared by the reaction of 7 with [
18
F]-
KHF2 in aqueous solution at pH 4.5 (Figure 3). After silica column purification, [
18
F]-8 
was injected into the tail vein of a 16-week-old female mouse. PET images showed that 
the [
18
F]-8 accumulated in the bladder, liver, and salivary glands. Surprisingly, no radio-
signal accumulation in bones was observed. This result is noteworthy because it is the 
 5 
 
first demonstration that a [
18
F]-labeled trifluoroborate is stable in vivo. To further 
validate the use of phenyl boronate ester for 
18
F fluoride anion capture, 1 was conjugated 
to marimastat, a noncovalent matrix metalloproteinase (MMP) inhibitor (Figure 3).
8,9
 
Matrix metalloproteinases are zinc-dependent endopeptidases that are strongly 
associated with pathogenic markers of cancer. The marimastat-arylboronic ester 
conjugate (9) was used as a captor for aqueous 
18
F fluoride anion in a rapid one-step 
reaction at ambient temperature.
9
 In an in vivo imaging study, [
18
F]-marimastat 
aryltrifluoroborate (10) demonstrated detectable and specific uptake in the primary 
tumor of tumor-bearing mice at 60 min post injection.
8
 Moreover, in a control 
experiment, no tumor localization was observed after the injection of the [
18
F]-1 into 
tumor-bearing nude mice. These results illustrate that [
18
F]-10 is a good candidate for 
clinical applications.   
 
 
Figure 3. Scheme showing the fluorination reaction of 7 and 9. 
 
 The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC or “click”) reaction 
is an appealing approach for prosthetic group conjugation in PET radiopharmaceutical 
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research. Although the click chemistry of aryltrifluoroborate was first studied by Molado 
and co-worker
10
, Perrin and his colleague developed this reaction for radiochemical 
research. In Perrin’s work, a B(dan)-protected radiosynthon connected with an alkyne 
functional group (11) was used as a precursor to generate [
18
F]-aryltrifluoroborate 12 by 
treatment with [
18
F]-KF at acidic pH (pH 2) (Figure 4).
11
 To obtain an accurate specific 
activity (SA), [
18
F]-12 was clicked to rhodamine-N3 in the presence of copper(II) sulfate 
and sodium ascorbate. This method produced the [
18
F]-rhodamine conjugated 
aryltrifluoroborate (13) with high specific activity (15 Ciμmol-1).  They also confirmed 
that the specific activity of the conjugated radiotracer can be reliably calculated by 
tripling the specific activity of the [
18
F]-fluoride anion.
11
 This one-pot two-step labeling 
protocol is mild, fast (30 min), and efficient (high specific activity), and it can be applied 
to the radiosynthesis of biomolecules.
11-13
   
 
 
Figure 4. Scheme showing the radiosynthesis of [
18
F]-13. 
 
   To broaden the collection of potential aryltrifluoroborate prosthetics, Perrin and 
coworkers reported a new route to the synthesis of a new heteroaryl-BF3
-
 featuring 
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bromine substituents (14).
14
 The B-F bonds in this compound are stabilized by the 
inductive electron withdrawing effects derived from the bromo substituents, the amide 
functional group, and the pyridyl nitrogen atom. Compound 14 was conjugated to azide 
containing RGD peptide via a copper catalyzed cycloaddition reaction (Figure 5). Prior 
to testing the stability of the RGD conjugated heteroaryltrifluoroborate (15), the authors 
decided to examine the solvolytic stability of the parent 2-amino-3,5-dibromopyridyl-4-
trifluoroborate (hArBF3) by nuclear magnetic resonance (NMR) of fluorine nuclei. The 
19
F NMR spectroscopy revealed that the rate of hArBF3 hydrolysis is extremely slow. 
The solvolysis decomposition data were fitted to a first-order rate equation, with a rate 
constant of 4.2 x 10
-5
 min
-1
 and a half-life of 16500 min. This half-life is 10-fold longer 
than that of the previous trifluoro-substituted aryltrifluoroborate. Then, compound 15 
was radiofluorinated by an 
18
F-
19
F isotopic exchange reaction with mild heating (45 °C) 
under acidic conditions (pH = 2). [
18
F]-15 was obtained with good radiochemical yield 
(20 % decay corrected) and high specific activity (3 Ci μmol-1). This [18F]-radiotracer 
also showed good stability in vitro in mouse plasma incubated at 37 °C with <1% 
degradation observed after 150 min. The stability was also confirmed by in vivo imaging 
showing that minimal bone uptake was observed (~0.5%) after 60 min.            
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Figure 5. Scheme showing biomolecule conjugation of 14 via click chemistry. 
 
1.3 Boron-based dyes for PET/fluorescence dual modality imaging  
[
18
F]-positron emission tomography is a powerful imaging technique used to 
monitor metabolic pathways in vivo. However, because of the relatively low spatial 
resolution (1–2 mm) provided by this technique, combining PET imaging with a second 
imaging technique such as fluorescence gives much higher spatial and temporal 
resolution. This approach necessitates the incorporation of a fluorophore into a 
radiolabeled component. In 2010, Tsien and coworkers combined a novel 
organoboronate ester for [
18
F]-fluoride anion trapping with a near-infrared fluorophore, a 
cyanine derivative, into a single molecule (16) (Figure 6).
15
 This molecule was tagged 
with Lymphoseek, a mannosylated 16 kDa dextran conjugate that was developed for 
sentinel lymph node mapping through an amide coupling reaction at the N-
hydroxysuccinimide (NHS) ester functional group. The sentinel lymph node is the target 
organ primarily reached by cancer cells from a tumor. Therefore, detection of the 
sentinel lymph node prior to cancerous dissemination is highly significant for medical 
diagnosis. A Lymphoseek-conjugated radioactive species was successfully prepared by 
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treatment with [
18
F]-KHF2 in 0.25 M HCl/25% MeOH/75% H2O solution at 40 °C. 
Gratifyingly, it can target mouse sentinel lymph nodes (SLNs) within 1 h, which is 
superior to the current SLN mapping agents.   
  
 
Figure 6. Illustration of PET/fluorescence dual modality imaging agent 16. 
 
In 2008, Gabbai and coworkers were the first group to investigate the late stage 
B-F bond formation of the BODIPY dye. The BODIPY boronium cation 17 was 
prepared from a reaction of the corresponding difluoro BODIPY dye with 
trimethylsilyltriflate (TMSOTf) followed by the addition of 4-dimethylaminopyridine 
(DMAP).
16
 This compound, which can react with tetrabutylammonium fluoride (TBAF) 
to afford the difluoro dye BODIPY, was developed for use as a fluoride anion sensor. To 
quench the fluorescent signal of 17, 10 equivalents of tetrabutylammonium iodide 
(TBAI) were added to a solution of 17 in chloroform. The addition of 1 equivalent of 
TBAF to the solution mixture of 17 and 10 equiv. of TBAI increased the fluorescence 
intensity by a factor f = 500%. This turn-on response, which could be detected with the 
 10 
 
naked eye, suggested that this approach can be used for fluoride anion sensing 
applications. Two years later, our group reported a method for synthesizing a new B-OH 
containing BODIPY dye, 18.
17
 This hydroxide derivative (18) was prepared from the 
corresponding BODIPY-phenylboron chloride by simply passing a solution of the 
chloride derivative through silica gel. Although the B-Cl BODIPY precursor is sensitive 
to moisture, the B-OH BODIPY derivative (18) is air and water stable. Gratifyingly, 
compound 18 can be easily transformed to the BODIPY-phenylboron fluoride species by 
the reaction of 18 with potassium hydrogen bifluoride (KHF2) in THF. These results are 
significant because they suggest that both 17 and 18 can be used as precursors for the 
preparation of 
18
F-labeled BODIPY dyes. 
         
 
Figure 7. Illustration of activated BODIPY 17 and 18. 
 
With these preliminary results in hand, our group decided to develop a new 
18
F 
incorporation reaction that would proceed in aqueous conditions from the stable 
BODIPY precursor.
18,19
 To reach this goal, we synthesized a new ammonium BODIPY-
phenylboron hydroxide (19) and attempted its fluorination. Delightfully, conversion into 
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the fluoro derivative (20) can be achieved by the addition of KHF2 to an acidic mixed 
MeOH/water (1/1 vol.) solution of 19 (Figure 8). This approach was applied to the 
18
F 
radiofluorination of 19, affording [
18
F]-20 in 22 ± 3 % radiochemical yield (decay 
corrected) with a specific activity of 25 ± 4 mCi/μmol. In vitro stability studies of [18F]-
20 in phosphate buffer solution pH 7.5 showed only 5% decomposition after 6 h, 
suggesting that this compound has high stability in aqueous solution. To further confirm 
its potential for in vivo PET imaging, [
18
F]-20 was injected into normal nude mice. 
Splendidly, the PET images showed no bone uptake signals even at 4 h post injection. 
(Figure 8)      
 
 
Figure 8. Scheme showing the radiosynthesis of 19 and in vivo images of [
18
F]-20. 
  
 Subsequently, Mazitschek and coworkers investigated the 
18
F-incorporation 
reaction of our reported DMAP-activated BODIPY dye (17).
19
 They found that efficient 
conversion into [
18
F]-1,3,5,7,8-pentamethyl BODIPY difluoroborate ([
18
F]-21) can only 
be done at high temperature (100 °C) in DMF (Figure 9, Scheme A). This fluorination 
 12 
 
condition and the prolonged heating required to synthesize the DMAP intermediate tend 
to be incompatible with certain sensitive functional groups typically present in complex 
biologically active small molecules such as N-hydroxysuccinimide (NHS) ester. To 
avoid this problem, the Mazitschek group has developed a mild fluorination condition 
for this protocol. They discovered that TMSOTf can be used to abstract one fluoride 
from the BODIPY core in a quantitative yield at 0 °C in less than 5 minutes. The 
activated BODIPY triflate (22) can be easily transformed into its starting material (21) 
upon the addition of fluoride anion into organic medium. In addition, to avoid the 
formation of TMSF species, tert-butyl alcohol was added to the reaction to quench any 
excess TMSOTf. Mazitschek and coworkers also proved that this approach can be 
applied to the fluorination of more sensitive derivatives such as BODIPY N-
hydroxysuccinimide ester. With these results in hand, the construction of [
18
F]-21 can be 
done within 2 minutes (Figure 9, Scheme B) with 67% radiochemical yield and a 
specific activity of 0.96 Ci/μmol. Moreover, [18F]-BODIPY NHS ester, which can be 
prepared by the same condition with 73% radiochemical yield, was successfully 
conjugated to Trastuzumab, the monoclonal antibody that is normally used to treat HER-
2 positive breast cancer. These results are significant because they manifest the viability 
of this approach for the labeling of biological macromolecules.              
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Figure 9. Scheme showing the radiosynthesis of 21. 
 
A new strategy to use the –BF2 unit as a specific site for isotopic exchange with 
[
18
F]-fluoride anion to form [
18
F]-BODIPY was developed by Li and coworkers.
20
 This 
protocol is promising because the time-consuming process of preparing an activated 
hydroxide, triflate, or DMAP BODIPY derivative is not necessary. In this study, Lewis 
acidic reagents were used to promote the fluoride exchange process. Initially, the 
18
F-
19
F 
isotopic exchange of 23 was performed in aqueous medium under acidic conditions. 
Regrettably, the radiochemical yield of this process was extremely low (<2 %). Then, 
they directed their attention to the radiofluorination process of 23 in organic medium. 
They found that the Lewis acid SnCl4 noticeably promoted the 
18
F-
19
F isotopic exchange 
of 23 at ambient temperature (25 °C) in acetonitrile with excellent radiochemical yield 
(> 95%) (Figure 10). They also proved that the starting radioactivity (50 vs 10 mCi) did 
not significantly affect the yield. However, the use of a more polar solvent such as 
DMSO lowered the radiochemical yield due to a high solvent-Lewis acid interaction. 
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Favorably, Li and coworkers also discovered that [
18
F]-23 can be selectively 
accumulated in cardiac muscle based on a cellular uptake assay and the biodistribution 
signal in microPET images.
21
 The biodistribution data showed a high level of [
18
F]-23 
accumulation in heart tissue as well as good heart-to-blood and heart-to-lung contrast. 
With these results in hand, they concluded that [
18
F]-23 is a good candidate to use in 
myocardial perfusion imaging applications. This approach is also applicable for the 
18
F 
labeling of BODIPY N-succinimide ester, a more sensitive derivative that can be used to 
construct a radiolabeled BODIPY-peptide conjugate (Figure 11 A).  
 
 
Figure 10. Scheme showing the radiosynthesis of 23.      
 
Although most approaches to synthesize [
18
F]-BODIPY conjugates tend to 
incorporate 
18
F into the BODIPY dye before its conjugation to a biomolecule
19,20
, Li and 
coworkers recently reported a new protocol that addresses this limitation.
22
 In this report, 
they showed that 
18
F-
19
F isotopic exchange can be performed directly on a 
BODIPY®FL-RGD conjugate in the presence of a Lewis acid (Figure 11 B). In this 
 15 
 
case, they found that the SnCl4 was not a good activator for this radio-fluoride exchange 
reaction as a relatively low yield of the [
18
F]-BODIPY-peptide conjugate was acquired 
in this condition due to the decomposition of BODIPY®FL-RGD. Therefore, milder 
Lewis acids such as ZnCl2 and SnCl2 were selected for use in this application. 
Interestingly, SnCl2 can efficiently transform BODIPY®FL-RGD into [
18
F]-
BODIPY®FL-RGD at room temperature with high radiochemical yield (82.8%). This 
new method is significant because the two-step synthesis of [
18
F]-BODIPY®FL-RGD 
conjugate was simplified into a one-step process, thereby shortening the radio-synthetic 
time. Moreover, this protocol can also be applied to the radiolabeling of the near-infrared 
(NIR) dye BODIPY®R6G. Radioactive NIR fluorescent dyes are important for in vivo 
imaging applications because they can efficiently penetrate into targeted tissue. 
              
 
Figure 11. Scheme showing the radiosynthesis of [
18
F]-BODIPY®FL-RGD. 
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This acid-catalyzed protocol was further studied by Weissleder and coworkers.
23
 
In this case, trifluormethanesulfonic acid (TfOH) was generated in situ by the addition of 
trifluormethanesulfonic anhydride (Tf2O) and tert-butyl alcohol (t-BuOH) into a solution 
of BODIPY dye in the presence of azeotropically dried 
18
F source at 50 °C to promote 
the 
18
F-
19
F isotopic exchange process (Figure 12). It is important to note that the addition 
of commercial TfOH to the reaction mixture led to the rapid decomposition of the 
BODIPY precursor. Based on their kinetic study, they found that the rate of this isotopic 
exchange reaction is dependent on both the Tf2O/t-BuOH ratio and the amount of 
BODIPY dye in the solution. This approach is promising because it can be applied to the 
radio-labeling of several commercially bioconjugable BODIPY molecules and 
BODIPY-conjugated biomolecules.   
   
 
Figure 12. Scheme showing the radiosynthesis of BODIPY dyes using in situ generated 
TfOH as a catalyst. 
 
 
 
 
17 
1.4 Influence of the cationic moiety on the Lewis acidity of the boron atom and its 
application for the construction of boron-based radiotracers 
Gabbai and coworkers have been developing novel cationic organoboranes to use 
as anion receptors for the past decade. In this approach, a cationic moiety is used to 
increase the Lewis acidity of the boron atom via Coulombic effects. They discovered 
that Coulombic stabilization increases when the cationic substituent is conjugated close 
to the boron center, as shown in reports on ammonium
24
, phosphonium
25,26
, stibonium
27
,
sulfonium
28
, and telluronium
29
 boranes. In the case of ammonium boranes, they showed
that ortho-ammonium borane (24) can capture fluoride anions in aqueous solution with a 
fluoride binding constant of 910 (±50) M
-1
, whereas the para-derivative (25) cannot take
fluoride anion under the same condition (Figure 13).
24
 The increased Lewis acidity of
the boron atom in 24 may also be facilitated by the formation of stabilizing hydrogen 
bonds between the C-H in the trimethyl ammonium group and the B-F moiety. 
Figure 13. Scheme showing the fluorination reaction of 24 and 25. 
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In addition, ortho-phosphonium borane (26) also shows excellent fluoride 
affinity in methanol with an extremely high fluoride binding constant (K > 10
6
 M
-1
), 
which is at least four orders of magnitude higher than the measured binding constant of 
para-isomer (27) (K = 400 (±50) M
-1
) (Figure 14).
25
 The high fluoride affinity of 26 is 
also supplemented by the formation of a B-F→P donor-acceptor interaction between the 
fluorine lone-pair electron and the σ* orbital of the P-C bond. These results support the 
concept that the anionic affinity of such complexes can be enhanced by closer 
positioning of the cationic group.  
      
 
Figure 14. Scheme showing the fluorination reaction of 26 and 27. 
 
 Similar effects are observed with sulfonium boranes (Figure 15) as the Lewis 
acidity of the boron center is enhanced by the proximal sulfonium group. Based on a 
spectrophotometric tritration experiment, 28 starts to bind hydroxide at pH ≥ 7, whereas 
29 is stable up to pH 9.5, which suggests that 28 is more acidic than 29.
28
 This unusual 
difference can be explained by the presence of an lp(S)→p(B) donor-acceptor interaction 
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that partially quenches the Lewis acidity of the boron center. The more convergent 
orientation of the sulfonium and boron moiety in 29 leads to a strong lp(S)→p(B) donor-
acceptor interaction, thus lowering the Lewis acidity. Surprisingly, the more Lewis 
acidic 28 can be used as a selective cyanide sensor in pure water via a fluorescence turn-
off response.  
 
 
Figure 15. Illustration of sulfonium boranes 28 and 29. 
 
 Once Gabbai and coworkers had established the concept that the fluoride affinity 
of organoboranes can be noticeably increased by introduction of a proximal cationic 
moiety as shown in 24, 26, and 28, they decided to investigate whether a similar protocol 
could be used to stabilize aryltrifluoroborates against hydrolysis. With this in mind, they 
synthesized the zwitterionic aryltrifluoroborates 30, 31, and 32 (Figure 16) and 
examined the stability of these compounds in aqueous solution (pH = 7.5). The fluoride 
dissociation reaction of aryltrifluoroborate can be treated properly by a simple first order 
rate equation (rate = kobs[ArBF3]). Based on the kinetic data, 30 is the most stable species 
as the lowest rate constant (kobs) was obtained. It is more stable than either 31 or 32. The 
lower stability of 32 may derive from the lone-pair electron of sulfur, which may 
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destabilize the BF3 unit through electron repulsions. Fortunately, such repulsions do not 
exist in the case of 30 and 31, thereby retarding the rate of fluoride dissociation. The 
stability of 30 and 31 may also be supplemented by the accepting ability of the 
phosphonium center and hydrogen bond interactions, respectively. These results are 
noteworthy as they indicate that both phosphonium and ammonium trifluoroborates are 
appealing candidates to use as radiotracers in PET imaging.       
     
 
Figure 16. Illustration of zwitterionic aryltrifluoroborate 30, 31, and 32, and their 
hydrolytic rate constants. 
 
 Recently, Perrin and coworkers reported a new zwitterionic 
alkylammoniomethyltrifluoroborate (AMBF3) (33) (Figure 17) to use as a potential 
18
F-
radioprosthetic group.
30
 This compound is noteworthy as it has greatly improved 
qualities for radiotracer development. These qualities consist of 1) in vitro and in vivo 
stability, 2) simple labeling by 
18
F-
19
F isotopic exchange, 3) HPLC-free purification, 4) 
synthetic simplicity, and 5) in vivo imaging of several tumor targets. AMBF3 is easily 
synthesized by the akylation of a tertiary amine followed by treatment with KHF2 in 
aqueous solution. This synthetic approach is also applicable for preparing an azidoethyl-
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AMBF3 and a tris–propargylether AMBF3, which can provide considerable synthetic 
simplicity for bioconjugation 
.   
 
Figure 17. Scheme showing the synthesis of 33. 
 
 To test the efficacy of AMBF3 labeling, 33 was conjugated to octreotate and 
B9858/B9958 peptides for use as radiotracers for imaging somatostatin receptor subtype 
2 and the bradykinin B1 receptor, respectively. Somatostatin receptor subtype 2 (sstr2) is 
overexpressed in many neuroendocrine tumors, whereas the bradykinin B1 receptor 
(B1R) is upregulated in inflamed and cancer tissues. Because sstr2 and B1R are not 
normally expressed in healthy tissues, they are attractive targets for the development of 
therapeutic agents for cancer treatment. In the case of the octreotate-based imaging 
agent, the [
18
F]-alkyltrifluoroborate-octreotate conjugate (
18
F-AMBF3-TATE) (Figure 
18) was efficiently prepared in a one-step 
18
F-
19
F exchange reaction with high 
radiochemical yield (20-25 %, non-decay-corrected) and high specific activity (3 Ci/ 
μmol). Gratifyingly, 18F-AMBF3-TATE displayed more than 5-fold higher sstr2 binding 
affinity than did a gallium –DOTATATE radiotracer under the same conditions. In 
addition, 
18
F-AMBF3-TATE is highly stable in vitro and in vivo because only negligible 
decomposition products of 
18
F-AMBF3-TATE were observed in a plasma stability assay 
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(37 °C) and minimal bone uptake signal was noted in the PET/CT images. In the case of 
the B1R imaging agent, AMBF3 was conjugated to two potent peptides, B9858 and 
B9958, which have different amino acid sequence and units, to compare their binding 
affinity toward B1R. Following the previous method, 
18
F-AMBF3- B9858/ B9958 
(Figure 18) were prepared in one step by isotopic exchange at 80 °C under acidic 
conditions (pH 2) within 30 min. Biodistribution and imaging studies proved that both 
18
F-AMBF3-B9858 and 
18
F-AMBF3-B9958 selectively bound to B1R tumors. However, 
18
F-AMBF3-B9958 is a promising candidate for clinical translation because it provided 
better tumor-to-background contrast. Overall, these tumor-imaging results are significant 
because they support the concept that AMBF3 can be used broadly for peptide-based 
radiotracer development. 
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Figure 18. Illustration of peptide conjugated AMBF3 A) 
18
F-AMBF3-TATE, B)
 18
F-
AMBF3-B9858, and C) 
18
F-AMBF3-B9958.   
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1.5 Objectives 
As shown in our previous study, the zwitterionic aryltrifluoroborate with an 
ortho-phosphonium group (30) is the most stable species in aqueous solution compared 
to the ammonium and sulfonium aryltrifluoroborates (31 and 32). Thus, the 
phosphonium derivative is expected be a good candidate for use as an 
18
F-radiotracer as 
it would be stable in vivo. With this result in mind, we have decided to investigate the 
use of ortho-phosphonium aryltrifluoroborates as [
18
F]-fluoride anion receptors. As part 
of this objective, we will study how the nature of the phosphine substituent affects the 
stability of the zwitterionic aryltrifluoroborate. Another aspect of this project is related to 
the conjugation of our synthesized phosphonium aryltrifluoroborates with potential 
biomolecules, which will be used as targeted radiotracers. 
In addition to phosphonium aryltrifluoroborates, we were attracted by the 
remarkable stability of imidazolium trifluoroborates (34) (Figure 19). This compound, 
which can also be described as a carbene-BF3 adduct, can be recrystallized from boiling 
water, which suggests that it is highly resistant to hydrolysis.
31
 Therefore, we decided to 
investigate the applicability of this compound for use as a radioprosthetic group in 
radiopharmaceutical products. The objective of this experiment is to 1) synthesize novel 
carbene-BF3 adducts with a conjugable functional group and 2) examine their stability 
in vitro and in vivo.        
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Figure 19. Illustration of carbene-BF3 adduct 34.  
 
As mentioned above, BODIPY dyes have been extensively developed for use as 
PET/fluorescent dual modality imaging agents. The major studies have focused on the 
methodology used to radiofluorinate BODIPY dyes. With these results in mind, we 
wondered whether such methods could be applied to other boron-containing dyes. To 
satisfy our curiosity, we decided to synthesize a new fluorescent dye class called 
triazaborolopyridinium, which was recently developed by Arterburn and coworkers.
32
 
The objective for this experiment is to 1) prepare and characterize novel 
triazaborolopyridinium dyes with different functionalities; and 2) examine whether these 
dyes are resistant to hydrolysis.   
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CHAPTER II  
ORTHO-PHENYLENE PHOSPHINO-BORANES FOR [
18
F]-FLUORIDE ANION 
CAPTURE AND IN VIVO STABILITY STUDIES

 
 
2.1 Introduction  
  Positron emission tomography (PET) has become a popular imaging technique 
widely used for diagnostic purposes. This technique necessitates the incorporation of a 
positron emitting atom in the biomolecule under study.
1
 To date, much attention has 
been devoted to 
18
F-fluoride because of the characteristic of its nuclear decay, as well as 
its relative ease of preparation from [
18
O]water.
33,34
 However, with a half-life of 110 
minutes, the incorporation of 
18
F-fluorine into biomolecules needs to be carried out in a 
swift and efficient manner to minimize any loss of activity. These synthetic and kinetic 
considerations constitute one of the critical barriers to progress in the field of 
18
F-PET 
imaging. In turn, the discovery of general and reliable protocols for the rapid 
incorporation of 
18
F-fluorine atoms into biomolecules would be highly beneficial, 
especially if these protocols can be carried out directly in the irradiated [
18
O]water. 
  An approach that has gained interest in the past few years involves the use of a 
                                                 

Reprinted in part permission from, “Harvesting 18F-fluoride ions in water via direct 
18
F–19F isotopic exchange: radiofluorination of zwitterionic aryltrifluoroborates and in 
vivo stability studies”; Li, Z.; Chansaenpak, K.; Liu, S.; Wade, C.R.; Conti, P.S.; Gabbai, 
F. P. Med. Chem. Commun., 2012, 3, 1305. Copyright 2012 by the Royal Society of 
Chemistry.  
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fluoride binding agent (referred to as a fluoride captor) that is appended to a biomolecule 
and treated with 
18
F-fluoride just prior to injection.
35-39
 Such an approach is appealing 
because time-consuming synthetic steps can be carried out before introduction of the 
relatively short-lived 
18
F radionuclide. In turn, this method can be used to optimize the 
specific activity of radiolabeled biomolecules thus facilitating their in vivo imaging. 
However, this field of research remains relatively underdeveloped with only a few types 
of captors investigated thus far. In one of the most elegant approaches, Perrin and 
coworkers has shown that arylboronic acids or esters featuring electron-withdrawing 
substituents quickly react with fluoride ions to form the corresponding 
arylfluoroborates.
40,41 
 This approach has been employed for the radiolabeling of 
different biomolecules which have been imaged in vivo.
35,42-46
 In passing, we will note 
that similar concepts have been used by us
47
 and subsequently others
48,49
 for the 
radiosynthesis of [
18
F]BODIPY dyes as dual modality PET/fluorescence imaging agents. 
  One of the key aspects in the chemistry of [
18
F]arylfluoroborates lies in the use of 
an electron-withdrawing substituent. The latter slows down the hydrolytic release of free 
fluoride ions making it essentially negligible on the time scale of the 
18
F nuclear decay.
40
 
Such electron-withdrawing substituents effectively prevent the release of 
18
F-fluoride 
ions that would otherwise bind to the bones giving unwanted and interfering background 
signals. Despite the elegance of this approach, some problems remain. In particular, 
these syntheses are usually implemented with a carrier-added fluoride source such as 
KHF2. Although the use of KHF2 does not necessarily invalidate this elegant approach as 
documented by recent successes,
35,42-46
 it occurred to us that boron-based fluoride 
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captors with enhanced fluoride affinity could become amenable to direct 
radiofluorination reactions. 
  As part of our investigations in the chemistry of cationic boranes as fluoride 
anion receptors,
50
 we have discovered that fluoroborate moieties are efficiently stabilized 
by neighboring onium ions.
51-55
 These effects are illustrated by the kinetic stability of the 
phosphoniumtrifluoroborate 30 which is hydrolyzed in water/MeCN at a rate (kobs = 3.4 
× 10
-6
 min
-1
) 7200 times lower than that of K[C6H5BF3] (kobs = 24.5 × 10
-3
 min
-1
).
56
 
Encouraged by these results we have now decided to investigate the radiofluorination 
and in vivo stability of such zwitterions.  In this paper, we report the results that we have 
obtained with the known zwitterion 30 as well as 35, 36, and 37, three new 
phopshosphiumtrifluoroborate species that we synthesized to assess substituents effects. 
 
 
Figure 20. Illustration of the ortho-phenylene phosphine-boranes 30, 35, 36, and 37.   
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2.2 Synthesis and characterizations 
  Inspired by a recent report from Bourissou and coworkers,
57
 we synthesized 35 in 
a 67% overall yield by reaction of the known ortho-(i-Pr2P)C6H4(BMes2)
57
 with 
methyliodide, followed by treatment of the resulting phosphonium salt with pyridine-HF 
(Figure 21).  The carboxylic acid functionalized diphenylphosphonium derivative 36 was 
prepared by reaction of ortho-(Ph2P)C6H4(Bpin)
58
 (Bpin = pinacolboryl) with 3-
iodoproprionic acid followed by treatment of the resulting phosphonium salt with KHF2. 
Finally, the carboxylic acid functionalized di-iso-propylphosphonium derivative 37 was 
prepared by the deprotonation of the known [ortho-(iPr2PH)C6H4(Bpin)][BF4]
59
 
followed by treatment of 3-iodoproprionic acid at elevated temperature and KHF2 at 
room temperature, respectively. These new derivatives have been fully characterized. 
The presence of the phosphonium moiety is confirmed by the detection of a 
31
P NMR 
resonance at 41.10 ppm for 35, 30.60 for 36, and 42.9 for 37.  The trifluoroborate moiety 
gives rise to a 
11
B NMR resonance at 2.4 ppm for 35, 2.8 for 36, and 3.1 for 37 as well 
as a 
19
F NMR resonance at -136.3 ppm for 35, -133.6 for 36 and -134.4 for 37.   
 30 
 
 
Figure 21. Scheme showing the synthesis of 35, 36, and 37. 
 
  The structure of these compounds has also been confirmed by single crystal X-
ray diffraction as shown in Figure 22, 23, and 24. As in the structure of 30,
56
 the short 
B(1)-P(1) separation of 3.386 Å in 35, 3.491 Å in 36 and 3.429 Å  in 37 suggests that 
these zwitterions benefits from a strong Coulombic stabilization. These strong 
Coulombic effects may be supplemented by a F(lone pair) → P–C(σ*) donor acceptor 
interaction as suggested by the F(1)-P(1) separation of 3.013 Å for 35, 3.064 Å for 36, 
and 3.048 Å for 37.  In the case of 35 and 37, hydrogen bonding interactions between the 
CH group of the i-Pr ligands and one of the fluorine atoms may also play a stabilizing 
role.
51,57,60
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Figure 22. Crystal structure of 35. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 35: P1-B1 3.386, B1-F1 1.414(2), B1-F2 1.403(2), B1-
F3 1.404(2); P1-C1-C6 123.05(13), C1-C6-B1 127.21(16).    
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Figure 23. Crystal structure of 36. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 36: P1-B1 3.491, B1-F1 1.368(10), B1-F2 1.391(11), 
B1-F3 1.367(10), C21-O1 1.305(8), C21-O2 1.202(8); P1-C1-C6 122.3(5), C1-C6-B1 
132.2(6). 
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Figure 24. Crystal structure of 37. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 37: P1-B1 3.429, B1-F1 1.395(3), B1-F2 1.425(3), B1-
F3 1.400(3), C11-O1 1.336(3), C11-O2 1.195(3); P1-C1-C6 122.28(16), C1-C6-B1 
129.4(2). 
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2.3 Kinetic studies 
  Next, we decided to compare the rate of hydrolysis of these new compounds with 
those of 30 which has been previously investigated. This hydrolysis reaction, which 
converts the trifluoroborate moiety into the corresponding boronic acid according to a 
first order rate process (ν = kobs[ArBF3]), was monitored by 
19
F NMR spectroscopy in 
D2O/CD3CN (8/2 vol.) at pH 7.5 ([phosphate buffer] = 500 mM, [ArBF3] = 20 mM with 
ArBF3 = zwitterionic trifluoroborate).  Surprisingly, we observed that the first order 
hydrolysis rate constant of 35, 36, and 37 (kobs (35) = 3.9 × 10
-5
 min
-1
, kobs (36) = 1.5 × 
10
-5
 min
-1
, kobs (37) = 5.2 × 10
-5
 min
-1
) are significantly higher than that of 1 (kobs (1) = 
3.4 × 10
-6
 min
-1
). The kinetic plots for the hydrolysis of 35, 36, and 37 were shown in F 
igure 25. While it is difficult to rationalize the difference observed in the hydrolytic 
sensitivity of 35, 36 and 37, these experiments show us that subtle substituent changes 
have an impact on the stability of the complexes. 
 
 
 
 
 35 
 
 
 
Figure 25. Kinetic plots for the hydrolysis of 30, 35, 36, and 37.The data were obtained 
at room temperature in D2O/CD3CN (8/2 vol.) at pH 7.5.  The data shown for 30 has 
been previously reported
5
 and is provided for the sake of comparison. 
 
 
 
 
 
 
 
 
 
30 
35 
36 
37 
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2.4 Zwitterionic stibonium aryltrifluoroborate and its stabilization against hydrolysis 
 Because of the increased size, polarizability, and electropositivity of the heavier 
pnictogen elements, stibonium moeities display stronger Lewis acidity than their 
corresponding phosphonium congeners.
61
 With this in mind, we prepared a new 
zwitterionic stibonium aryltrifluoroborate by the reaction of the reported ortho-
(Ph2MeSb)C6H4(BMes2)
61
 with HF-pyridine (Figure 26). The product was obtained in 
42% yield. This new compound has been characterized by NMR spectroscopy. The 
presence of a trifluoroborate moiety was confirmed by the 
11
B NMR and 
19
F NMR 
signals at 2.7 ppm and -135.8 ppm, respectively. The 
1
H NMR of the methyl group 
displayed a quartet at 2.30 ppm (JH-F = 1.53 Hz) indicating coupling of the three fluorine 
nuclei.  
 
 
Figure 26. Scheme showing the synthesis of 38. 
 
Next, we determined the rate of hydrolysis of this compound. Unfortunately, the 
first order rate constant of 38 (kobs = 4.0 × 10
-4
 min
-1
) is close to that of the sulfonium 
derivative (32) and much higher than that of the phosphonium derivatives (30, 35, 36, 
and 37). The poor stability of 38 towards hydrolysis may result from the exceptionally 
strong Lewis acidity of stibonium moiety. To understand the effect of the stibonium 
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group, we chose to perform DFT calculations (Optimized structure shown in Figure 27). 
In the optimized structure, the Sb(1)-F(1) separation was found to be 2.424 Å, which is 
considerably shorter than sum of the Sb-F Van der Waals radii (3.70 Å).
62
 This suggests 
a strong donor-acceptor interaction between the stibonium center and one of the 
trifluoroborate fluorine atoms. This result was also supplemented by natural bond orbital 
(NBO) analysis, which revealed the presence of a strong F(lone pair) → Sb-C(σ*) 
interaction, as suggested by deletion energy of 31.04 kcal mol
-1
. In addition, the B(1)-
F(1) separation of 1.516 Å in the optimized structure is longer than a typical B-F 
covalent bond (1.410 Å).
63
 Based on these computational results, the stibonium center 
tends to abstract a fluorine atom from trifluoroborate moiety suggested by B(1)-F(1) 
bond elongation. This process may lower the activation energy of fluoride dissociation 
pathway yielding rapid rate of trifluoroborate hydrolysis. 
 
 
Figure 27. Optimized structure of 38.  
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2.5 Radiofluorination
1
  
  Because of its greater resistance to hydrolysis, compound 30 was chosen as the 
first candidate for radiofluorination.  Emulating the elegant approach developed by 
Perrin for the preparation of related [
18
F]-radiolabeled trifluoroborate derivatives,
35,42-46
 
we investigated the reaction of the pinacolboryl precursor [o-MePh2P(C6H4)Bpin]OTf
56
 
(250 μg, 0.45μmol in 100 μL, MeOH) with a solution of [19F]-KHF2 (8.0μL, 0.1 mol L
−1
) 
and [
18
F]-fluoride ions (30 ± 3 mCi in 100 μL unfixed target [18O]-water). The resulting 
solution was heated to 60ºC for 10 minutes. After dilution with 800 μL of water, the 
crude mixture was loaded onto a reverse phase HPLC which indicated the formation of 
[
18/19
F]1 with a % conversion of 76 ± 3 % (based on HPLC, n = 4). The specific activity 
of the final product was calculated to be 47 ± 15 mCi/μmol by comparing its UV 
absorption with the standard titration curve. The identity of [
18/19
F]30 was confirmed by 
the comparison of its elution time with that of its non-radioactive analog 30 (Figure 28). 
This experiment has been repeated four times and the results are consistent. The use of 
MeOH/H2O as a stationary phase led to analogous results, thus helping us to confirm the 
identity of [
18/19
F]30. 
 
 
                                                 
1
 This experiment was carried out by our collaborator, Dr. Zibo Li, at department of 
Radiology, University of Southern California, Los Angeles, CA. 
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Figure 28. HPLC profiles obtained in the radiofluorination of 30. (A) Radio signal. (B) 
UV signal.  
 
  While we were very pleased to establish a quick and robust radiofluorination 
protocol that can be implemented in water/methanol mixtures, in the matter of minutes, 
it occurred to us that higher specific activity could be obtained in the absence of KHF2.  
With this in mind, we decided to attempt the generation of [
18/19
F]30 by direct 
18
F-
19
F 
isotopic exchange, a strategy that has proven successful for the radiofluorination of main 
group molecules, including BF4
-64,65
 as well as fluorosilane derivatives.
36,37
  Inspired by 
the acidic conditions used for the preparation of [
18
F]BF4
-
,
64,65
 we found that simple 
stirring of a [
18
O]water solution (100 ± 10 μl) containing 30 ± 3 mCi 18F, 30 (2.5 × 10-3 
mol L
-1
, dissolved in MeCN first) and HCl (pH = 1.5) at room temperature for 20 
minutes afforded [
18/19
F]30 with a % conversion of 87.0 ± 4.5% (Table 1, entry 1).  This 
radiosynthetic result is noteworthy for the following two reasons: i), we demonstrate for 
the first time that 
18
F-
19
F isotopic exchange is a very efficient strategy for the synthesis 
of trifluoroborates with elevated specific activities; ii) we demonstrate that such 
18
F-
19
F 
isotopic exchange reaction can be implemented directly in the irradiated [
18
O]water 
  [
18/19
F]30 [
18/19
F]30 
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solution, thus alleviating the need for any time consuming drying steps. 
 
 
Figure 29.  Direct 
18
F-
19
F isotopic exchange reaction employed for the radiolabeling of 
30, 35, and 36 in aqueous solutions. 
 
  As illustrated by entries 1-4 (Table 1), 30 undergoes efficient fluoride exchange 
but only at low pH.  When a lower quantity of 30 is employed as in entries 5 and 6, a net 
decrease in the extent of conversion is observed, a trend that underscores the effect of 
dilution on reaction kinetics.  Fortunately, the same effects can be used to achieve high 
levels of conversion and specific activities that are comparatively higher.  Indeed, when 
the reaction is carried out under much more concentrated conditions as in entry 7, the % 
conversion exceeds 90%, affording [
18/19
F]30 with a specific activity of 520 ± 174 
(mCi/µmol). Gratifyingly, the fluoride exchange reaction can also be applied to 35 and 
36, which are efficiently radiofluorinated, albeit under acidic conditions (entries 8-12).  
When the reaction is carried out at a higher 
18
F-fluoride/35 ratios (entry 11), a 
comparatively high specific activity can be obtained.  The carboxylate functionalized 
borane 36 behaves similarly to 30 and is also amenable to facile radiofluorination by 
isotopic exchange.  A comparison of the measured and estimated specific activities 
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indicates that the former are typically lower than the latter.  This difference is assigned 
to decomposition of part of the starting material that does not participate in the reaction.  
It is also possible that experimental factors inherent to the handling of small sample sizes 
play a role in the noted deviations. 
 
Table 1. Radiosynthetic results. 
Entry
a
 Cpd Amount 
(µmol) 
pH Conversion 
(%)
c
 
Measured 
SA
e
 
(mCi/µmol) 
Estimated 
SA
e,f
 
(mCi/µmol)
e
 
1
a,d
 30 0.73 1.5 87 ± 4.5 38 ± 7 27.8 ± 2.8 
2
a
 30 0.73 6.5 < 5 N/D 1.60 ± 0.2 
3
a
 30 0.73 5.3 < 8 N/D 3.3 ± 0.4 
4
a
 30 0.73 3.0 85 35.4 35 ± 4 
5
a
 30 0.036 1.5 23 N/D 149 ± 15 
6
a
 30 0.0073 1.5 11 N/D 351 ± 35 
7
b,d
 30 0.036 1.5 >90 520 ± 174 514 ± 52 
8
a,d
 35 1.4 1.5 >90 20 ± 4 15.0 ± 1.5 
9
a
 35 0.14 1.5 87 185.2 145 ± 15 
10
a
 35 0.14 6.5 0 - - 
11
a
 35 0.029 1.5 51 421 410.0 ± 41 
12
a
 36 0.73 1.5 >90 N/D 28.7 ± 2.9 
 
  For all reactions, the isotopic exchange reaction was allowed to proceed for 20 
min with an initial 
18
F activity of 30 ± 3 mCi.  Reactions at acidic pH (pH 3 or 1.5) are 
carried out in 0.001 and 0.032 M HCl.  Reactions at elevated pH are carried out using 
0.1 M NH4OAc (pH = 5.3) and 0.1 M phosphate (pH = 6.5) buffer. 
a
The reactions are 
performed in 100 ± 10 µL of [
18
O]-water solution containing 15 ± 5µL of MeCN used 
for solubilization of the phosphonium trifluoroborate.  The reaction was performed at 
room temperature for 20 min. 
b
The irradiated [
18
O]-water solution containing 30 ± 3 mCi 
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activity was dried under a nitrogen flow and the activity was taken up with a solution of 
30 in MeCN and water (1:3 v/v, 5 µL, pH = 1.5). 
c
The percentages of conversion have 
been determined by HPLC and are relative to the starting 
18
F activity. 
d
The reactions 
have been repeated four times with the SA representing the average of these four 
measurements (n = 4). 
e
SA: specific activity.  
f
Estimated SA based on the percentage of 
conversion, the starting activity and the amount of precursor; the values are decay-
corrected with an overall processing time of 40 min for entries 1-6, 8-12 and 60 min for 
entry 7.  N/D: not determined. 
   
2.6 In vivo stability studies
2
 
   To conclude this study, we injected 100 ± 10 µCi of [
18/19
F]30 and [
18/19
F]35 in 
female nude mice. At 0.5, and 2 h post injection, static microPET scans were achieved 
and the sagittal images for each compound are shown in Figure 30. [
18/19
F]30 shows a 
clear localization of activity in the liver of the animal, in accordance with the lipophilic 
nature of this molecule.
47
 The absence of any signal from the skeleton of the animal 
indicates that the [
18
F]-fluoride ions are not released during the time frame of the 
imaging experiments. At 0.5 h post injection, [
18/19
F]35  also showed relatively good in 
vivo stability.  This compound appears to have better clearance properties, possibly 
because of their increased hydrophilicity, and are quickly cleared through the urinary 
track as indicated by the quick disappearance of the signal from the liver as well as a 
                                                 
2
 This experiment was carried out by our collaborator, Dr. Zibo Li, at department of 
Radiology, University of Southern California, Los Angeles, CA. 
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strong signal from the bladder of the animal. We also note that [
18/19
F]35 also resulted in 
gallbladder and intestine uptake. At 2 h post injection, [
18/19
F]35 did show some 
defluorination in vivo as we observed certain level of bone uptake.  This fluoride release 
reaction can be correlated to the higher hydrolysis rate constant measured for this 
compound.  Based on the hydrolysis rate constant measured for 35, ~1.5 mol% of F
-
 
should be liberated after 2 hours, an amount that may suffice to explain the observed 
bone signal.  We also note that, in vivo, fluoride release may be accelerated by a variety 
of processes including pH variations and enzymatic and/or oxidative decompositions.  
 
 
 
Figure 30. Decay-corrected whole-body microPET Sagittal images of athymic female 
nude mice from a static scan at 0.5, and 2 h after injection of [
18/19
F]30 and [
18/19
F]35. 
The images are corrected based on the injected activity. The signal intensity is reported 
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in % of the injected dose per gram (%ID/g).  Preparations from entries 7 and 9 were used 
for these imaging experiments. 
 
2.7 Conclusion 
  First, the results presented in this paper allow us to firmly establish that ortho-
phosphonium groups can be used to enhance the in vivo stability of radiofluorinated 
aryltrifluoroborates, allowing for extended imaging times.  Our results also demonstrate 
that the stability of these compounds is very sensitive to the nature of the phosphorus 
atom substituents, with the diphenylmethylphosphonium derivative 30 being 
significantly more stable than the di-(iso-propyl)methylphosphonium derivative 35.  A 
second outcome of this work is the demonstration that 
18
F-
19
F isotopic exchange 
reactions can be used to radiolabel aryltrifluoroborates directly in the irradiated 
[
18
O]water.  Because of short reaction times and limited isotopic dilution, this simple 
method affords radiolabeled compounds with good reasonable activities. Finally, we will 
note that the carboxylic acid functionalized derivative 36 and 37 should be amenable to 
simple bioconjugation protocols, opening new horizons for the radiolabeling of amine 
terminated biomolecules.  
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2.8 Experimental 
General Consideration  
  Ortho-(i-Pr2P)C6H4(BMes2)
66
, ortho-(Ph2P)C6H4(Bpin)
2
 and [ortho-
(iPr2PH)C6H4(Bpin)][BF4]
59
 were prepared according to the published procedure. CH3I 
was purchased from Alfa Aesar. HF-pyridine was purchased from Sigma-Aldrich and 3-
iodoproprionic acid was bought from Oakwood Product, Inc.  Solvents were dried by 
passing through an alumina column (CH2Cl2) or refluxing under N2 over Na/K (Et2O). 
Air sensitive compounds were handled under a N2 atmosphere using standard Schlenk 
and glovebox techniques. Electrospray mass spectra were acquired from a MDS Sciex 
API QStar Pulsar. The spray voltage was 4.5 kV. Elemental analyses were performed at 
Atlantic Microlab (Norcross, GA). NMR spectra were recorded on a Varian Unity Inova 
300 NMR and an Inova 400 NMR spectrometer at ambient temperature. Chemical shifts 
are given in ppm, and are referenced to residual 
1
H and 
13
C solvent signals as well as 
external BF3-Et2O (
11
B), CFCl3 (
19
F) and H3PO4 (
31
P). 
 
Preparation of ortho-(iPr2MeP)C6H4(BF3) (35) 
  Methyl iodide (0.06 mL, 0.984 mmol) was added to a solution of ortho-(i-
Pr2P)C6H4(BMes2) (0.145 g, 0.328 mmol) in dichloromethane (7 mL) at room 
temperature. After being stirred overnight, the solution was concentrated in vacuo to a 
volume of 1 mL. To the concentrated solution, was added Et2O (10 mL) which resulted 
in the precipitation of a pale yellow solid (0.145g, 96% yield).
1
H NMR (299.9 MHz, 
CDCl3):  1.10 (dd, 6H, isopropyl-CH3, 
3
JH-P = 17.99 Hz, 
3
JH-H = 7.20 Hz), 1.16 – 1.29 
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(m, 6H, isopropyl-CH3), 1.34 (s, 3H, Mes-CH3), 1.84 (d, 3H, P-CH3, 
2
JH-P = 53.98), 1.87 
(s, 3H, Mes-CH3), 1.98 (s, 3H, Mes-CH3), 2.08 (s, 3H, Mes-CH3), 2.22 (s, 3H, Mes-
CH3), 2.26 (s, 3H, Mes-CH3), 2.56 – 2.70 (m, 1H, isopropyl-CH), 3.38 – 3.52 (m, 1H, 
isopropyl-CH), 6.68 – 6.84 (m, 4H, Mes-CH), 7.48 – 7.62 (m, 2H, phenyl-CH), 7.78 (t, 
1H, phenyl-CH, 
3
JH-H = 7.50 Hz), 8.33 (dd, 1H, phenyl-CH, 
3
JH-P = 11.0 Hz,   
3
JH-H = 
7.50 Hz). 
13
C NMR (125.6 MHz, CDCl3):  2.01, 2.41, 16.59, 17.28, 21.39 (d, JC-P = 
6.28 Hz), 23.21, 23.59, 23.85,24.87, 25.08, 25.56, 25.92, 105.16,121.75, 122.36, 129.20, 
129.50,129.77, 129.96, 131.59 (d, JC-P = 12.43 Hz), 133.58 (d, JC-P = 3.14 Hz), 136.25, 
136.35, 136.66, 136.76, 140.40, 141.26, 141.44, 141.95, 142.12, 142.45. 
11
B NMR 
(128.2 MHz, CDCl3): not observed. 
31
P NMR (121.4 MHz, CDCl3): 40.95. Anal. Calcd 
for C31H43PBI: C, 62.72; H, 7.42. Found: C, 62.22; H, 7.12. Without further purification, 
the pale yellow solid was treated with excess hydrogen fluoride pyridine in 
dichloromethane (2 mL) at room temperature. After being stirred for 18 h, the mixture 
was quenched by water (2 mL). The dichloromethane layer was separated from the 
mixture, dried with MgSO4, and filtered to remove MgSO4, respectively. The solvent 
was removed under reduced pressure. The residue was washed with Et2O (3  2 mL) 
yielding 35 as yellow solid (63.1 mg, 70% yield). 
1
H NMR (299.9 MHz, CDCl3):  1.07 
(dd, 6H, isopropyl-CH3, 
3
JH-P = 20.99 Hz, 
3
JH-H = 7.20 Hz), 1.37 (dd, 6H, isopropyl-CH3, 
3
JH-P = 17.99 Hz, 
3
JH-H = 7.50 Hz), 1.89 (d, 3H, P-CH3, 
2
JH-P = 11.70 Hz), 3.56 (m, 2H, 
isopropyl-CH), 7.41 – 7.46 (m, 2H, phenyl-CH), 7.59 (t, 1H, 3JH-H = 6.30 Hz), 8.13 (dd, 
1H, 
3
JH-P = 6.60 Hz, 
3
JH-H = 4.80 Hz). 
13
C NMR (75.4 MHz, CDCl3):  -1.83 (d, 
1
JC-P = 
54.06 Hz),  17.16 (d, 
2
JC-P = 2.26 Hz), 17.66 (d, 
2
JC-P = 2.19 Hz), 23.27 (d, 
1
JC-P = 4.98 
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Hz), 23.88 (d, 
1
JC-P = 4.45 Hz), 126.65 (d, JC-P = 12.14 Hz), 130.20 (d, JC-P = 11.00 Hz), 
132.83 (d, JC-P = 3.09 Hz), 136.41 (dd, 
1
JC-P = 15.98 Hz, 
3
JC-F = 3.32 Hz). 
11
B NMR 
(128.2 MHz, CDCl3):  2.37 (q, 
1
JB-F = 46.28 Hz). 
31
P NMR (121.4 MHz, CDCl3):  
41.10. 
19
F NMR (282.2 MHz; CDCl3): -136.3. Anal. Calcd for C13H21PBF3: C, 54.97; H, 
7.67. Found: C, 54.56; H, 7.38. 
 
Preparation of ortho-((HO2C(CH2)2)Ph2P)C6H4(BF3) (36) 
A solution of the ortho-(Ph2P)C6H4(Bpin) (0.428 g, 1.102 mmol) and 3-
iodoproprionic acid (0.225 g, 1.125 mmol) in toluene (5 mL) was heated to 90 °C for 18 
h. After 18 h, the mixture was concentrated in vacuo to a volume of 1 mL.  Addition of 
Et2O (10 mL) to the resulting solution resulted in the precipitation of a pale yellow solid 
(0.578 g). Without further purification, the precipitate was dissolved in methanol (4 mL) 
and treated with a solution of KHF2 (0.307 g, 3.931 mmol) in water (4 mL). The 
resulting solution was sonicated for 15 minutes and stirred for 1 h. The mixture was 
extracted by dichloromethane (3 x 15 mL) and the organic layer was dried with MgSO4. 
After filtration, the solution was concentrated to 1 mL and treated with Et2O (15 mL), 
leading to the precipitation of 36 as a pale yellow solid (0.421g, 72 % yield). 
1
H NMR 
(399.5 MHz, CD3CN):  2.66 (dt, 2H, -CH2COOH, 
3
JH-P = 6.79 Hz, 
3
JH-H = 8.79 Hz), 
3.62 (dt, 2H, -PCH2CH2COOH, 
2
JH-P = 13.18 Hz, 
3
JH-H = 8.79 Hz), 7.13 (dd, 1H, 
phenyl-CH, 
3
JH-P = 14.38 Hz, 
3
JH-H = 7.19 Hz), 7.32 (tdd, 1H, phenyl-CH, J = 7.59, 3.16, 
1.24 Hz), 7.51 – 7.68 (m, 9H, phenyl-CH), 7.75 (td, 2H, phenyl-CH, J = 7.59, 1.20 Hz), 
7.95 (dd, 1H, phenyl-CH, J = 7.59, 5.19 Hz). 
13
C NMR (125.6 MHz, CD3CN):  20.38 
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(d, -PCH2CH2COOH, 
1
JC-P = 55.26 Hz), 28.62 (d, -PCH2CH2COOH, 
2
JC-P = 2.39 Hz), 
122.96, 123.65, 127.95 (d, JC-P = 13.82 Hz), 130.45 (d, JC-P = 11.93 Hz), 131.18 (d, JC-P 
= 12.43 Hz), 134.06, 134.09, 134.13, 134.28 (d, JC-P = 9.17 Hz), 134.73 (d, JC-P = 3.01 
Hz), 136.06 (d, JC-P = 15.07 Hz), 136.24 (dq, JC-P = 17.58 Hz, JC-F = 3.26 Hz), 172.42 (d, 
JC-P = 15.07 Hz). 
11
B NMR (128.2 MHz, CD3CN):  2.83. 
31
P NMR (161.7 MHz, 
CD3CN):  30.6. 
19
F NMR (375.9 MHz; CD3CN):  -133.6. MS (ESI
-
) calcd for 3 
(C21H18BF3O2P)
-
: 400.8211, found: 401.1122. 
 
Preparation of ortho-((HO2C(CH2)2)iPr2P)C6H4(BF3) (37) 
To a stirred solution of the [ortho-(iPr2PH)C6H4(Bpin)][BF4] (0.838 g, 2.07 
mmol) in CH3CN (15 mL) was added NaNH2 (0.081 g, 2.07 mmol) at room temperature. 
The mixture was stirred for 1 h. Then, the mixture was filtered through celite to remove 
a sodium salt. The solvent was removed in vacuo affording a pale yellow powder. 
Without further purification, the powder was dissolved in toluene (15 mL) and 3-
iodoproprionic acid (0.415 g, 2.07 mmol) was added to the solution. The reaction 
mixture was heated to 90 °C for 18 h. After 18 h, toluene was removed under vacuum 
yielding a pale yellow solid. Then, the solid was dissolved in methanol (6 mL) and 
treated with a solution of KHF2 (0.485 g, 6.21 mmol) in water (6 mL). The resulting 
solution was sonicated for 15 minutes and stirred for 1 h. The mixture was extracted by 
dichloromethane (3 x 15 mL) and the organic layer was dried with MgSO4. After 
filtration, the solution was concentrated to 1 mL and treated with Et2O (15 mL), leading 
to the precipitation of 37 as a pale yellow solid (0.456 g, 66.2 % yield). 
1
H NMR (399.5 
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MHz, CD3CN):  1.25 (dd, 6H, isopropyl-CH3, 
3
JH-P = 16.78 Hz, 
3
JH-H = 7.59 Hz), 1.37 
(dd, 6H, isopropyl-CH3, 
3
JH-P = 16.78 Hz, 
3
JH-H = 7.19 Hz), 2.62 (m, 2H, -
PCH2CH2COOH), 2.90 (m, 2H, -PCH2CH2COOH), 3.37 (m, 2H, isopropyl-CH), 7.43 
(m, 1H, phenyl-CH), 7.52 – 7.64 (m, 2H, phenyl-CH), 7.97 (dd, 1H, JH-H = 7.19, 
4.39Hz). 
13
C NMR (100.5 MHz, CD3CN):  11.39 (d, JC-P = 3.52 Hz), 11.89 (d, JC-P = 
3.02 Hz), 16.35 (d, JC-P = 3.12 Hz), 17.25 (d, JC-P = 3.12 Hz), 23.69 (d, JC-P = 3.72 Hz), 
24.14 (d, JC-P = 3.72 Hz), 27.58, 127.04 (d, JC-P = 12.26 Hz), 132.53, 132.76 (d, JC-P = 
10.75 Hz), 136.19 (d, JC-P = 3.82 Hz), 136.35 (d, JC-P = 3.82 Hz). 
11
B NMR (128.2 MHz, 
CD3CN):  3.05 (q, JB-F = 47.56 Hz). 
19
F NMR (375.9 MHz, CD3CN):  -134.36. 
31
P 
NMR (161.7 MHz, CD3CN):  42.92. Mass (ESI
-
): calcd for C15H23BF3O2P (M-H)
-
, 
333.14; found 332.83. 
 
Preparation of ortho-(Ph2MeSb)C6H4(BF3) (38) 
Ortho-(Ph2MeSb)C6H4(BMes2) (0.112 g, 0.182 mmol) was treated with excess 
hydrogen fluoride pyridine in dichloromethane (2 mL) at room temperature. After being 
stirred for 18 h, the mixture was quenched by water (2 mL). The dichloromethane layer 
was separated from the mixture, dried with MgSO4, and filtered to remove MgSO4, 
respectively. The solvent was removed under reduced pressure. The residue was washed 
with Et2O (3  2 mL) yielding 38 as yellow solid (33.2 mg, 42 % yield). 
1
H NMR 
(399.5 MHz, CDCl3):  2.30 (q, 3H, JH-F = 1.53 Hz -CH3), 7.01 (d, 1H, JH-H = 7.99 Hz, 
phenyl-CH) 7.46 – 7.63 (m, 10H, phenyl-CH), 7.96 (m, 2H, phenyl-CH) 8.77 (d, 1H, JH-
H = 7.99 Hz, phenyl-CH). 
13
C NMR (100.5 MHz, CDCl3):  29.67, 128.29, 130.24, 
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132.28, 132.48, 132.85, 133.29, 134.38, 134.84, 134.98. 
11
B NMR (128.2 MHz, CDCl3): 
 2.73. 19F NMR (375.9 MHz, CDCl3):  -135.81. 
  
Crystallographic Measurements  
  Single crystals of 35 were obtained by slow diffusion of Et2O into a CH2Cl2 
solution of 35.  In addition, single crystals of 36 were obtained by slow diffusion of 
pentane into a THF solution of 36. Finally, single crystals of 37 were obtained by slow 
diffusion of CH2Cl2 from a 4:2 CH2Cl2/toluene solution of 37. The crystallographic 
measurement of 35, 36, and 37 were performed using a Bruker APEX-II CCD area 
detector diffractometer, with graphite-monochromated Mo-Kα radiation (λ = 0.71069 Å). 
A specimen of suitable size and quality was selected and mounted onto a nylon loop. 
The semi-empirical method SADABS was applied for absorption correction.
3
 The 
structure was solved by direct methods, and refined by the full-matrix least-square 
method against F
2
 with the anisotropic temperature parameters for all non-hydrogen 
atoms.  All H atoms were geometrically placed and refined using the riding model 
approximations.
4
 Data reduction and further calculations were performed using the 
Bruker SAINT+ and SHELXTL NT program packages. The crystal data are included in 
Table 2-4. 
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Table 2. Crystal data, data collections, and structure refinements of 35. 
Crystal data 35 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C13H21BF3P 
276.08 
0.25 x 0.2 x 0.2 
110(2) K 
0.71073 Å 
Orthorhombic 
Pna2(1) 
a = 11.372(4) Å  α = 90° 
b = 11.428(5) Å  β = 90° 
c = 11.129(4) Å  γ = 90° 
1446.3(10) Å
3
 
4 
1.268 g cm
-3
 
0.203 mm
-1
 
584.0 
ω, φ 
-14 → +14 
-14 → +15 
-14 → +15 
16834 
3484 [0.0393]  
3484 
163 
0.776 
0.0317, 0.0991 
0.293,  -0.183 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.0382 and b = 0.2933. 
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Table 3. Crystal data, data collections, and structure refinements of 36. 
Crystal data 36 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C21H19BF3O2P 
382.99 
0.33 x 0.07 x 0.02 
110(2) K 
0.71073 Å 
Monoclinic 
P21/c 
a = 9.163(1) Å  α = 90° 
b = 12.426(14) Å β = 100.483(2)° 
c = 17.335(2) Å γ = 90° 
1941(4) Å
3
 
4 
1.376 g cm
-3 
0.181 mm
-1
 
756.0 
ω, φ 
-9 → +10 
-14 → +14 
-20 → +19 
11319 
3212 [0.0675] 
3212 
253 
1.032 
0.0895, 0.2884 
1.001,  -0.405 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.1533 and b = 2.95. 
 
 
 
 
 
 
 53 
 
Table 4. Crystal data, data collections, and structure refinements of 37. 
Crystal data 37 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C15H23BF3O2P 
334.11 
0.17 x 0.17 x 0.06 
110(2) K 
0.71073 Å 
Monoclinic 
P21/n 
a = 8.174(8) Å  α = 90° 
b = 14.54(1) Å β = 92.57(1)° 
c = 13.76(1) Å  γ = 90° 
1634(3) Å
3 
4 
1.358 g cm
-3 
0.202 mm
-1 
704 
ω, φ 
-10 → +10 
-19 → +18 
-16 → +17 
14358 
3926 [0.0576] 
3926 
199 
1.046 
0.0483, 0.1230 
0.36,  -0.39 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.0522 and b = 0.4268. 
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Kinetic studies of the hydrolysis reactions 
As previously reported for 30,
5
 a sample of 35, 36, and 37 (5 mg) was dissolved 
in 0.2 mL CD3CN and 1.0 mL D2O phosphate buffer (pH 7.5, 500 mM). The 
19
F NMR 
spectra of 35, 36, and 37 were collected periodically. The decomposition of 
aryltrifluoroborate species were monitored by integration of the decreasing 
aryltrifluoroborate signal in conjunction with the increasing signal corresponding to free 
F
-
.  All spectra were processed using the VNMRJ Version 2.2 NMR software. The rate 
constant, kobs, was calculated using a well-established NMR method reported in the 
literature.
6 
 This method is based on the fact that the concentration in ArBF3 species is 
proportional to the 
19
F NMR integration of ArBF3 signal divided by the sum of the 
integration of ArBF3 signal and the free fluoride signal.  For convenience, the value of 
the ArBF3 integration is arbitrarily set at 100 and the free fluoride integration 
determined.  The resulting data is provided in Table 5-7. 
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Table 5. Kinetic data for the hydrolysis of 35.  The values provided for F
-
 and ArBF3 
correspond to the integration of the corresponding NMR signal. 
 
 
    
Data for 
35     
        kobs = 3.90E-05 
      exp. ratio calc. ratio 
Time 
(min) F
-
 ArBF3 
ArBF3/ 
( ArBF3+F
-
) 
ArBF3/ 
(ArBF3+F
-
) 
0 0 100 1.000 1.000 
520 3.8 100 0.96 0.98 
1280 7.7 100 0.93 0.95 
2210 11.6 100 0.90 0.92 
3160 15.1 100 0.87 0.88 
4280 18.8 100 0.84 0.85 
10100 48.3 100 0.67 0.67 
14420 76.2 100 0.57 0.57 
20110 126.2 100 0.44 0.46 
25000       0.38 
30000       0.31 
35000       0.25 
40000       0.21 
45000       0.17 
50000       0.14 
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Table 6. Kinetic data for the hydrolysis of 36. The values provided for F
-
 and ArBF3 
correspond to the integration of the corresponding NMR signal. 
 
    
Data for 
36     
        kobs = 1.50E-05 
      exp. ratio calc. ratio 
Time 
(min) F
-
 ArBF3 
ArBF3/ 
( ArBF3+F
-
) 
ArBF3/ 
(ArBF3+F
-
) 
0 0 100 1.000 1.000 
1440 3.9 100 0.96 0.98 
2940 5.3 100 0.95 0.96 
8610 12.4 100 0.89 0.88 
12990 20.7 100 0.83 0.82 
28800 53.1 100 0.65 0.65 
35000       0.59 
40000       0.55 
45000       0.51 
50000       0.47 
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Table 7. Kinetic data for the hydrolysis of 37. The values provided for F
-
 and ArBF3 
correspond to the integration of the corresponding NMR signal. 
 
Data for 37 
        Kobs = 5.2E-5 
      exp. Ratio calc. ratio 
Time (min) [F
-
] [BF3] [BF3]/([BF3]+[F
-
] [BF3]/([BF3]+[F
-
] 
0 0 100 1.000 1.000 
1030 5.4 100 0.95 0.95 
2491 14.86 100 0.87 0.88 
5367 32.58 100 0.75 0.77 
6800 43.52 100 0.70 0.70 
8240 52.59 100 0.66 0.65 
9689 63.75 100 0.61 0.60 
11189 76.21 100 0.57 0.56 
20000       0.35 
30000       0.21 
40000       0.13 
50000       0.07 
60000       0.04 
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Radiochemistry Experiments 
All chemicals obtained commercially were of analytic grade and used without 
further purification. The syringe filter and polyethersulfone membranes (pore size, 0.22 
µm; diameter, 13 mm) were obtained from Nalge Nunc International (Rochester, NY). 
Analytical reversed-phase high-performance liquid chromatography (HPLC) was 
accomplished on a Waters 515 chromatography system with a Waters 2487 dual λ 
absorbance detector (218 and 254 nm) and model 2200 scaler ratemeter radiation 
detector from Ludlum Measurements, Inc. (Sweetwater, TX). Empower 2 software from 
Waters Corporation (Milford, MA) was used to record chromatograms. HPLC was 
performed on a phenomenex Luna 5µ C18 column (250 × 4.6 mm). The flow was 1 
mL/min, with the mobile phase starting from 95% solvent A (0.1% TFA in water) and 
5% solvent B (0.1% TFA in acetonitrile) (0–2 min) to 5% solvent A and 95% solvent B 
at 22 min.  
 
Radiochemistry 
Unless otherwise noted, the reactions were performed using the following 
protocol. 18F-Fluoride was produced with an in-house cyclotron. Zwitterions 30, 35, or 
36 (dissolved in MeCN, 15 ± 5µL) was added to 30 ± 3 mCi 
18
F-fluoride in 100 ± 10 µL 
[
18
O]water (The activity/volume ratio was adjusted by dilution when necessary). The 
reaction mixture stayed at room temperature for 20 min. The final % conversion of each 
reaction was measured by loading approximately 30 µCi reaction mixture onto a reverse 
phase analytical HPLC equipped with radio detector. The retention time of [
18/19
F]30, 
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[
18/19
F]35 and [
18/19
F]36 is 18.1, 11.6, and 17.4 min, respectively. The identities of the 
compounds were confirmed by comparison of the retention times with those of the 
starting (non-radioactive) compounds as well as by co-injection of the starting and 
radiofluorinated derivatives.  
 
Specific activity 
 In order to determine the specific activity of the product after labeling, a 
standard solution was made at a concentration 0.1 mg/mL. This solution was used to 
establish a UV-HPLC calibration curve, which could be easily done by correlating the 
volume of the injection with the resulting UV peak area. To determine the specific 
activity of the product at the time of analysis, a portion of crude reaction mixture (4µL) 
was taken out. The total amount of radio-activity of the portion was measured using a 
dosimeter. The % of activity incorporated in the captor compound was then determined 
by radio-HPLC, which was then converted to the absolute amount of activity by 
multiplying the % of activity conversion with the total amount of activity (mCi). The 
specific activity of the product was calculated by dividing the total amount of product 
activity by the amount of product (µmol, based on the integration of the UV-HPLC-UV 
and determined with the calibration curve (Figure 31). For entry 1, 7 and 8, the 
experiments were repeated four times and the average values reported. The radio traces 
obtained for the four independent syntheses in entry 7 are shown in Figure 32 for 
illustrative purposes. 
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Figure 31. Calibration curves of compound 30 and 35 used for specific activity 
measurements. The standard injection volume is 200 µL. The first data point is obtained 
by diluting 10 µL of the standard solution to a total volume of 200 µL. The second data 
point is obtained by diluting 20 µL of the standard solution to a total volume of 200 µL. 
The third data point is obtained by injecting 200 µL of the stock solution. 
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Figure 32. Four representative independent 
18
F-fluorination of compound 30 using 
condition mentioned at Table 1, entry 7. HPLC was performed on a phenomenex Luna 
5µ C18 column (250 × 4.6 mm). The flow was 1 mL/min, with the mobile phase starting 
from 95% solvent A (0.1% TFA in water) and 5% solvent B (0.1% TFA in MeCN) (0–2 
min) to 5% solvent A and 95% solvent B at 22 min. 
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MicroPET Imaging  
Animal procedures were performed according to a protocol approved by the 
University of Southern California Institutional Animal Care and Use Committee. The 
animal care and use program at USC meets the requirements of the Federal Law (89-544 
and 91-570). The USC program is also accredited by the American Association for 
Accreditation of Laboratory Animals. MicroPET scans were performed on a microPET 
R4 rodent model scanner (Siemens Medical Solutions USA, Inc., Knoxville, TN). The 
scanner has a computer-controlled bed and 10.8-cm transaxial and 8-cm axial fields of 
view (FOVs). It has no septa and operates exclusively in the 3-dimensional (3D) list 
mode. Animals were placed near the center of the FOV of the scanner. For static 
microPET scans, normal nu/nu mice were injected with about 3.7 MBq (100 µCi) of 
radio products ([
18/19
F]30, [ 
18/19
F]35) via the tail vein. At 0.5 h, and 2 h post injection 
(p.i.), the mice were anesthetized with isoflurane (5% for induction and 2% for 
maintenance in 100% O2) using a knock-down box.  
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With the help of a laser beam attached to the scanner, the mice were placed in the 
prone position and near the center of the field of view of the scanner. The 3-min static 
scans were then obtained. Images were reconstructed by use of a 2-dimensional ordered-
subsets expectation maximization (OSEM) algorithm. No background correction was 
performed. Regions of interest (ROIs; 5 pixels for coronal and transaxial slices) were 
drawn over the tumor on decay-corrected whole-body coronal images. The maximum 
counts per pixel per minute were obtained from the ROI and converted to counts per 
milliliter per minute by using a calibration constant. With the assumption of a tissue 
density of 1 g/ml, the ROIs were converted to counts per gram per min. Image ROI-
derived %ID/g values were determined by dividing counts per gram per minute by 
injected dose. No attenuation correction was performed. Finally, the animals are awake 
between the scans, which can accelerate the rate of excretion.  
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CHAPTER III  
SYNTHESIS AND IN VIVO EVALUATION OF [
18
F]-ZWITTERIONIC 
ARYLTRIFLUOROBORATE/INDOMETHACIN CONJUGATES AS POTENTIAL 
PET PROBES 
 
3.1 Introduction 
Cyclooxygenase (COX) enzymes play a vital role in the biotransformation of 
arachidonic acid into a wide variety of prostaglandins, which are important mediators of 
inflammation.
67
 They are also the pharmacological targets of nonsteroidal anti-
inflammatory drugs.  There are two types of COX enzymes which are COX-1 and COX-
2.
68
  Despite similarities in amino acid sequence and three-dimensional structures, COX-
1 and COX-2 have different regulation, tissue localizations, and substrate specificity. 
The COX-1 enzyme is expressed in most tissues and plays an important role in the 
production of prostaglandins; however, the COX-2 enzyme is only expressed in a few 
normal tissues and is highly upregulated in inflamed tissues as well as in many 
premalignant and malignant tumours. Selective COX-2 inhibitors can be useful in the 
treatment of various cancers.
69,70
 Therefore, the conjugation of COX-2 inhibitors with 
fluorescent or radioactive compounds can be used for the selective imaging of 
inflammation and tumours in living beings. 
Indomethacin (Figure 33) is a powerful nonsteroidal anti-inflammatory drug that 
selectively binds and inhibits cyclooxygenase (COX) enzymes.
71-73
  Moreover, 
indomethacin also shows anticancer activity, especially gastrointestinal cancer.
74
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According to these studies, indomethacin significantly extends the lifespan of a group of 
patients suffering from cancers. Unfortunately, indomethacin manifests an 
approximately 15-fold higher selectivity for COX-1 relative to COX-2.
71-73
 The COX-1 
inhibition causes gastrointestinal toxicity and obstruct platelet function leading to 
increased bleeding times.
75
 Thus, a recent development of indomethacin based anti-
inflammatory and anticancer drugs is focused on modifying new derivatives that shows 
low COX-1 inhibitory activity.  
 
 
Figure 33. Chemical structure of the indomethacin compound. 
 
Since the COX-2 active site is about 25% larger than the COX-1 active site, 
indomethacin derivatives of larger size have been targeted, 
71-73
 for example by 
increasing the length of the carboxylic side chain or enlarging the acyl group attached to 
the indole nitrogen. 
76
 Furthermore, many different amides and esters of indomethacin 
derivatives also showed a significant COX-2 selectivity.
77
 This approach is noteworthy 
as it was applied to construct such as the carboxy-X-rhodamine conjugate (Figure 34) 
which can be used for COX-2-targeted fluorescent imaging agent.
78
 Based on the 
imaging results shown in this work, this fluorescent compound highly accumulated in 
inflamed and tumour tissues providing an ample in vivo fluorescent signal.
78
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Figure 34. Chemical structure of the carboxy-X- rhodamine conjugated indomethacin. 
  
These results suggested to us that a similar approach based on indomethacin as a 
targeting group could be extended to the design of Positron Emission Tomography 
(PET) probes for inflammation and cancer imaging.  With this objective in mind, we 
have decided to conjugate indomethacin with zwitterionic phosphonium trifluoroborates 
(Figure 35),
79
 a class of 
18
F fluoride anions captors that we developed based on the 
pioneering work of Perrin on [
18
F]-arylfluoroborates
7,11
 as PET probes.
18-20,22,23
  In this 
dissertation, we report the results of these efforts.  We also describe the radiofluorination 
of the resulting conjugates and their evaluation as PET probes in a tumour bearing 
murine model. 
 
 
          Figure 35. Chemical structures of the zwitterionic phosphonium trifluoroborates. 
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3.2 Synthesis and characterizations 
In order to connect an amine functional group to cyclooxygenase targeting 
molecule, indomethacin was linked to tert-butyl (2-aminoethyl)carbamate through the 
amide coupling reaction. The reaction of indomethacin with EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide), HOBt (1-hydroxybenzotriazole), DIEA (di-iso-
propylmethylamine) and tert-butyl (2-aminoethyl) carbamate in DMF yielded 39 as a 
white powder in 94% (Figure 36). Formation of 39 was first confirmed by 
1
H NMR 
spectroscopy which shows two broad triplets at 6.75 ppm and 7.98 ppm corresponding to 
the amide functional groups.  Since the COX-2 active site is larger than the COX-1 
active site, indomethacin derivatives with longer carboxylic chains are also good 
candidates for selective COX-2 targeting. For this reason, we have prepared two analogs 
of 39 (namely compounds 40 and 41) which feature longer diamine linkers. These 
analogs have been obtained by reaction of tert-butyl (2-aminobutyl)carbamate and tert-
butyl (2-aminooctyl)carbamate with indomethacin compound using the amide coupling 
conditions used in the synthesis of 39 (Figure 36). Using this protocol, the 
indomethacin/butyl carbamate  (40) and the indomethacin / octyl cabamate (41) have 
been obtained in 84 and 85 % yield, respectively. The 
1
H NMR spectrum of these 
derivatives shows two triplets corresponding to the two amide groups.  These signals are 
observed at 6.72 ppm and 7.97 ppm for 40 and 6.70 ppm and 7.96 ppm for 41.  With 
these new compounds in hand, we next focused on the deprotection of the the tert-butyl 
carbamate group which could be easily carried out by treatment of 39, 40, and 41 with 
50% v/v trifluoroacetic acid (TFA) in CH2Cl2 at room temperature (Figure 36).  These 
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reactions produce ethylammonium (42), butylammonium (43), and octylammonium (44) 
derivatives in high yields (97% yield for 42, 95% yield for 43, and 96% yield for 44). 
The 
1
H NMR spectra in DMSO shows a singlet broad peak corresponding to an 
ammonium (-NH3
+
) group at 7.88, 7.72, and 7.74 ppm for 42, 43, and, 44, respectively. 
The singlet 
19
F NMR signal at -74.3 ppm for 42 and -74.2 ppm for 43 and 44 indicates 
that the products were obtained as the trifluoroacetate salts. Treatment of 42, 43, and 44 
with a strong base generates the indomethacin derivatives containing a carboxylic acid-
reactive amine functionality which is suitable for an amide coupling reaction with a 
carboxylic functionalized fluoride captor. 
        
    
Figure 36. Scheme showing the synthesis of the indomethacin containing ammonium 
group with various chain lengths. 
 
 The fluoride captors/indomethacin conjugates were synthesized by reaction of 
42, 43, or 44 with the ortho-phenylene phosphine-borane/ carboxylic acid derivatives 36 
and 37 using EDCI, HOBT, and DIEA as coupling reagents (Figure 37). The di-iso-
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propylphosphonium trifluoroborate/indomethacin conjugate 45 was obtained as a pale 
yellow powder in a 57 % yield. This compound has been fully characterized. The 
presence of the phosphonium moiety is confirmed by the detection of a 
31
P NMR 
resonance at 44.2 ppm. The trifluoroborate moiety gives rise to a 
11
B NMR resonance at 
3.00 ppm and a 
19
F NMR resonance at -133.9 ppm. The connection between the 
indomethacin unit and the phosphino-borane is indicated by the detection of two 
1
H 
NMR signals at 6.67 and 6.75 ppm, corresponding to the two amide functional groups. 
Moreover, the 
1
H NMR spectrum shows two doublets of doublets at 1.18 ppm and 1.35 
ppm and a multiplet at 3.37 ppm which are the characteristic signals of the iso-propyl 
moiety. 
      
 
Figure 37. Scheme showing the synthesis of ortho-phenylene phosphine-boranes 
connecting indomethacin compound. 
 
 The diphenylphosphonium trifluoroborate derivatives 46, 47, and 48 were also 
obtained in moderate yield (62.8 % yield for 46, 58.2 % yield for 47, and 62.3 % yield 
for 48). These compounds were characterized by multinuclear NMR spectroscopy. The 
31
P NMR spectrum showed a singlet peak at 30.6 ppm for 46, 30.9 ppm for 47, and 48 
 70 
 
confirming the existence of phosphonium moiety. In addition, the trifluoroborate group 
of each compound was detected as a broad singlet signal by 
11
B NMR spectroscopy at 
2.9 ppm for 46, at 3.0 ppm for 47, and at 2.7 ppm for 48 as well as 
19
F NMR 
spectroscopy at -133.4 ppm for 46, at -131.3 ppm for 47, and at -134.1 ppm for 48. The 
1
H NMR spectrum of each compound displays two triplets at 6.70 and 6.80 ppm for 46, 
7.82 and 7.98 ppm for 47, and 7.72 and 7.96 ppm for 48 corresponding to the amide 
signals and thus confirming successful conjugation of the captors with the indomethacin 
unit. 
 
3.3 Kinetic studies 
As shown in various studies
5,79,80
, aryltrifluoroborates undergo hydrolysis in 
aqueous media producing the corresponding boronic acids according to a first order rate 
reaction (ν = kobs[ArBF3]).
4,81
 To probe the possible influence of the phosphorus 
substituents, we first investigated the hydrolysis of the bis(iso-propyl) derivative 37 by 
19
F NMR spectroscopy.  As done for 30, 35 and 36, 37 was dissolved in D2O–CD3CN 
(8/2 vol) at pH 7.5 ([phosphate buffer] = 500 mM, [ArBF3] = 20 mM with ArBF3 = 
zwitterionic trifluoroborate) and monitored periodically.  Based on the amount of ArBF3 
in solution determined by 
19
F NMR vs. times, we found that the first order hydrolysis 
rate constant of 37 (kobs = 5.2 x 10
-5
 min
-1
) is slightly higher than 35 (kobs = 3.9 x 10
-5
 
min
-1
) and 36 (kobs = 1.5 x 10
-5
 min
-1
) and noticeably higher than 30 (kobs = 3.4 x 10
-6
 
min
-1
).  These experiments confirm that the presence of iso-propyl substituents decreases 
the kinetic stability of the complexes.  A comparison between the hydrolysis rate 
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constants of 35 and 37 also show that the pendent carboxylic acid functionality plays a 
labilizing role.   
Next, we decided to examine the stability of our new indomethacin conjugates 
compounds 45, 46, 47, and 48 in aqueous media. Unfortunately, all zwitterionic 
aryltrifluoroborate/indomethacin conjugates did not dissolved in D2O–CD3CN (8/2 vol) 
phosphate buffer solution. To address this solubility problem, we decided to use the 
neutral surfactant triton X-100.  We found that all conjugates could be dissolved in 10% 
w/v triton X-100 in H2O/ DMSO (7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 mM, 
[ArBF3] = 20 mM with ArBF3 = zwitterionic trifluoroborate).  In order to get a reference 
point in this new medium, we first evaluated the stability of 37 and obtained a hydrolysis 
rate constant (kobs) of 1.2 x 10
-5 
min
-1
.  This hydrolysis rate constant is about five time 
lower than that measured in D2O–CD3CN (8/2 vol), which reflects the lower water 
content of the new H2O/ DMSO (7/3 vol) medium.  Using these new conditions, we 
observed that the hydrolysis reaction of the indomethacin conjugates is extremely slow.  
In the case of the diphenylphosphonium derivatives 46, 47, and 48, we did not see any 
evidence of hydrolysis even after 7 days. In the case of the di-iso-propylphosphonium 
derivative 45, we did notice a trace amount of free fluoride at the same period of time. 
By expanding this experiment to a longer timescale, we have been able to calculate kobs 
= 4.0 x 10
-7
 for 45. The kinetic plots for the hydrolysis of 37 and 45 were demonstrated 
in Figure 38. These results are consistent with the previous studies on the stability of the 
ortho-phosphonium aryltrifluoroborates that the rate of hydrolysis of the 
diphenylphosphonium derivatives 30 and 36 is slower than that of the di-iso-
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propylphosphonium derivative 35 and 37, respectively.
79,80
 These results also show that 
the targeting group, in this case indomethacin, may have a drastic effect on the 
hydrolytic stability of the trifluoroborate.  
 
 
Figure 38. Kinetic plots for the hydrolysis of 37 and 45 in aqueous conditions. 
 
3.4 Radiochemistry
3
  
  Using the conditions that we developed for the radiofluorination of zwitterionic 
aryltrifluoroborates,
79
 we decided to radiolabel the novel indomethacin conjugates by 
18
F-
19
F isotopic exchange.  This radiosynthetic approach, which is gaining interest, has 
also been used for the radiofluorination of main group molecules, for example, BF4
-82
, 
organoboranes
14,30,83
 and fluorosilane derivatives.
84,85
 In a typical experiment,  46 (0.28 
                                                 
3
 This experiment was carried out by our collaborator, Dr. Zibo Li, at department of 
Radiology, University of Southern California, Los Angeles, CA. 
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μmol) was dissolved in DMSO (20 μL) and mixed with a solution of irradiated [18O] 
water (100μL, pH 2) containing 45 mCi of 18F at 75ºC for 10 minutes (Figure 39).  The 
same approach was applied to the radiofluorination of conjugate 45. 
 
 
Figure 39. Reaction scheme showing direct 
18
F-
19
F isotopic exchange reaction 
proceeded for the radiolabeling of 45 and 46 in aqueous solution. 
 
  As shown in the crude radio-signal HPLC profile (Figure 40), [
18/19
F]-45 and 
[
18/19
F]-46 are cleanly obtained by the isotopic exchange process. The identity of [
18/19
F]-
45 and [
18/19
F]-46 were confirmed by comparing the radio HPLC trace with the elution 
time of the non-labelled analogue. The radiochemical yields based on the radio-activity 
of isolated product and the starting radio-activity were calculated as 7% and 12% for 
[
18/19
F]-45 and [
18/19
F]-46, respectively. 
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Figure 40. Crude radio-signal HPLC profiles obtained in the radiofluorination of 
[
18/19
F]46 (A) and [
18/19
F]45 (B). 
 
3.5 In vivo imaging studies
4
 
  Next, we endeavoured to evaluate the in vivo imaging potential of these probes in 
a murine model bearing human gliobastoma (U87MG), a type of tumours known to 
overexpress COX-2
20
.  We injected 0.02 mCi of [
18/19
F]-45 and [
18/19
F]-46 into female 
nude mice. At 15, 40, and 90 minutes post-injection, static microPET scans were 
obtained.  The resulting sagittal images for [
18/19
F]-45 and [
18/19
F]-46 are shown in Figure 
41 (above). At 15 min post injection, [
18/19
F]-46 showed a clear localization in the liver 
because of its lipophilic property while [
18/19
F]-45 was more quickly cleared through the 
urinary track as indicated by the appearance of a signal in the bladder of the animal. 
Surprisingly, [
18/19
F]-45 was the only tracer that accumulated into the tumour. In the 
                                                 
4
 This experiment was carried out by our collaborator, Dr. Zibo Li, at department of 
Radiology, University of Southern California, Los Angeles, CA. 
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microPET quantification analysis, the tumour uptake of  [
18/19
F]-45 was determined to be 
0.42, 0.47, and 0.55 %ID/g at 15, 40, and 90 min post-injection as shown in Figure 41 
(below). This finding indicates that the indomethacin conjugate with more hydrophilic 
radio-prosthetic group ([
18/19
F]-45) display better tumour binding properties than the 
more hydrophobic analogue ([
18/19
F]-46).  These results are important because that they 
show that changes in the structure of the radio-prosthetic group have an impact on the 
tumour binding property of the tracers. In addition, we also observed that the [
18/19
F]-45 
undergoes a high degree of defluorination in vivo as confirmed by a distinct skeletal 
signal especially obvious in the sagittal images at 40 min and 90 min post-injection. 
MicroPET quantification analysis shows that the use of [
18/19
F]-45 leads to a bone uptake 
of 2.8, 3.1, and 4.7 %ID/g at 15, 40, and 90 min post-injection (Figure 41 (below)).  
These values, which are significantly higher than those measured for [
18/19
F]-46 (0.6, 0.8, 
and 1.2 %ID/g at 15, 40, and 90 min post-injection), can be correlated to the higher 
hydrolysis rate constants measured for the di-iso-propyl derivatives when compared to 
their diphenyl analogues. 
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Figure 41. (Above) Decay-corrected whole-body microPET Sagittal images of nude 
mice bearing U87MG tumor from a static scan at 15, 40, and 90 min after injection of 
[
18/19
F]45 and [
18/19
F]46. The images are corrected based on the injected activity. The 
signal intensity is reported in % of the injected dose per gram (%ID/g). (Below) 
MicroPET quantifications for U87MG tumor and bone uptake for [
18/19
F]45 and 
[
18/19
F]46.   
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3.6 Conclusion 
  This report establishes that phosphonium aryltrifluoroborates can be conjugated 
with molecules of biological interest such as indomethacin using simple synthetic 
approaches. The resulting conjugates are amenable to late stage radiofluorination via 
simple isotopic 
18
F-
19
F exchange in aqueous solution. This approach affords PET probes 
which have been tested in vivo in a tumour bearing murine model.  One of the key 
findings of these animal studies is the influence of the captor structure which largely 
governs the bio-distribution of the probe and its affinity for the tumour. 
     
3.7 Experimental   
General consideration  
Tert-butyl (2-aminoethyl) carbamate
86
, tert-butyl (4-aminobutyl) carbamate
86
, 
tert-butyl (8-Aminooctyl) carbamate
86
, ortho-(Ph2(CH2CH2COOH)P) C6H4(BF3)
79
, and 
[ortho-(iPr2PH)C6H4(Bpin)][BF4]
59
 were synthesized according to the published 
procedure. Indomethacin was purchased from Enzo life sciences; 1,2-diaminoethane was 
purchased from Mallinckrodt; 1,4-diaminobutane and 1,8-diaminooctane were purchased 
from Sigma Aldrich; hydroxylbenzotriazole (HOBT) was purchased from Advanced 
ChemTech; tert-butylcarbamate, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI), N, N-di-iso-propylethylamine, and trifluoroacetic acid were purchased from 
Alfar Aesar. All chemicals were used without further purification. CH2Cl2 were dried by 
passing through an alumina column. Electrospray mass spectra were acquired from a 
MDS Sciex API QStar Pulsar. NMR spectra were recorded on a Varian Unity Inova 400 
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NMR and an Inova 500B spectrometer at ambient temperature. Chemical shifts are given 
in ppm, and are referenced to residual 
1
H and 
13
C solvent signals as well as external 
H3PO4 (
31
P NMR) and BF3-Et2O (
11
B NMR and 
19
F NMR). 
 
Synthesis of tert-butyl (2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)ethyl)carbamate (39) 
To a stirred solution of indomethacin (0.870 g, 2.43 mmol) in DMF (25 mL) was 
added HOBt (0.558 g, 3.65 mmol) and EDCI (0.512 g, 2.67 mmol) at 0 °C. The solution 
was stirred at 0 °C for 15 min. After 15 min, tert-butyl (2-aminoethyl) carbamate (1.170 
g, 7.32 mmol) and DIEA (1.30 mL, 7.36 mmol) were added to the mixture. The reaction 
mixture was stirred at room temperature for 16 h. Removal of solvent in vacuo afforded 
a residue, to which 30 mL water was added and extracted with EtOAc (3 x 25 mL). The 
organic layer was dried over MgSO4, concentrated in vacuo, and precipitated from 
hexane affording 39 as a yellow powder (1.260 g, 93.8 % yield). 
1
H NMR (299.9 MHz, 
DMSO-d6):  1.37 (s, 9H, CH3), 2.22 (s, 3H, CH3), 3.00 (m, 2H, -CH2-), 3.09 (m, 2H, -
CH2-), 3.50 (s, 2H, CH2CO), 3.77 (s, 3H, OCH3), 6.72 (dd, JH-H = 9.00, 2.34 Hz, 1H, 
indolyl H-6), 6.79 (t, JH-H = 4.80 Hz, 1H, amide-H), 6.97 (d, JH-H = 9.00 Hz, 1H, indolyl 
H-7), 7.10 (d, JH-H = 2.40 Hz, indolyl H-4), 7.65 (d, JH-H = 8.10 Hz, 2H, p-chlorobenzoyl 
H-3, H-5), 7.71 (d, JH-H = 8.40 Hz, 2H, p-chlorobenzoyl H-2, H-6), 8.04 (t, JH-H = 5.40 
Hz, 1H, amide-H). 
13
C NMR (125.58 MHz, DMSO-d6):  13.81, 28.62, 31.58, 55.83, 
78.10, 102.29, 111.71, 114.64, 115.05, 129.46, 130.71, 131.32, 131.57, 134.69, 135.57, 
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137.96, 155.98, 156.04, 168.27, 169.95. Mass (ESI
+
): calcd for C26H30ClN3O5Na 
(M+Na)
+
, 522.98; found 522.16. 
 
 
Figure 42. 2-Dimentional NMR spectrum of 39. 
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Synthesis of tert-butyl (4-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)butyl)carbamate (40) 
To a stirred solution of indomethacin (0.870 g, 2.43 mmol) in DMF (25 mL) was 
added HOBt (0.558 g, 3.65 mmol) and EDCI (0.512 g, 2.67 mmol) at 0 °C. The solution 
was stirred at 0 °C for 15 min. After 15 min, tert-butyl (2-aminoethyl) carbamate (1.372 
g, 7.29 mmol) and DIEA (1.30 mL, 7.36 mmol) were added to the mixture. The reaction 
mixture was stirred at room temperature for 16 h. Removal of solvent in vacuo afforded 
a residue, to which 50 mL water was added and extracted with EtOAc (3 x 50 mL). The 
organic layer was dried over MgSO4, concentrated in vacuo, and precipitated from 
hexane affording 40 as a yellow powder (1.072 g, 83.6 % yield). 
1
H NMR (499.4 MHz, 
DMSO-d6):  1.37 (s, br, 13H, CH3 and -CH2-), 2.23 (s, 3H, CH3), 2.89 (m, 2H, -CH2-), 
3.04 (m, 2H, -CH2-), 3.49 (s, 2H, CH2CO), 3.77 (s, 3H, OCH3), 6.71 (dd, JH-H = 9.49, 
2.75 Hz, 1H, indolyl H-6), 6.77 (t, JH-H = 5.50 Hz, 1H, amide-H), 6.95 (d, JH-H = 8.49 Hz, 
1H, indolyl H-7), 7.12 (d, JH-H = 2.35 Hz, indolyl H-4), 7.65 (d, JH-H = 8.49 Hz, 2H, p-
chlorobenzoyl H-3, H-5), 7.70 (d, JH-H = 8.49 Hz, 2H, p-chlorobenzoyl H-2, H-6), 8.02 
(t, JH-H = 5.49 Hz, 1H, amide-H). 
13
C NMR (125.59 MHz, DMSO-d6):  13.85, 27.00, 
27.46, 28.73, 31.64, 38.96, 55.89, 77.81, 102.31, 111.74, 114.93, 115.02, 129.51, 
130.75, 131.40, 131.62, 134.76, 135.56, 138.01, 156.02, 156.05, 168.33, 169.67. Mass 
(ESI
+
): calcd for C28H34ClN3O5Li (M+Li)
+
, 534.23; found 534.21. 
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Figure 43. 2-Dimentional NMR spectrum of 40. 
 
Synthesis of tert-butyl (8-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl) 
acetamido)octyl)carbamate (41) 
To a stirred solution of indomethacin (0.870 g, 2.43 mmol) in DMF (25 mL) was 
added HOBt (0.558 g, 3.65 mmol) and EDCI (0.512 g, 2.67 mmol) at 0 °C. The solution 
was stirred at 0 °C for 15 min. After 15 min, tert-butyl (2-aminoethyl) carbamate (1.782 
g, 7.29 mmol) and DIEA (1.30 mL, 7.36 mmol) were added to the mixture. The reaction 
mixture was stirred at room temperature for 16 h. Removal of solvent in vacuo afforded 
a residue, to which 50 mL water was added and extracted with EtOAc (3 x 50 mL). The 
organic layer was dried over MgSO4, concentrated in vacuo, and precipitated from 
hexane affording 41 as a yellow powder (1.211 g, 85.3 % yield). 
1
H NMR (499.4 MHz, 
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DMSO-d6):  1.20 (s, br, 8H, -CH2-), 1.37 (s, br, 13H, CH3 and -CH2-), 2.23 (s, 3H, 
CH3), 2.88 (m, 2H, -CH2-), 3.05 (m, 2H, -CH2-), 3.48 (s, 2H, CH2CO), 3.76 (s, 3H, 
OCH3), 6.71 (dd, JH-H = 8.99, 2.10 Hz, 1H, indolyl H-6), 6.75 (t, JH-H = 4.99 Hz, 1H, 
amide-H), 6.95 (d, JH-H = 9.49 Hz, 1H, indolyl H-7), 7.12 (d, JH-H = 2.10 Hz, indolyl H-
4), 7.65 (d, JH-H = 8.99 Hz, 2H, p-chlorobenzoyl H-3, H-5), 7.69 (d, JH-H = 7.99 Hz, 2H, 
p-chlorobenzoyl H-2, H-6), 8.00 (t, JH-H = 5.99 Hz, 1H, amide-H). 
13
C NMR (125.59 
MHz, DMSO-d6):  13.85, 26.72, 26.83, 28.74, 29.17, 29.24, 29.61, 29.95, 31.71, 39.11, 
55.85, 77.73, 102.35, 111.68, 114.99, 129.49, 130.75, 131.36, 131.61, 134.77, 135.53, 
138.01, 156.01, 168.32, 169.62. Mass (ESI
+
): calcd for C32H42ClN3O5Li (M+Li)
+
, 
590.30; found 590.27. 
 
 
Figure 44. 2-Dimentional NMR spectrum of 41. 
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Synthesis of 2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido) 
ethanaminium trifluoroacetate (42) 
Compound 39 (1.260 g, 2.521 mmol) was dissolved in 50%v/v solution of 
trifluorocarboxylic acid (TFA) in dichloromethane (20 mL). The reaction mixture was 
stirred at room temperature for 24 h. Then, the solution was concentrated in vacuo to a 
volume of 2 mL and hexane (20 mL) was added to precipitate 42 as a light brown solid 
(1.256 g, 96.9 % yield). 
1
H NMR (299.9 MHz, DMSO-d6):  2.22 (s, 3H, CH3), 2.86 (m, 
2H, CH2C), 3.29 (m, 2H, CCH2), 3.53 (s, 2H, CH2CO), 3.75 (s, 3H, OCH3), 6.71 (dd, JH-
H = 9.00, 2.55 Hz, 1H, indolyl H-6), 6.94 (d, JH-H = 9.30 Hz, 1H, indolyl H-7), 7.08 (d, 
JH-H = 2.43 Hz, indolyl H-4), 7.64 (d, JH-H = 8.70 Hz, 2H, p-chlorobenzoyl H-3, H-5), 
7.69 (d, JH-H = 8.70 Hz, 2H, p-chlorobenzoyl H-2, H-6), 7.82 (s, br, 3H, NH3
+
), 8.23 (m, 
1H,  NHCOCH2). 
13
C NMR (125.58 MHz, DMSO-d6):  13.36 31.07 36.66 38.66 55.42 
101.93 111.21 113.90 114.57 129.06 130.31 130.33 131.16 134.21 135.34 137.65 
155.59 158.47 (q, JC-F = 36.42 Hz) 167.87 170.38. 
19
F NMR (469.92 MHz, DMSO-d6): 
 -74.32. Mass (ESI+): calcd for C21H23ClN3O3 (M+H)
+
, 400.50; found 400.12. 
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Figure 45. 2-Dimentional NMR spectrum of 42. 
 
 
Synthesis of 4-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido) 
butan-1-aminium trifluoroacetate (43) 
Compound 40 (1.072 g, 2.030 mmol) was dissolved in 50%v/v solution of 
trifluorocarboxylic acid (TFA) in dichloromethane (20 mL). The reaction mixture was 
stirred at room temperature for 24 h. Then, the solution was concentrated in vacuo to a 
volume of 2 mL and hexane (20 mL) was added to precipitate 43 as a light brown solid 
(1.047 g, 95.2 % yield). 
1
H NMR (499.4 MHz, DMSO-d6):  1.43 – 1.56 (m, 4H, -CH2-
), 2.24 (s, 3H, CH3), 2.79 (m, 2H, -CH2-), 3.07 (m, 2H, -CH2-), 3.51 (s, 2H, CH2CO), 
3.77 (s, 3H, OCH3), 6.72 (dd, JH-H = 9.49, 2.00 Hz, 1H, indolyl H-6), 6.94 (d, JH-H = 9.49 
Hz, 1H, indolyl H-7), 7.12 (d, JH-H = 2.25 Hz, indolyl H-4), 7.65 (d, JH-H = 8.49 Hz, 2H, 
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p-chlorobenzoyl H-3, H-5), 7.69 (d, JH-H = 8.49 Hz, 2H, p-chlorobenzoyl H-2, H-6), 7.72 
(s, br, 3H, NH3
+
), 8.11 (t, JH-H = 5.49 Hz, 1H, amide-H). 
13
C NMR (125.59 MHz, 
DMSO-d6):  13.85, 24.98, 26.66, 31.61, 38.54, 39.00, 55.90, 102.41, 111.63, 114.80, 
115.01, 129.52, 130.75, 131.38, 131.62, 134.71, 135.62, 138.07, 156.01, 158.81 (q, JC-F 
= 36.54 Hz), 168.32, 169.85. 
19
F NMR (469.92 MHz, DMSO-d6):  -74.19. Mass 
(ESI
+
): calcd for C23H27ClO3N3 (M+H)
+
, 428.17; found 428.14. 
 
 
Figure 46. 2-Dimentional NMR spectrum of 43. 
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Synthesis of 8-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido) 
octan-1-aminium trifluoroacetate (44) 
Compound 41 (0.946 g, 1.620 mmol) was dissolved in 50%v/v solution of 
trifluorocarboxylic acid (TFA) in dichloromethane (20 mL). The reaction mixture was 
stirred at room temperature for 24 h. Then, the solution was concentrated in vacuo to a 
volume of 2 mL and hexane (20 mL) was added to precipitate 44 as a light brown solid 
(0.926 g, 95.7 % yield). 
1
H NMR (499.4 MHz, DMSO-d6):  1.23 (s, br, 8H, -(CH2)4-), 
1.39 (m, 2H, -CH2-), 1.50 (m, 2H, -CH2-), 2.23 (s, 3H, CH3), 2.76 (m, 2H, -CH2-), 3.05 
(m, 2H, -CH2-), 3.49 (s, 2H, CH2CO), 3.77 (s, 3H, OCH3), 6.71 (dd, JH-H = 9.00, 2.15 
Hz, 1H, indolyl H-6), 6.95 (d, JH-H = 9.00 Hz, 1H, indolyl H-7), 7.13 d, JH-H = 2.15 Hz, 
indolyl H-4), 7.65 (d, JH-H = 8.49 Hz, 2H, p-chlorobenzoyl H-3, H-5), 7.69 (d, JH-H = 
8.49 Hz, 2H, p-chlorobenzoyl H-2, H-6), 7.72 (s, br, 3H, NH3
+
), 8.05 (t, JH-H = 5.49 Hz, 
1H, amide-H). 
13
C NMR (125.59 MHz, DMSO-d6):  13.77, 26.16, 26.68, 27.38, 28.88, 
28.96, 29.53, 31.64, 39.03, 55.79, 55.81, 102.30, 111.62, 114.96, 116.27, 118.66, 
129.44, 130.69, 131.30, 131.54, 134.69, 135.47, 137.94, 155.95, 158.63 (q, JC-F = 31.78 
Hz), 168.26, 169.61. 
19
F NMR (469.92 MHz, DMSO-d6):  -73.18. Mass (ESI
+
): calcd 
for C27H35ClO3N3 (M+H)
+
, 484.24; found 484.18.
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Figure 47. 2-Dimentional NMR spectrum of 44. 
 
Synthesis of (2-((3-((2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl) 
acetamido)ethyl)amino)-3-oxopropyl)diisopropylphosphonio)phenyl) trifluoroborate 
(45) 
To a stirred solution of ortho-(iPr2(CH2CH2COOH)P)C6H4(BF3) (0.288 g, 0.86 
mmol) in DMF (25 mL) was added HOBt (0.198 g, 1.29 mmol) and EDCI (0.182 g, 0.95 
mmol) at 0 °C. In the separated vial, DIEA (0.45 mL, 2.58 mmol) was added to a 
solution of compound 42 (0.575 g, 1.12 mmol) in DMF (5 mL). Then, the solution of 
compound 42 was transferred to the solution of ortho-(iPr2(CH2CH2COOH)P)C6H4(BF3) 
at 0 °C. The reaction mixture was stirred at room temperature for 16 h. Removal of 
solvent in vacuo afforded a residue, to which 30 mL water was added and extracted with 
EtOAc (3 x 25 mL). Combined organic layer was washed by 2 M HCl (3 x 30 mL), 
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saturated NaHCO3 (3 x 30 mL), and brine (1 x 30 mL), respectively. Finally, the washed 
organic layer was dried over MgSO4, concentrated in vacuo, and precipitated from 
hexane affording 45 as a yellow powder (0.351 g, 57.03 % yield). 
1
H NMR (499.4 MHz, 
CD3CN):  1.14 (dd, 6H, isopropyl-CH3, 
3
JH-P = 16.48 Hz, 
3
JH-H = 7.49 Hz), 1.31 (dd, 
6H, isopropyl-CH3, 
3
JH-P = 16.48 Hz, 
3
JH-H = 7.49 Hz), 2.25 (s, 3H, CH3), 2.35 (m, 2H, 
CH2CH2P), 2.76 (m, 2H, CH2CH2P), 3.18 (m, 4H, NHCH2CH2NH), 3.32 (m, 2H, 
isopropyl-CH), 3.53 (s, 2H, CH2), 3.76 (s, 3H, OCH3), 6.62 (s, br, 1H, amide-H), 6.64 
(dd, 1H, JH-H = 8.90, 2.40 Hz, indolyl H-6), 6.70 (s, br, 1H, amide-H), 6.94 (d, 1H, JH-H 
= 9.00 Hz, indolyl H-7), 6.97 (d, 1H, JH-H = 2.40 Hz, indolyl H-4), 7.37 (m, 1H), 7.46 – 
7.58 (m, 4H), 7.68 (m, 2H), 7.93 (m, 1H). 
13
C NMR (125.59 MHz, CD3CN):  13.01, 
16.39 (d, 
2
JC-P = 2.14 Hz), 17.25 (d, 
2
JC-P = 2.14 Hz), 23.73 (d, 
1
JC-P = 4.40 Hz), 24.08 
(d, 
1
JC-P = 4.40 Hz), 28.93 (d, 
1
JC-P = 4.02 Hz), 31.57, 39.33, 39.54, 55.43, 101.41, 
111.61, 113.77, 115.19, 126.85, 126.93, 129.14, 129.18, 131.06, 131.18, 131.37, 132.34 
(d, JC-P = 3.39 Hz), 132.60, 132.68, 134.69, 136.11 (d, JC-P = 3.89 Hz), 136.24 (d, JC-P = 
3.52 Hz), 136.34, 138.55, 156.22, 168.49, 170.39, 170.49, 170.60. 
11
B NMR (128.2 
MHz, CD3CN):  3.00. 
19
F NMR (375.9 MHz, CD3CN):  -133.9. 
31
P NMR (161.7 
MHz, CD3CN):  44.2. Mass (ESI
+
): calcd for C36H43ClN3O4PBF3Li (M+Li)
+
, 722.91; 
found 722.30. 
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Figure 48. 2-Dimentional NMR spectrum of 45. 
 
Synthesis of (2-((3-((2-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)ethyl)amino)-3-oxopropyl)diphenylphosphonio)phenyl) trifluoroborate 
(46) 
To a stirred solution of ortho-(Ph2(CH2CH2COOH)P)C6H4(BF3) (0.280 g, 0.53 
mmol) in DMF (25 mL) was added HOBt (0.122 g, 0.80 mmol) and EDCI (0.112 g, 0.58 
mmol) at 0 °C. In the separated vial, DIEA (0.28 mL, 1.60 mmol) was added to a 
solution of compound 42 (0.409 g, 0.80 mmol) in DMF (5 mL). Then, the solution of 
compound 42 was transferred to the solution of ortho-(Ph2(CH2CH2COOH)P)C6H4(BF3) 
at 0 °C. The reaction mixture was stirred at room temperature for 16 h. Removal of 
solvent in vacuo afforded a residue, to which 30 mL water was added and extracted with 
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EtOAc (3 x 25 mL). Combined organic layer was washed by 2 M HCl (3 x 30 mL), 
saturated NaHCO3 (3 x 30 mL), and brine (1 x 30 mL), respectively. Finally, the washed 
organic layer was dried over MgSO4, concentrated in vacuo, and precipitated from 
hexane obtaining 46 as a yellow powder (0.261 g, 62.83 % yield)
 1
H NMR (499.4 MHz, 
CD3CN):  2.27 (s, 3H, CH3), 2.46 (m, 2H, CH2CH2P), 3.17 (s, br, 4H, NHCH2CH2NH), 
3.56 (m, 2H, CH2CH2P), 3.56 (s, 2H, CH2), 3.79 (s, 3H, OCH3), 6.62 (dd, 1H, JH-H = 
8.99, 2.35 Hz, indolyl H-6), 6.68 (s, br, 1H, amide-H), 6.78 (s, br, 1H, amide-H), 6.96 (d, 
1H, JH-H = 8.49 Hz, indolyl H-7), 7.02 (d, 1H, JH-H = 1.70 Hz, indolyl H-4), 7.16 (dd, 
1H, phenyl-CH, 
3
JH-P = 13.98 Hz, 
3
JH-H = 6.49 Hz), 7.36 (m, 1H, phenyl-CH), 7.53 – 
7.81 (m, 11H, phenyl-CH), 7.99 (m, 1H, phenyl-CH). 
13
C NMR (125.59 MHz, CD3CN): 
 12.98, 29.44, 31.56, 39.19, 39.57, 55.43, 101.43, 111.57, 113.82, 115.13, 122.39, 
123.08, 127.06, 127.17, 129.12 (d, JC-P = 2.26 Hz), 129.16, 129.48, 129.59, 129.68, 
131.05, 131.20, 131.35, 132.95, 133.02, 133.22 (d, JC-P = 3.77 Hz), 133.42, 133.49, 
133.83 (d, JC-P = 3.01 Hz), 134.72, 135.17, 135.28, 135.41, 135.54, 136.31, 138.51, 
156.17, 168.49, 170.34, 170.38, 170.51. 
 11
B NMR (128.2 MHz, CD3CN):  2.88. 
19
F 
NMR (375.9 MHz, CD3CN):  -133.4. 
31
P NMR (161.7 MHz, CD3CN):  30.6. Mass 
(ESI
+
): calcd for C42H39ClN3O4PBF3Li (M+Li)
+
, 790.25; found 790.23. 
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Figure 49. 2-Dimentional NMR spectrum of 46. 
 
Synthesis of (2-((3-((4-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)butyl)amino)-3-oxopropyl)diphenylphosphonio)phenyl) trifluoroborate 
(47) 
To a stirred solution of ortho-(Ph2(CH2CH2COOH)P)C6H4(BF3) (0.235 g, 0.445 
mmol) in DMF (25 mL) was added HOBt (0.102 g, 0.670 mmol) and EDCI (0.094 g, 
0.489 mmol) at 0 °C. I n the separated vial, DIEA (0.24 mL, 1.350 mmol) was added to 
a solution of compound 43 (0.362 g, 0.667 mmol) in DMF (5 mL). Then, the solution of 
compound 43 was transferred to the solution of ortho-(Ph2(CH2CH2COOH)P)C6H4(BF3) 
at 0 °C. The reaction mixture was stirred at room temperature for 16 h. Removal of 
solvent in vacuo afforded a residue, to which 30 mL water was added and extracted with 
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EtOAc (3 x 30 mL). Combined organic layer was washed by 2 M HCl (3 x 30 mL), 
saturated NaHCO3 (3 x 30 mL), and brine (1 x 30 mL), respectively. Finally, the washed 
organic layer was dried over MgSO4, concentrated in vacuo, and precipitated from 
hexane obtaining 47 as a yellow powder (0.210 g, 58.2 % yield). 
1
H NMR (499.4 MHz, 
DMSO-d6):  1.35 (s, br, 4H, -CH2CH2-), 2.23 (s, 3H, CH3), 2.45 (m, 2H, CH2CH2P), 
2.95 (dt, 2H, JH-H = 5.49, 6.49 Hz, NHCH2(CH2)2CH2NH), 3.00 (dt, 2H, JH-H = 5.49, 
6.49 Hz, NHCH2(CH2)2CH2NH), 3.48 (s, 2H, -CH2-), 3.64 (m, 2H, CH2CH2P), 3.74 (s, 
3H, OCH3), 6.66 (dd, 1H, JH-H = 9.49, 2.05 Hz, indolyl H-6), 6.89 (d, 1H, JH-H = 8.99 
Hz, indolyl H-7), 7.00 (dd, 1H, phenyl-CH, 
3
JH-P = 14.48 Hz, 
3
JH-H = 7.49 Hz), 7.07 (d, 
1H, JH-H = 2.75 Hz, indolyl H-4), 7.32 (m, 1H, phenyl-CH), 7.53 – 7.67 (m, 11H, 
phenyl-CH), 7.74 (m, 2H, phenyl-CH), 7.82 (m, 2H, phenyl-CH), 7.98 (m, 1H, phenyl-
CH). 
13
C NMR (125.59 MHz, DMSO-d6):  13.85, 19.37, 19.83, 26.85, 27.04, 29.28, 
31.64, 38.84, 38.95, 55.88, 102.33, 111.71, 114.93, 115.00, 119.11, 119.77, 122.28, 
122.96, 127.36, 127.46, 129.51, 129.92, 130.02, 130.73, 131.38, 131.61, 133.20 (d, JC-P 
= 2.89 Hz), 133.64, 133.72, 134.04 (d, JC-P = 2.26 Hz), 134.74, 134.81, 134.93, 135.56, 
138.02, 156.00, 168.32, 169.34, 169.47, 169.69. 
11
B NMR (128.2 MHz, DMSO-d6):  
3.01. 
19
F NMR (375.9 MHz, DMSO-d6):  -131.3. 
31
P NMR (161.7 MHz, DMSO-d6):  
30.9. Mass (MALDI
+
): calcd for C44H43O4N3ClPBF3Li (M+Li)
+
, 818.29; found 818.10.
  
 93 
 
 
Figure 50. 2-Dimentional NMR spectrum of 47. 
 
Synthesis of (2-((3-((8-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)octyl)amino)-3-oxopropyl)diphenylphosphonio)phenyl) trifluoroborate 
(48) 
To a stirred solution of ortho-(Ph2(CH2CH2COOH)P)C6H4(BF3) (0.227 g, 0.429 
mmol) in DMF (25 mL) was added HOBt (0.099 g, 0.646 mmol) and EDCI (0.090 g, 
0.469 mmol) at 0 °C. In the separated vial, DIEA (0.22 mL, 1.292 mmol) was added to a 
solution of compound 44 (0.513 g, 0.858 mmol) in DMF (5 mL). Then, the solution of 
compound 44 was transferred to the solution of ortho-(Ph2(CH2CH2COOH)P)C6H4(BF3) 
at 0 °C. The reaction mixture was stirred at room temperature for 16 h. Removal of 
solvent in vacuo afforded a residue, to which 30 mL water was added and extracted with 
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EtOAc (3 x 30 mL). Combined organic layer was washed by 2 M HCl (3 x 30 mL), 
saturated NaHCO3 (3 x 30 mL), and brine (1 x 30 mL), respectively. Finally, the washed 
organic layer was dried over MgSO4, concentrated in vacuo, and precipitated from 
hexane obtaining 48 as a yellow powder (0.233 g, 62.3 % yield). 1H NMR (499.4 MHz, 
DMSO-d6):  1.20 (m, 8H, -(CH2)4-), 1.31 (s, br, 2H, -CH2-), 1.39 (s, br, 2H, -CH2-), 
2.46 (m, 2H, CH2CH2P), 2.97 (dt, 2H, JH-H = 6.49, 6.99 Hz, NHCH2(CH2)6CH2NH), 
3.04 (dt, 2H, JH-H = 5.99, 6.49 Hz, NHCH2(CH2)6CH2NH), 3.49 (s, 2H, -CH2-), 3.64 (m, 
2H, CH2CH2P), 3.76 (s, 3H, OCH3), 6.71 (dd, 1H, JH-H = 8.99, 3.00 Hz, indolyl H-6), 
6.95 (d, 1H, JH-H = 8.99 Hz, indolyl H-7), 7.04 (dd, 1H, phenyl-CH, 
3
JH-P = 13.98 Hz, 
3
JH-H = 7.49 Hz), 7.13 (d, 1H, JH-H = 2.75 Hz, indolyl H-4), 7.36 (m, 1H, phenyl-CH), 
7.56 – 7.71 (m, 11H, phenyl-CH), 7.78 (m, 2H, phenyl-CH), 7.85 (m, 2H, phenyl-CH), 
8.02 (m, 1H, phenyl-CH). 
13
C NMR (125.59 MHz, DMSO-d6):  13.86, 26.81, 26.84, 
29.13, 29.17, 29.19, 29.29, 29.39, 29.60, 31.70, 39.10, 39.25, 55.87, 102.36, 111.68, 
115.00, 119.14, 119.81, 122.29, 122.97, 127.34, 127.45, 129.50, 129.91, 130.00, 130.75, 
131.37, 131.61, 133.19 (d, JC-P = 3.14 Hz), 133.66, 133.74, 134.03 (d, JC-P = 3.01 Hz), 
134.76, 135.53, 138.01, 156.01, 168.32, 169.28, 169.41, 169.64. 
11
B NMR (128.2 MHz, 
DMSO-d6):  2.65. 
19
F NMR (375.9 MHz, DMSO-d6):  -134.1. 
31
P NMR (161.7 MHz, 
DMSO-d6):  30.9.   Mass (MALDI
+
): calcd for C44H43O4N3ClPBF3Li (M+Li)
+
, 875.11; 
found 875.34. 
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Figure 51. 2-Dimentional NMR spectrum of 48. 
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Kinetic studies 
A sample of 37 (5 mg) was dissolved in 0.2 mL CD3CN and 0.8 mL D2O 
phosphate buffer (pH 7.5, 500 mM). The 
19
F NMR spectrum of 37 was collected 
periodically. The decomposition of aryltrifluoroborate species were monitored by 
integration of the decreasing aryltrifluoroborate signal in conjunction with the increasing 
signal corresponding to free F
-
. In addition, a sample of 37, 45, 46, 47, and 48 was also 
dissolved in 0.3 mL DMSO and 0.7 mL of 10% w/v triton X-100 in H2O phosphate 
buffer (pH 7.5, 500 mM) for the stability test. The rate of aryltrifluoroborate  hydrolysis 
was monitored by 
19
F NMR spectroscopy. All spectra were processed using the VNMRJ 
Version 2.2 NMR software. The rate constant, kobs, was calculated using a well-
established NMR method reported in the literature.
4 
 This method is based on the fact 
that the concentration in ArBF3 species is proportional to the 
19
F NMR integration of 
ArBF3 signal divided by the sum of the integration of ArBF3 signal and the free fluoride 
signal.  For convenience, the value of the ArBF3 integration is arbitrarily set at 100 and 
the free fluoride integration determined. The resulting data is provided in Table 8, 9, and 
10.  
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Table 8. Kinetic data for the hydrolysis of 37 in D2O–CD3CN (8/2 vol) at pH 7.5 
([phosphate buffer] = 500 mM).  The values provided for F
-
 and ArBF3 correspond to the 
integration of the corresponding NMR signal. 
 
Data for 37 in D2O–CD3CN (8/2 vol) at pH 7.5 
        kobs = 5.2E-5 
      exp. Ratio calc. ratio 
Time (min) [F
-
] [BF3] [BF3]/([BF3]+[F
-
] [BF3]/([BF3]+[F
-
] 
0 0 100 1.0000 1.0000 
1030 5.4 100 0.9488 0.9478 
2491 14.86 100 0.8706 0.8785 
5367 32.58 100 0.7543 0.7565 
6800 43.52 100 0.6968 0.7022 
8240 52.59 100 0.6554 0.6515 
9689 63.75 100 0.6107 0.6042 
11189 76.21 100 0.5675 0.5589 
20000       0.3535 
30000       0.2101 
40000       0.1249 
50000       0.0743 
60000       0.0442 
 
 
 
 
 
 
 
 
 98 
 
Table 9. Kinetic data for the hydrolysis of 37 in 10% w/v triton X-100 in H2O/ DMSO 
(7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 mM).  The values provided for F
-
 and 
ArBF3 correspond to the integration of the corresponding NMR signal. 
 
Data for 37 in 10% w/v triton X-100 in H2O/ DMSO (7/3 vol) at pH = 7.5 
        kobs= 1.2E-5 
      exp. Ratio calc. ratio 
Time (min) [F] [BF3] [BF3]/([BF3]+[F] [BF3]/([BF3]+[F] 
0 0 100 1.0000 1.0000 
1626 3.54 100 0.9658 0.9800 
7512 9.38 100 0.9142 0.9111 
10376 11.76 100 0.8948 0.8793 
17576 21.44 100 0.8235 0.8042 
20000       0.7804 
25000       0.7334 
30000       0.6894 
35000       0.6479 
40000       0.6090 
50000       0.5379 
60000       0.4752 
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Table 10. Kinetic data for the hydrolysis of 45 in 10% w/v triton X-100 in H2O/ DMSO 
(7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 mM).  The values provided for F
-
 and 
ArBF3 correspond to the integration of the corresponding NMR signal. 
 
Data for 44 in 10% w/v triton X-100 in H2O/ DMSO (7/3 vol) at pH = 7.5 
        kobs = 4.0E-7 
      exp. Ratio calc. ratio 
Time (min) [F] [BF3] [BF3]/([BF3]+[F] [BF3]/([BF3]+[F] 
0 0 100 1.0000 1.0000 
18720 0.49 100 0.9951 0.9926 
25920 1.15 100 0.9886 0.9898 
36012 1.26 100 0.9876 0.9859 
44652 1.66 100 0.9837 0.9825 
50000 
   
0.9804 
60000 
   
0.9766 
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Radiochemistry Experiments  
All chemicals are analytic grade and used without further purification. Analytical 
reversed-phase high-performance liquid chromatography (HPLC) was accomplished on 
a Waters 515 chromatography system. A Waters 2487 dual λ absorbance detector and 
model 2200 scaler ratemeter radiation detector were added to the HPLC. HPLC was 
performed on a phenomenex Luna 5μ C18 column with a flow of 1ml/min. The mobile 
phase was programmed to change from 95% solvent A and 5% solvent B (0~2min) to 
5% solvent A and 95% solvent B at 22min, where solvent A is 0.1% TFA in water and 
solvent B is 0.1% TFA in acetonitrile. 
 
Radiochemistry  
The radio label reactions were carried out using the following protocol. 
Compound 45 and 46 (0.28 μmol) were dissolved in 20 μl DMSO. 45mCi of [18F]-
fluoride in 100 μl [18O] water was added. pH was adjusted to 2 by adding 6N HCl. The 
reaction mixture was incubated at 75ºC for 10min. Then the reaction mixture was loaded 
onto the HPLC to measure the percentage of the reaction conversion. The labeled 
compounds were confirmed by comparison of the radio signal HPLC profile with the 
UV signal HPLC of the starting non-radioactive compounds. 
  
MicroPET Imaging 
MicroPET imaging were acquired using the Genesys
4
 (Sofie Biosciences, Culver 
City, CA). The scanner has a 9.5cm axial and 4.4cm transaxial fields of view (FOV). For 
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PET image acquiring, each human gliobastoma (U87MG) tumor-bearing female nude 
mice was injected with 7.4MBq (0.02mCi) of [
18/19
F]45 and [
18/19
F]46 via the tail vein. 
At 15, 40 and 90min post injection, the mice were anesthetized using isoflurane (2% in 
oxygen), then placed into imaging chambers equipped with a heated coil to maintain 
body temperature and gas anesthesia as well. The static microPET acquisition were then 
achieved and reconstructed with the maximum likelihood and expectation maximization 
(MLEM) algorithm using the Sofie Biosciences software. Region of interest (ROIs) were 
drawn over the tumor and bone on decay-corrected whole body coronal sections. With 
the assumption of 1g/ml tissue density, ROIs were converted to counts per gram per min. 
Then dividing this by injected dose gave the image ROI derived %ID/g values. 
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Figure 52. MicroPET images of nude mice bearing U87MG tumor after injection of 
[
18/19
F]45 at 15, 40, and 90 min. 
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Figure 53. MicroPET images of nude mice bearing U87MG tumor after injection of 
[
18/19
F]46 at 15, 40, and 90 min. 
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CHAPTER IV  
CARBENE-BORANE ADDUCTS FOR 
18
F FLUORIDE ANION CAPTURE AND IN 
VIVO STABILITY STUDIES 
 
4.1 Introduction 
Positron Emission Tomography (PET) is a rapidly growing imaging technique 
that relies on the use molecular radiotracers containing a positron emitting isotope.
1
  To 
date, a great deal of attention has been devoted to the use of fluorine-18 (
18
F), a 
radionuclide that can be easily generated from [
18
O]-water and whose nuclear decay 
characteristics are ideally suited for applications in PET imaging.  One difficulty faced 
in the synthesis of 
18
F-containing molecular radiotracers is the short half-life of the 
isotope (110 min).  It follows that the best methods to access 
18
F-containing molecular 
radiotracers should be fast and preferably carried out in the late stages of the synthesis of 
the radiopharmaceutical probe.  An attractive approach that provides a possible solution 
to these challenges is based on molecules containing a boron atom as a fluoride binding 
site.  This approach was pioneered by Perrin who showed that arylboronic acids or esters 
featuring electron-withdrawing groups quickly react with fluoride ions to form the 
corresponding aryltrifluoroborates.
4,7
  Over the years, Perrin and other groups have 
investigated a number of backbones designed to stabilize the trifluoroborate unit and 
prevent its decomposition in vivo (Figure 54).
11,14,15,30,79
  Although the rate of hydrolysis 
can be slowed down drastically, all fluoroborates investigated to date are unstable 
toward hydrolysis.  This hydrolysis reaction is potentially problematic because the 
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fluoride ions liberated by hydrolysis of the radiotracer lead to unwanted background 
signal in particular from the skeleton. 
  
 
Figure 54. Chemical structure of organoboranes used for 
18
F fluoride captor in Positron 
Emission Tomography (PET) application and their hydrolysis rate constant (kObs). 
   
Recently we introduced a strategy based on the use of zwiterrionic 
trifluoroborates.  In particular, we found that the trifluoroborate moiety can be 
significantly stabilized against hydrolysis by a proximal cationic functionality such as a 
phosphonium as in the case of D and E.
79,80
 This approach is further validated by the 
recent work of Perrin who showed that ammonium trifluoroborate moieties of type C 
show sufficient stability for in vivo imaging.
30,83
  As part of our continued interest in this 
chemistry, we were drawn by the remarkable stability of N-heterocyclic cabene (NHC) 
boron trifluoride adducts such as 34.
31
  This compound which can also be described as a 
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carbene-BF3 adduct can be recrystallized from boiling water suggesting that it is highly 
resistant to hydrolysis.  Encouraged by these properties, we questioned whether such 
carbene-BF3 could be radiofluorinated and used as prosthetic groups for PET imaging.  
In this chapter, we describe the initial results that we have obtained while working 
toward this goal. 
 
4.2 Synthesis and characterization  
As a starting point for these studies, we synthesized the carbene-BF3 adduct (49) 
as a model compounds.  Using the method recently employed by Brozov for the 
monoethyl analog (34), compound 49 was obtained by thermolysis of 1, 3-dimethyl-1H-
imidazolium tetrafluoroborate under reduced pressure in a 87% yield (Figure 55).  The 
presence of the trifluoroborate moiety is confirmed by the detection of a quartet 
11
B 
NMR resonance at 0.21 ppm (JB-F = 37.0 Hz) and a quartet 
19
F NMR resonance at -139.2 
ppm (JB-F = 37.0 Hz).  The 
1
H NMR spectrum shows two singlet peaks at 3.85 ppm and 
7.11 ppm corresponding to the methyl and the methine groups, respectively.  The 
structure of this compound has also been studied by single crystal X-ray diffraction 
(Figure 57).  The B(1)-C(1) bond connecting the NHC ligand to the boron center 
(1.637(5) Å) is comparable to the boron-carbon bond of 34 (1.644(3) Å),
31
 indicating a 
strong coordination of the NHC ligand to the boron atom. 
 
   
 107 
 
 
Figure 55. Scheme showing the synthesis of 49. 
  
Next, we turned our attention toward the synthesis of a NHC-BF3 adduct that 
could be easily conjugated with biomolecules for targeted disease imaging.  After 
reviewing different functionalization possibilities, we decided to synthesize the amino-
substituted derivative 52.  We successfully accessed this new derivative by reaction of 
the known nitrocarbene-AgI complex 50 with BF3-OEt2.  This reaction afforded the 
nitrocarbene-BF3 adduct 51 as a white solid in 83 % yield (Figure 56).  Hydrogenation 
of 51 over palladium afforded 52 in a 78% yield.  The 
1
H NMR spectrum of 51 and 52 
display two singlets (3.94 ppm and 4.16 ppm for 51 and 3.61 and 3.73 ppm for 52) 
corresponding to the methyl group and a singlet (8.21 ppm for 51 and 6.37 ppm for 52) 
corresponding to the methine proton.  The presence of an amino group in 52 is 
confirmed by the detection of a broad signal at 4.02 ppm.  As in the case of 49, quartets 
are observed in 
11
B NMR and 
19
F NMR of 51 and 52 are similar to those of 49 (
11
B 
NMR signal at 0.13 ppm with JB-F = 33.6 Hz for 51 and 0.27 ppm with JB-F = 37.2 Hz for 
52; 
19
F NMR signal at -137.9 ppm with JB-F = 33.6 Hz for 51 and -138.0 ppm with JB-F = 
37.2 Hz for 52).  The crystal structure of 51 has also been determined.  The carbene-BF3 
moiety is essentially analogous to that in 49.  The only notable difference is observed in 
the B(1)-C(1) separation (1.657(2) Å) which is slightly longer than in 49 (1.637(5) Å) 
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(Figure 58).  This elongation is assigned to the electron withdrawing properties of the 
nitro group and the associated weaker donor properties of the carbene-carbon atom. 
Compound 52 can be transformed into the succinimide derivative 53 by reaction 
with succinic anhydride in a presence of di-iso-propylethylamine (DIEA). Subsequent 
addition of NaOH to the solution of 53 in H2O/THF mixture yielded the succinic acid 
derivative (54) in a 88% yield. The 
1
H NMR spectrum of 53 showed a singlet peak at 
2.89 ppm corresponding to the methylene group of the succinimide ring, while the 
1
H 
NMR spectrum of 54 displayed two triplet peaks at 2.44 and 2.62 ppm indicating two 
different methylene groups in succinic acid functional group. The trifluoroborate moiety 
gives rise to a quartet 
11
B NMR resonance at 0.29 ppm (JB-F = 35.4 Hz) for 53 and -0.33 
ppm (JB-F = 38.4 Hz)  for 54 as well as a quartet 
19
F NMR resonance at -138.5 ppm (JB-F 
= 35.4 Hz) for 53 and -137.5 ppm (JB-F = 38.4 Hz) for 54.  
Compound 52 can also be easily converted into the maleimide derivative 56 by 
reaction with maleic anhydride and acetic anhydride/ sodium acetate.  The spectroscopic 
properties of 56 are close to those of 52. The methine signal is observed at 7.08 ppm.  
The trifluoroborate moiety gives rise to a quartet at 0.29 ppm in the 
11
B NMR spectrum 
(JB-F = 35.6 Hz) as well as a quartet at -138.5 ppm in the 
19
F NMR spectrum (JB-F = 35.6 
Hz).  The structure of this derivative has also been confirmed by X-ray diffraction 
(Figure 59) which shows a that the B(1)-C(1) separation (1.656(9) Å) is close to that in 
51, a characteristic consistent with the electron withdrawing effect of the maleimide 
functional group.  
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Figure 56. Scheme showing the synthesis of Arduengo carbene borane adducts tethered 
nitro (51), amine (52), succinimide (53), succinic acid (54), maleic acid (55), and 
maleimide (56) functional groups.  
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Figure 57. Crystal structure of 49. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 49: B1-C1 1.637(3), B1-F1 1.389(4), B1-F2 1.398(3), 
B1-F3 1.398(3); N1-C1-N2 105.8(3).  
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Figure 58. Crystal structure of 51. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 51: B1-C1 1.6575(18), B1-F1 1.3928(16), B1-F2 
1.3948(16), B1-F3 1.3933(15); N1-C1-N2 106.50(10).  
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Figure 59. Crystal structure of 56. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 56: B1-C1 1.656(9), B1-F1 1.347(9), B1-F2 1.395(9), 
B1-F3 1.390(10); N1-C1-N2 106.8(5).  
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To expand our captors to the di-functional group derivatives, the di-cyano and 
the di-methylester BF3-carbene adducts were synthesized by the reaction of the di-
cyanocarbene-AgI and di-methylestercarbene-AgI complexes (57 and 59) with BF3-
OEt2, respectively.  These reactions afforded the di-cyanocarbene-BF3 adduct 58 and the 
di-methylestercarbene-BF3 60 in a good yield (78 % yield for 58 and 72% for 60) 
(Figure 60). Gratifyingly, the dicarboxylic acid carbene-BF3 adduct can be successfully 
prepared by the treatment of 60 with NaOH in aqueous solution. These new di-
functional group carbene-BF3 adducts were fully characterized by NMR spectroscopy. 
The presence of the trifluoroborate moiety is confirmed by the detection of a quartet 
11
B 
NMR resonance at -0.20 ppm (JB-F = 31.7 Hz) for 58, 0.17 ppm (JB-F = 34.3 Hz) for 60, 
and 0.40 ppm (JB-F = 35.6 Hz) for 61, as well as, a quartet 
19
F NMR resonance at -138.9 
ppm (JB-F = 31.7 Hz) for 58, 137.5 ppm (JB-F = 34.3 Hz) for 60, and -136.3 ppm (JB-F = 
35.6 Hz) for 61. The 
1
H NMR spectra showed only one singlet peak at 3.99 ppm for 58 
and 4.09 ppm for 61 corresponding to the N,N dimethyl groups on the imidazole ring. 
The 
1
H NMR spectrum of 60 displayed the expected two singlet peaks at 3.92 and 3.95 
ppm corresponding to the N,N dimethyl and the dimethylester groups, respectively.    
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Figure 60. Scheme showing the synthesis of 58 and 61.  
 
4.3 Kinetic studies 
Next, we decided to investigate the rates of hydrolysis reaction of these new 
NHC-BF3 adducts (49, 51, 52, 56).  This hydrolysis reaction, which is expected to 
produce the corresponding boronic acid according to a first order rate process (ν = 
kobs[NHC-BF3]), was monitored by 
19
F NMR spectroscopy in D2O/CD3CN (8/2 vol) at 
pH 7.5 ([phosphate buffer] = 500 mM, [NHC-BF3] = 20 mM).  Surprisingly, we found 
that the hydrolysis of the adducts was extremely slow. After a week, we did not observe 
any free fluoride for 51 and 56 indicating that these two derivative are essentially 
immortal.  Their stability is assigned to the electron withdrawing nature of the nitro or 
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maleimide functionality which increases the Lewis acidity of the boron center thereby 
preventing fluoride anion dissociation.  Compounds 49 and 52 are also surprisingly 
stable and only show a trace amount of free fluoride after a week in D2O/CD3CN (8/2 
vol) at pH 7.5.  By extending this experiment to a longer timescale, we have been able to 
calculate the rate of hydrolysis for these two compounds.  These rates, which are 
respectively equal to kobs = 1.2 x 10
-6
 min
-1
 for 49 and 1.1 x 10
-6
 for 52 are lower than 
those measured under the same condition for the phosphonium borane D.  Altogether, 
these results illustrate the remarkable resistance of NHC-BF3 adducts to hydrolysis and 
suggest that they could be used as prosthetic groups for PET imaging. 
 
4.4 Radiofluorination and in vivo imaging studies
5
 
Employing the approach developed by our group for the preparation of 
[
18
F]BODIPY dye, we decided to investigate the radiofluorination of these NHC-BF3 
adducts via 
18
F-
19
F isotopic exchange using SnCl4 as a Lewis acid promoter.
87
  We first 
tested this approach with the non-functionalized NHC-BF3 adduct 49 which was mixed 
with SnCl4 (5-15 eq) in MeCN and combined with a solution of [
18
F]fluoride (as the 
tetra-n-butylammonium salt) in MeCN (Scheme 3, Table 1).  The reaction mixture was 
then shaken for 10 min before being quenched by addition of water.  The radiolabeled 
compound ([
18
F]49) was immobilized on a Sep-Pak cartridge (Sep-Pak Plus tC18) and 
                                                 
5
 This experiment was carried out by our collaborator, Dr. Zibo Li, at department of 
Radiology, University of North Carolina, Chapel Hill, NC. 
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washed with water. [
18
F]49 was eluted off the cartridge with MeCN.  An aliquot of the 
resulting MeCN solution was subjected to HPLC analysis.  
    
 
Figure 61. Scheme showing the radiolabeling of 49 employed by SnCl4 assisted isotopic 
18
F-
19
F exchange. 
 
Because we pre-processed the sample before HPLC analysis, we cannot calculate 
the radiochemical yield (RCY) based on HPLC integration. Therefore, we determined 
the RCY based on the radio-activity of isolated product and the starting radio-activity. 
As shown in Table 11, the RCY ranges from 35-56% for different reaction conditions. It 
was found that increasing the concentration of precursor leads to higher isolation yield 
(Entry 1-3).  Interestingly, variation in the concentration of the Lewis acid promoter 
(Entry 3-5) or in the temperature (Entry 6-7) of the reaction had little impact on the 
RCY.  When a long reaction time was employed as in entries 8 and 9, a decrease of 
isolation yield was observed due to product decomposition. The highest specific activity 
of the final product obtained in this experiment was calculated to be 53.5 mCi/µmol 
(Entry 8). 
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Table 11. Radiosynthetic results. 
Entry [49] 
(mM) 
SnCl4 
(equiv.) 
Temp. 
(°C) 
Time 
(Min) 
SA
a
 
(mCi/ 
μmol) 
RCY
b
 
(%) 
1 15 5 25 10 26.4 35.5 
2 30 5 25 10 40.6 42.1 
3 60 5 25 10 40.8 47.3 
4 30 10 25 10 47.5 48.4 
5 30 15 25 10 47.8 48.1 
6 30 5 40 10 45.5 56.4 
7 30 5 60 10 49.5 53.4 
8 30 5 25 20 53.5 49.9 
9 30 5 25 30 36.8 39.9 
 
a
Specific activity is determined by dividing the product activity by the amount of 
the product (based on the integration of UV-HPLC and compare with the UV 
chromatogram of the  standard). 
b
RCY = activity of the isolated product/starting 
18
F 
activity. All yields are decay corrected. 
 
Using condition from entry 7, we have also been able to prepare [
18
F]56 with 
specific activity of 51.3 mCi/μmol (RCY = 54%, Scheme 3). The identity of [18F]56 was 
confirmed by the co-injection with the non-radiolabeled standard (Figure 63). This 
radiofluorinated NHC-BF3 adduct could be conveniently conjugated with the model 
peptide H-Cys-Phe-OH via a thiol-Michael addition reaction.  This synthesis was carried 
out by mixing a solution of [
18
F]56 in MeCN with an aqueous solution of H-Cys-Phe-
OH (400 μg, 1.5 μmol) (Figure 62). After shaking for 10 min at room temperature, a 
portion of the reaction mixture (0.01 mCi) was loaded onto the HPLC for purification 
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affording [
18
F]56/H-Cys-Phe-OH with a 95.7% purity. The identity of [
18
F]56/H-Cys-
Phe-OH peptide was confirmed by its mass spectrum as well as by co-injection with the 
independently synthesized non-radiolabeled standard (Figure 64). The specific activity 
of [
18
F]56/H-Cys-Phe-OH peptide was calculated as 40.8 mCi/μmol. 
 
 
Figure 62. Scheme showing the preparation of [
18
F]-56/ H-Cys-Phe-OH conjugate. 
 
 
Figure 63. Left: UV trace of 56 as the standard reference. Right: Crude radio-HPLC 
profile for the 
18
F-labeling of 56. 
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Figure 64. Left: UV traces of BF3-carbene-Cys-Phe as the standard reference. Right: 
Crude radio-HPLC profile for the 
18
F-labeling of BF3-carbene-Cys-Phe.  
 
After confirming these encouraging radiofluorination and conjugation results, the 
stability of [
18
F]56/H-Cys-Phe-OH was investigated in vivo. As a prelude to these 
studies, we first tested the stability of the conjugate in a 1x PBS buffer at 37° (Figure 
65).  Even after 2 hours, the conjugate is not compromised as shown by the fact that its 
purity remains >90% pure.  In vivo PET/CT imaging in a normal nude mouse afford 
consistent results.  The microPET/CT images collected 1 h, 2 h, and 4 h post injection 
show liver and urinary track clearance of the conjugate.  More importantly, no bone 
uptake is observed even 4 h post injections. Indicating that [
18
F]-fluoride release by the 
radiofluorinated carbene unit is negligible (Figure 66) 
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Figure 65. A: [
18
F]56-peptide standard Radio-HPLC profile. B,C,D: [
18
F]56-peptide in 
1x PBS for 0.5h, 1h and 2h with purity of 96.6%, 93.9%, and 92.5%, respectively.  
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Figure 66. Decay-corrected whole-body microPET-CT sagittal images of nude mice 
from a static scan at 1, 2 h and 4 h after injection of [
18
F]56/ H-Cys-Phe-OH conjugate. 
 
4.5 Conclusion 
In summary, we have identified a new boron-based fluoride captor with an 
unsurpassed resistance to hydrolytic fluoride release.  The stability of this new probe is 
ascribed to its zwitterionic nature, with the cationic charge of the imidazolium unit 
acting as an electrostatic anchor for the boron-bound fluoride anions.  These NHC-BF3 
fluoride captors are a new incarnation of the concepts underlying the stability of the 
phosphonium trifluoroborates of type D and E developed by us or ammonium 
trifluoroborates of type C recently reported by the Perrin group. 
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4.6 Experimental 
General Consideration 
 1, 3-dimethyl-1H-imidazolium tetrafluoroborate
88
, and 1, 3-dimethyl-4-
nitroimidazolium silver complex
89
 (50) were synthesized according to the reported 
procedure. 1-Methylimidazole, boron trifluoride diethyl etherate (BF3-OEt2), methyl 
iodide (CH3I), 10% palladium supported carbon, and succinic anhydride were purchased 
from Alfar Aesar; 4-nitroimidazole was purchased from Tokyo Chemical Industry Co., 
Ltd; N, N-di-iso-propylethylamine (DIEA), and maleic anhydride were purchased from 
Sigma Aldrich; silver oxide was purchased from Strem chemicals; acetic anhydride was 
purchased from EM industries, Inc; sodium acetate was purchased from Mallinckrodt. 
All chemicals were used without further purification. Solvents were dried by passing 
through an alumina column (CH2Cl2), refluxing under N2 over Na (Et2O and THF), 
refluxing under N2 over CaH2 (CH3CN). Electrospray mass spectra were acquired from a 
MDS Sciex API QStar Pulsar. NMR spectra were recorded on a Varian Unity Inova 400 
NMR and an Inova 500B spectrometer at ambient temperature. Chemical shifts are given 
in ppm, and are referenced to residual 
1
H and 
13
C solvent signals as well as external BF3-
Et2O (
11
B NMR and 
19
F NMR). 
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Preparation of 1, 3-dimethylimidazolium-2-trifluoroborate (49) 
1, 3-Dimethyl-1H-imidazolium tetrafluoroborate (0.252 g, 1.37 mmol) was 
placed into a sublimation apparatus, connected via a liquid-N2-cooled trap to a high-
vacuum line. The powder was heated by a heating mantle under reduced pressure to 200 
°C at which point compound 49 started condensing on the cold finger. The sublimation 
was continued for 15 min. Compound 49 (0.196 g, 1.19 mmol) was obtained in a 87 % 
yield. 
1
H NMR (499.4 MHz, CD3CN):  3.85 (s, 6H, -CH3), 7.11 (s, 2H, =CH). 
13
C 
NMR (125.6 MHz, CD3CN):  35.93 (-CH3), 122.64 (=CH). 
11
B NMR (128.2 MHz, 
CD3CN):  0.21 (q, JB-F = 37.0 Hz). 
19
F NMR (282.2 MHz, CD3CN):  -139.2 (q, JB-F = 
37.0 Hz). HRMS (ESI
-
) calcd for [M-F]
+
: 145.0748, found: 145.0758. 
 
Preparation of 1, 3-dimethyl-4-nitroimidazolium-2-trifluoroborate (51) 
BF3-OEt2 (0.34 mL, 2.75 mmol) was added to a suspension of 50 (0.691 g, 0.92 
mmol) in CH2Cl2 (15 mL) at room temperature. The suspension was stirred for 4 h and 
filtered. The filtrate was purified by flash chromatography using silica gel as a stationary 
phase and CH2Cl2 as a mobile phase to remove an excess BF3-OEt2 and an imidazolium 
salt impurity.   The purified solution was dried in vacuo resulting 51 as a white powder 
(0.160 g) in a 83 % yield. 
1
H NMR (499.4 MHz, CD3CN):  3.94 (s, 3H, -CH3), 4.16 (s, 
3H, -CH3), 8.21 (s, 1H, =CH). 
13
C NMR (125.6 MHz, CD3CN):  35.84 (CH3), 37.61 
(CH3), 126.04 (=CH), 138.55 (=CNO2). 
11
B NMR (128.2 MHz, CD3CN):  0.13 (q, JB-F 
= 33.5 Hz). 
19
F NMR (469.9 MHz, CD3CN):  -137.86 (q, JB-F = 33.5 Hz). HRMS (ESI
-
) 
calcd for [M-H]
-
: 208.0505, found: 208.0517. 
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Preparation of 1, 3-dimethyl-4-amino-imidazolium-2-trifluoroborate (52) 
10% palladium on carbon (0.235 g, 0.221 mmol Pd) was added to a solution of 
51 (0.461 g, 2.21 mmol) in CH2Cl2 (20 mL). Hydrogen gas was bubbled through the 
solution for 30 min. The mixture was stirred under a hydrogen atmosphere overnight at 
room temperature. The solution was then filtered over celite and the solvent was 
removed under vacuum yielding 52 as a white powder (0.307 g) in a 78 % yield. 
1
H 
NMR (499.4 MHz, CD3CN):  3.61 (s, 3H, -CH3), 3.73 (s, 3H, -CH3), 4.02 (s, 2H, -
NH2), 6.37 (s, 1H, =CH). 
13
C NMR (125.6 MHz, CD3CN):  30.67 (CH3), 35.51 (CH3), 
104.57 (=CH), 138.20 (=CNH2). 
11
B NMR (128.2 MHz, CD3CN):  0.27 (q, JB-F = 37.2 
Hz). 
19
F NMR (375.9 MHz, CD3CN):  -138.0 (q, JB-F = 37.2 Hz). HRMS (ESI
-
) calcd 
for [M-H]
-
: 178.0763, found: 178.0741. 
 
Preparation of 1, 3-dimethyl-4-succinimide-imidazolium-2-trifluoroborate (53) 
A solution of 52 (0.0587 g, 0.328 mmol), succinic anhydride (0.1650 g, 1.650 
mmol) and diisopropylethylamine (DIEA) (0.23 mL, 1.320 mmol) in DMF (7 mL) was 
heated to 70 °C for 15 h. After 15 h, the solvent was removed in vacuo. The crude 
product was purified by flash chromatography using silica gel as a stationary phase and 
99:1 CH2Cl2:MeOH solution as a mobile phase. The resulting solution was dried by 
rotary evaporator obtaining 53 (0.0568 g) as a pale yellow powder in a 66 %. 
1
H NMR 
(399.5 MHz, CD3CN):  2.89 (s, 4H, succinimide-CH2), 3.63 (s, 3H, -CH3), 3.89 (s, 3H, 
-CH3), 7.23 (s, 1H, =CH). 
13
C NMR (125.6 MHz, CD3CN):  28.75 (succinimide-CH2), 
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32.44 (CH3), 36.67 (CH3), 120.65 (=CH), 122.81 (=CN(C(O)CH2)2) 176.19 (C=O). 
11
B 
NMR (128.2 MHz, CD3CN):  0.29 (q, JB-F = 35.4 Hz). 
19
F NMR (375.9 MHz, CD3CN): 
 -138.5 (q, JB-F = 35.4 Hz). HRMS (ESI
-
) calcd for [M-H]
-
: 260.0818, found: 260.0855. 
 
Preparation of 1, 3-dimethyl-4-succinimic acid-imidazolium-2-trifluoroborate (54) 
0.70 mL of 0.5 M NaOH (0.350 mmol) was slowly added to a solution of 53 
(0.0884 g, 0.339 mmol) in 1:1 water/THF mixture (6 mL) at room temperature. The 
reaction mixture was stirred for 3 h and then neutralized by addition of 0.5M HCl. The 
solvents were removed in vacuum and the resulting powder was re-dissolved in CH3CN 
(10 mL). The suspension was filtered to remove NaCl salt. The filtrate was dried by 
rotary evaporator resulting 54 as a white powder (0.0835 g) in a 88 %. 
1
H NMR (399.5 
MHz, D2O):  2.44 (t, 2H, CH2, JH-H = 6.49 Hz), 2.62 (t, 2H, CH2, JH-H = 6.49 Hz), 3.55 
(s, 3H, -CH3), 3.74 (s, 3H, -CH3), 7.14 (s, 1H, =CH). 
13
C NMR (125.6 MHz, CD3CN):  
32.93 (CH3), 33.36 (-CH2-), 33.74 (-CH2-), 37.37 (CH3), 118.45 (=CH), 128.83 
(=CN(CO)(CH2)2COOH), 177.33 (C=O), 181.50 (C=O). 
11
B NMR (128.2 MHz, D2O):  
-0.33 (q, JB-F = 38.4 Hz). 
19
F NMR (375.9 MHz, D2O):  -137.5 (q, JB-F = 38.4 Hz). 
HRMS (ESI
-
) calcd for [M-H]
-
: 278.0164, found: 278.0943. 
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Preparation of 1, 3-dimethyl-4-maleic acid-imidazolium-2-trifluoroborate (55) 
Maleic anhydride (0.172 g, 1.76 mmol) was added to a solution of 52 (0.1572g, 
0.88 mmol) in THF (8 mL). The reaction mixture was stirred for 20 h at room 
temperature resulting in a white precipitate. The powder was collected by filtration and 
then dried in vacuo yielding 55 (0.180 g) in a 74 % yield. 
1
H NMR (399.5 MHz, D2O):  
3.46 (s, 3H, -CH3), 3.61 (s, 3H, -CH3), 6.22 (d, 1H, =CH(CO)), 6.39 (d, 1H, =CH(CO)), 
7.08 (s, 1H, =CH) . 
13
C NMR (125.6 MHz, CD3CN):  31.64 (CH3), 35.96 (CH3), 
116.92 (=CH), 126.56 (=CN(CO)(CH=CH)COOH), 129.99 (-HC=CH-), 131.67 (-
HC=CH-), 167.35 (C=O), 168.71 (C=O). 
11
B NMR (128.2 MHz, D2O):  -0.30 (q, JB-F = 
40.0 Hz). 
19
F NMR (469.9 MHz, D2O):  -137.4 (q, JB-F = 40.0 Hz). HRMS (ESI
-
) calcd 
for [M-H]
-
: 276.0767, found: 276.0748. 
 
Preparation of 1, 3-dimethyl-4-maleimide-imidazolium-2-trifluoroborate (56) 
A solution of 55 (0.131 g, 0.47 mmol) and sodium acetate (NaOAc) (0.064 g, 
0.47 mmol) in acetic anhydride (Ac2O) (15 mL) was heated to 70 °C for 3 h. After 3 h, 
the acetic anhydride was removed in vacuum. The crude product was re-dissolved in 
CH2Cl2 (30 mL) and then, the solution was washed with water (3x30 mL). The organic 
layer was dried with MgSO4. Finally, the solvent was removed in vacuum yielding 56 
(0.088 g) as a white powder in a 72 % yield. 
1
H NMR (499.4 MHz, CD3CN):  3.65 (s, 
3H, -CH3), 3.91 (s, 3H, -CH3), 7.08 (s, 2H, maleimide=CH), 7.30 (s, 1H, =CH). 
13
C 
NMR (125.6 MHz, CD3CN):  32.36 (CH3), 36.70 (CH3), 121.33 (=CH), 121.52 
(=CN(C(O)CH)2), 135.86 (maleimide=CH), 168.75 (C=O). 
11
B NMR (128.2 MHz, 
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CD3CN):  0.29 (q, JB-F = 35.6 Hz). 
19
F NMR (375.9 MHz, CD3CN):  -138.5 (q, JB-F = 
35.6 Hz). HRMS (ESI
-
) calcd for [M+Na]
-
: 282.0638, found: 282.0650.  
 
Preparation of (4,5-dicyano-1,3-dimethyl-1H-imidazol-3-ium-2-yl)trifluoroborate (58) 
BF3-OEt2 (0.55 mL, 4.35 mmol) was added to a suspension of Ag complex 57 
(0.5509 g, 1.45 mmol) in CH2Cl2 (15 mL) at room temperature. The suspension was 
stirred for 4 h and then filtered to remove silver iodide by-product. The filtrate was 
purified by flash chromatography using silica gel as a stationary phase and CH2Cl2 as a 
mobile phase to remove an excess BF3-OEt2 and an imidazolium salt impurity.   The 
purified solution was dried in vacuo resulting 58 as a white powder (0.1595 g) in a 78 % 
yield. 
1
H NMR (399.5 MHz, CD3CN):  3.99 (s, 6H, -CH3). 
13
C NMR (100.45 MHz, 
CD3CN):  36.84, 106.43, 116.03. 
11
B NMR (128.2 MHz, CD3CN):  -0.20 (q, JB-F = 
31.7 Hz). 
19
F NMR (375.9 MHz, CD3CN):  -138.91 (q, JB-F = 31.7 Hz). HRMS (ESI
+
) 
calcd for [M-F]
+
: 195.0653, found: 195.0748. 
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Preparation of (4,5-dicarboxy-1,3-dimethyl-1H-imidazol-3-ium-2-yl)trifluoroborate (61) 
 
 
Figure 67. Scheme showing the synthesis of 61.  
 
 
SOCl2 (0.40 mL, 5.51 mmol) was added to a solution of i (0.3212 g, 1.89 mmol) 
in methanol (15 mL). The solution mixture was refluxed for 18 h. Upon cooling to 40 
°C, solid NaHCO3 was added to raise the pH to 8. The mixture was filtered and the 
filtrate was evaporated under reduced pressure affording ii (0.2920 g) in a 78 % yield. 
1
H 
NMR (399.5 MHz, CDCl3):  3.83 (s, 3H, -CH3), 3.89 (s, 3H, -CH3), 3.90 (s, 3H, -CH3), 
7.47 (s, 1H). Without further purification, ii (0.2920 g, 1.47 mmol) was treated with MeI 
(0.20 mL, 3.21 mmol) in MeCN (15 mL) at 50 °C for 18 h. The solution mixture was 
concentrated to the volume of 1 mL. Then, Et2O (15 mL) was added to precipitate iii 
(0.3610 g) in a 72 % yield. 
1
H NMR (399.5 MHz, CD3CN):  3.94 (s, 6H, -CH3), 3.96 
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(s, 6H, -CH3), 8.92 (s, 1H). Next, iii (0.1239 g, 0.36 mmol) was treated with Ag2O 
(0.0420 g, 0.18 mmol) in CH2Cl2 (20 mL) at 50 °C for 3 h. The solvent was removed in 
vacuo yielding 59 (0.1401 g) in a 86 %. 
1
H NMR (399.5 MHz, CD3CN):  3.88 (s, 6H, -
CH3), 3.96 (s, 6H, -CH3). Then, BF3-OEt2 (0.12 mL, 0.97 mmol) was added to a 
suspension of Ag complex 59 (0.1401 g, 0.31 mmol) in CH2Cl2 (20 mL) at room 
temperature. The suspension was stirred for 4 h and then filtered to remove silver iodide 
by-product. The filtrate was purified by flash chromatography using silica gel as a 
stationary phase and CH2Cl2 as a mobile phase to remove an excess BF3-OEt2 and an 
imidazolium salt impurity. The purified solution was dried in vacuo resulting 60 (0.0541 
g) in a 62 % yield.
 1
H NMR (399.5 MHz, CD3CN):  3.92 (s, 6H, -CH3), 3.95 (s, 6H, -
CH3).
 11
B NMR (128.2 MHz, CD3CN):  0.17 (q, JB-F = 34.3 Hz). 
19
F NMR (375.9 
MHz, CD3CN):  -137.5 (q, JB-F = 34.3 Hz). Finally, 2 mL of 1 M NaOH was added to a 
solution of 60 (0.00541 g, 0.19 mmol) in 1:1 water/THF mixture (6 mL) at room 
temperature. The reaction mixture was stirred for 4 h and then neutralized by addition of 
2 mL of 1 M HCl. The solvents were removed in vacuum and the resulting powder was 
re-dissolved in CH3CN (10 mL). The suspension was filtered through celite to remove 
NaCl salt. The filtrate was dried by rotary evaporator resulting 61 (0.0432 g) in a 89 %. 
1
H NMR (399.5 MHz, CD3CN):  4.09 (s, 6H, -CH3). 
11
B NMR (128.2 MHz, CD3CN): 
 0.40 (q, JB-F = 35.6 Hz). 
19
F NMR (375.9 MHz, CD3CN):  -136.3 (q, JB-F = 35.6 Hz). 
HRMS (ESI
-
) calcd for [M-H]
-
: 251.0450, found: 251.0214. 
              
  
 130 
 
Crystallographic Measurements  
  Single crystals of 49 were obtained by slow diffusion of Et2O into a CH3CN 
solution of 49.  Single crystals of 51 and 56 were obtained by slow diffusion of pentane 
into a THF solution of 51 and 56, respectively. The crystallographic measurement of 49, 
51, and 56 were performed using a Bruker APEX-II CCD area detector diffractometer, 
with graphite-monochromated Mo-Kα radiation (λ = 0.71069 Å). A specimen of suitable 
size and quality was selected and mounted onto a nylon loop. The semi-empirical 
method SADABS was applied for absorption correction. The structure was solved by 
direct methods, and refined by the full-matrix least-square metahod against F
2
 with the 
anisotropic temperature parameters for all non-hydrogen atoms.  All H atoms were 
geometrically placed and refined using the riding model approximations. Data reduction 
and further calculations were performed using the Bruker SAINT+ and SHELXTL NT 
program packages. The crystal data are included in Table 12, 13, and 14. 
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Table 12. Crystal data, data collections, and structure refinements of 49. 
Crystal data 49 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C5H8BF3N2 
163.94 
0.2 x 0.1 x 0.07 
110(2) K 
0.71073 Å 
Monoclinic 
P21/m 
a = 7.169(2) Å  α = 90.00° 
b = 6.8769(19) Å β = 105.675(3)° 
c = 7.474(2) Å  γ = 90.00° 
354.77(17) Å
3
  
2 
1.535 g cm
-3 
0.148 mm
-1 
168 
ω, φ 
-9 → +9 
-8 → +9 
-9 → +9 
4206 
927 [0.0269] 
927 
64 
1.105 
0.0596, 0.1980 
0.666,  -0.771 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.1112 and b = 0.47. 
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Table 13. Crystal data, data collections, and structure refinements of 51. 
Crystal data 51 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C5H7BF3N3O2 
208.95 
0.2 x 0.08 x 0.07 
110(2)K 
0.71073 Å 
Monoclinic 
P21/c 
a = 7.4533(5) Å  α = 90.00° 
b = 9.5695(6) Å  β = 105.0490(10)° 
c = 11.8645(8) Å            γ = 90.00° 
817.21(9) Å
3
 
4 
1.698 g cm
-3 
0.170 mm
-1 
424 
ω, φ 
-9 → +9 
-12 → +12 
-15 → +15 
10223 
2039 [0.0449] 
2039 
57 
1.066 
0.0371, 0.1085 
1.214,  -0.866 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.0579 and b = 0.39. 
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Table 14. Crystal data, data collections, and structure refinements of 56. 
Crystal data 56 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C9H9BF3N3O2 
259.00 
0.33 x 0.30 x 0.07 
110(2)K 
0.71073 Å 
Orthorhombic 
P212121 
a = 7.5804(12) Å α = 90.00° 
b = 7.9279(13) Å β = 90.00° 
c = 18.431(3) Å γ = 90.00° 
817.21(9) Å
3 
4 
1.553 g cm
-3 
0.142 mm
-1 
528 
ω, φ 
-9 → +9 
-10 → +10 
0 → +23 
4997 
2523 [0.0236] 
2523 
164 
1.099 
0.1079, 0.2763 
0.736,  -0.617 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.1000 and b = 7.4553. 
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Figure 68. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 49 in CD3CN. 
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Figure 69. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 51 in CD3CN. 
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Figure 70. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 52 in CD3CN. 
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Figure 71. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 53 in CD3CN. 
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Figure 72. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 54 in D2O. 
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Figure 73. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 55 in D2O. 
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Figure 74. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 56 in CD3CN. 
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Figure 75. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 58 in CD3CN. 
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Kinetic studies of the hydrolysis reactions 
A sample of 49, 51, 52, 54, 55, and 56 (5 mg) was dissolved in 0.2 mL CD3CN 
and 1.0 mL D2O phosphate buffer (pH 7.5, 500 mM). The 
19
F NMR spectra of 49, 51, 
52, 54, 55, and 56 were collected periodically. The decomposition of aryltrifluoroborate 
species were monitored by integration of the decreasing aryltrifluoroborate signal in 
conjunction with the increasing signal corresponding to free F
-
.  All spectra were 
processed using the VNMRJ Version 2.2 NMR software. The rate constant, kobs, was 
calculated using a well-established NMR method reported in the literature.
4 
 This method 
is based on the fact that that the concentration in ArBF3 species is proportional to the 
19
F 
NMR integration of ArBF3 signal divided by the sum of the integration of ArBF3 signal 
and the free fluoride signal.  For convenience, the value of the ArBF3 integration is 
arbitrarily set at 100 and the free fluoride integration determined. Based on the 
19
F NMR 
results, free F
-
 NMR signal was only observed in the aqueous solution of 49, 52, and 54 
after a week. The resulting data is provided in Table S4, S5, and S6.  
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Table 15. Kinetic data for the hydrolysis of 49.  The values provided for F
-
 and ArBF3 
correspond to the integration of the corresponding NMR signal. 
 
  
Data for 
49 
  
    
kobs = 1.2E-6 
   
exp. Ratio calc. ratio 
Time 
(min) [F] [BF3] [BF3]/([BF3]+[HF] [BF3]/([BF3]+[HF] 
0 0.00 100 1.0000 1.0000 
1141 0.34 100 0.9966 0.9986 
2594 0.41 100 0.9959 0.9969 
4152 0.48 100 0.9953 0.9950 
9776 0.76 100 0.9925 0.9882 
11000 
   
0.9867 
12000 
   
0.9855 
13000 
   
0.9843 
14000 
   
0.9831 
15000 
   
0.9820 
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Table 16. Kinetic data for the hydrolysis of 52.  The values provided for F
-
 and ArBF3 
correspond to the integration of the corresponding NMR signal. 
 
  
Data 
for 52 
  
    
kobs = 1.1E-6 
   
exp. Ratio calc. ratio 
Time 
(min) [F] [BF3] [BF3]/([BF3]+[HF] [BF3]/([BF3]+[HF] 
0 0.00 100 1.0000 1.0000 
1434 0.20 100 0.9980 0.9984 
2884 0.31 100 0.9970 0.9968 
4563 0.49 100 0.9952 0.9950 
10126 0.91 100 0.9910 0.9889 
11000 
   
0.9880 
12000 
   
0.9869 
13000 
   
0.9858 
14000 
   
0.9847 
15000 
   
0.9837 
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Table 17. Kinetic data for the hydrolysis of 54.  The values provided for F
-
 and ArBF3 
correspond to the integration of the corresponding NMR signal. 
 
  
Data for 54 
  
    
k= 4.89E-7 
   
exp. Ratio calc. ratio 
Time 
(min) [F] [BF3] [BF3]/([BF3]+[HF] [BF3]/([BF3]+[HF] 
0 0.00 100 1.0000 1.0000 
1402 0.09 100 0.9991 0.9993 
2851 0.11 100 0.9990 0.9986 
4298 0.19 100 0.9981 0.9979 
10032 0.53 100 0.9948 0.9951 
11000 
   
0.9946 
12000 
   
0.9941 
13000 
   
0.9937 
14000 
   
0.9932 
15000 
   
0.9927 
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Radiochemistry Experiment 
All chemicals from commercial were of analytic grade and used without further 
purification. Analytical reversed-phase HPLC using a Gemini 5μ C18 column (250 x 
4.6mm) was performed on a SPD-M30A photodiode array detector (Shimadzu) and 
model 105S single-channel radiation detector (Carroll & Ramsey Associates). The flow 
is set to 1mL/min. The mobile phase stayed at 95% solvent A and 5% solvent B from 0-
2min and then changed with a gradient from 95% solvent A 5% solvent B to 95% 
solvent B and 5% solvent A in 20min. Solvent A is 0.1% TFA in water and solvent B is 
0.1% TFA in acetonitrile.  
 
Radiochemistry          
The radio label reactions were carried out using the following protocol unless 
specified. 49 or 56 (0.61 μmol) was mixed with SnCl4 (15 eq) in MeCN (10 μL). The 
resulting solution was then combined with a MeCN solution (30 μL) of [18F]fluoride (40 
± 3mCi). After shaking at room temperature for 10 min, the reaction was quenched by 
adding 200 μL water. Then the mixture passed through a Sep-Pak cartridge (Sep-Pak 
Plus tC18) and washed with 3 mL water. The [
18
F]49 or [
18
F]56 was eluted off the 
cartridge with 1mL MeCN and an aliquot of the MeCN fraction (30 μCi) was taken for 
HPLC analysis. After HPLC purification, 0.1N NaOH was added to [
18
F]56 solution 
until the pH reaches 7. The resulting solution was then mixed with an aqueous solution 
of H-Cys-Phe-OH (200 μg, 0.75μmol). After shaking for 10 min at room temperature, a 
portion of the reaction mixture (0.01mCi) was loaded onto HPLC for further analysis 
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and purification. The HPLC containing [
18
F]56/H-Cys-Phe-OH was collected and HPLC 
eluent was removed using a rotary evaporator. [
18
F]56/H-Cys-Phe-OH was reconstituted 
in 1x PBS for stability test and small animal study.  
 
In Vitro Stability 
[
18
F]56/H-Cys-Phe-OH was incubated in 1x PBS buffer at 37 °C. An aliquot of 
the solution (10μCi) was taken out and loaded on HPLC at 0.5h, 1h and 2h time point for 
analysis. 
  
Small animal PET Imaging 
Animal procedures were performed according to a protocol approved by the 
UNC institutional Animal Care and Use Committee. PET scans were performed using a 
small animal PET/CT scanner (Vista eXplore, GE Healthcare, Inc) with a center 
resolution of 1.2- and 4.6-mm axial field of view. A CT scan was first acquired for 
subsequent attenuation correction and anatomic registration. A normal nude mouse was 
anesthetized using 2% isoflurane and injected with 3.1MBq (86μCi) of [18F]56-H-Cys-
Phe-OH via tail vein. At 1, 2, and 4h post injection, static emission scans were acquired 
for 10-20min. Raw PET images were reconstructed using 2D ordered subset expectation 
maximization (OSEM) algorithms with scatter, random and attenuation correction.  
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CHAPTER V  
TRIAZABOROLOPYRIDINIUMS FOR POSITRON EMISSION TOMOGRAPHY/ 
FLUORESCENCE DUAL MODALITY IMAGING 
         
5.1 Introduction 
  Molecular imaging is a fast-growing research field enabling the visualization, 
characterization, and quantification of biological processes that occur in living subjects. 
Although a single imaging technique can offer some insight into a disease process, the 
combination of two or more modalities will eventually provide a diagnosis because each 
imaging modality has its own limitation(s). Positron Emission Tomography (PET) is one 
of the powerful techniques that can provide critical in vivo information on the 
distribution of radiolabeled biomolecules in a non-invasive diagnosis; however, this 
technique gives data with poor resolution. Optical fluorescence imaging is another 
essential technique that has been used for tumor detection and provides a good spatial 
resolution data; nonetheless, it is difficult to quantify.
90
 Therefore, a system that 
combines these two imaging modalities could greatly benefit patient diagnosis. 
  Inspired by the potential synergistic properties of dual modality imaging agents 
that may be applied to clinical applications, our group has recently developed a 
radiofluorination protocol for BODIPY dyes.
18
 Based on this approach, we found that 
the incorporation of 
18
F into the dye could be performed from the corresponding 
hydroxide derivative in aqueous media at low pH. Subsequently, Weissleder and 
Mazitschek showed that the 
18
F-radiolabeling could be processed by allowing the 
18
F 
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fluoride anion to react with BODIPY dyes containing either a boron-triflate or boron-
DMAP moiety.
19
 Although the radioactive fluorescent dyes could be prepared in good 
radiochemical yields (61 – 67 %), the intermediate of an activated BODIPY dye with a 
labile hydroxide, triflate, or DMAP bound to a boron atom must be synthesized before 
radiofluorination (Figure 76). To circumvent the need for an activated dye, our group has 
investigated a new protocol for radiofluorination of BODIPY dyes by a Lewis acid-
assisted isotopic 
18
F-
19
F exchange process. We found that SnCl4 can be used to promote 
18
F-radiolabeling of BODIPY dyes with high radiochemical yield (> 95%) (Figure 76). 
We also provide evidence that this Lewis acid-assisted approach can be used to prepare 
BODIPY dyes conjugated with peptides for use as PET/fluorescence cancer imaging 
probes. The chosen peptide can be connected to the BODIPY dye either before
20
 or 
after
22
 
18
F-radiofluorination. 
 
 
Figure 76. Scheme showing the radiofluorination of a BODIPY dye through a) an 
activated BODIPY dye, b) a Lewis acid-assisted isotopic 
18
F-
19
F exchange. 
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  Although our major interest has focused on the methodological development of 
the radiofluorination of BODIPY-based PET/fluorescence dual modality imaging agents, 
we also question whether we can apply our approach to other boron-containing dyes. In 
2011, Arterburn and coworker reported a new class of fluorescent dye called 
triazaborolopyridinium HPY (Figure 77), which can be easily synthesized from 
hydrazone precursors.
32
 These HPY derivatives are ideal for our application as 
PET/Fluorescence dual modality agents because they are structurally related to BODIPY 
and share desirable characteristics such as cell permeability. In addition, the authors also 
demonstrated that the triazaborolopyridinium dyes are appropriate for use in the 
construction of small molecule probes. With these results in mind, we decided to 
synthesize novel triazaborolopyridinium derivatives with favorable photophysical 
properties by varying the hydrazone substituents and investigate their potential as 
PET/Fluorescence dual modality agents. 
 
 
Figure 77. Illustration of the triazaborolopyridinium dye invented by Arterburn’s group. 
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5.2 Synthesis and characterizations 
  First, we synthesized the hydrazone precursors 62, 63, and 64 by the reaction of 
2-hydrazinylpyridine with aldehyde precursors (i.e., benzaldehyde for 62, 4-
(dimethylamino) benzaldehyde for 63, and 4-nitrobenzaldehyde for 64) in pyridine at 80 
°C (Figure 78). The pale yellow powder of 62 and 63 and bright yellow powder of 64 
were obtained in high yield (87% for 62, 91% for 63, and 75% for 64). Their 
1
H NMR 
spectra show the expected pyridyl and phenyl backbone resonances in the aromatic 
region (6 – 8 ppm). The NH signal was shifted downfield to 10.76 ppm for 62, 10.48 
ppm for 63, and 11.30 ppm for 64. These hydrazone compounds were used without 
further purification.      
 
 
Figure 78. Scheme showing the synthesis of hydrazone precursors with different 
substituents. 
  Next, the triazaborolopyridinium dyes 65, 66, and 67 were synthesized by the 
reaction of the hydrazone precursors (62, 63, 64) with boron trifluoride diethyl etherate 
(BF3OEt2) in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene base (DBU) at an 
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elevated temperature (90 °C, Figure 79). After purification via silica gel column 
chromatography, 65 (yellow solid), 66 (orange solid), and 67 (red solid) were obtained 
in 56, 32, and 63 % yield, respectively. In addition, the nitro group in 67 can be reduced 
into the amine group by palladium-catalyzed hydrogenation in dichloromethane at room 
temperature. The amine-derivative dye 68 was obtained as a yellow solid in 72 % yield. 
These new dyes have been fully characterized. The existence of the BF2 moiety has been 
confirmed by the detection of a triplet 
11
B resonance at 3.43 ppm (JB-F = 30.51 Hz) for 
65, 3.28 ppm (JB-F = 30.77 Hz) for 66, 3.52 ppm (JB-F = 29.87 Hz) for 67, and 3.36 ppm 
(JB-F = 31.02 Hz) for 68, as well as a quartet of 
19
F resonance at -149.0 ppm (JB-F = 31.58 
Hz) for 65, -148.4 ppm (JB-F = 31.20 Hz) for 66, -149.5 ppm (JB-F = 30.07 Hz) for 67, 
and -148.7 ppm (JB-F = 31.01 Hz) for 68. The disappearance of the 
1
H NMR signal of N-
H in 65, 66, and 67 indicated the formation of a BF2 complex with the organic backbone. 
The appearance of the 
1
H NMR signal of NH2 in 68 confirmed that the nitro group in 67 
was successfully reduced.    
 
 
Figure 79. Scheme showing the synthesis of triazaborolopyridinium dyes 65, 66, 67, and 
68. 
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  The photophysical properties of these triazaborolopyridinium dyes have also 
been investigated. The synthesized HPY dyes exhibit absorption spectra with λmax = 462 
nm for 65, 486 nm for 66, 504 nm for 67, and 475 nm for 68. Further, these dyes exhibit 
emission spectra with λemi = 574 nm for 65, 537 nm for 66, 652 nm for 67, and 533 nm 
for 68. Compounds 65 and 67 give rise to large stoke shifts (112 nm for 65 and 148 nm 
for 67), which facilitate signal detection and improves the resolution by separating the 
absorption and emission spectra in fluorescent imaging applications.
91
 They also display 
high quantum yields, with Φf = 35% for 65 and 45% for 67. In contrast, compounds 66 
and 68 with an amino substituent give an expected low quantum yield (Φf = 1.5% for 66 
and Φf = 2.4% for 68) because of fluorescence quenching by the lone pair electrons on 
the amino functional group. 
  To eliminate fluorescence quenching, compound 66 was methylated with 
commercially available methyl trifluoromethanesulfonate (MeOTf) in diethyl ether at 
room temperature. The pale yellow powder was isolated in a 60 % yield. This compound 
has been fully characterized. The presence of the difluoroborate moiety has been 
confirmed by the detection of a triplet 
11
B NMR resonance at 3.73 ppm (JB-F = 23.72 Hz) 
and a quartet 
19
F NMR resonance at -145.7 ppm (JB-F = 25.56 Hz). Notably, the 
1
H NMR 
spectrum showed two singlet signals at 3.19 and 3.69 ppm, corresponding to a dimethyl 
amino group and a monomethyl substituent, respectively, suggesting that the dimethyl 
amino (NMe2) group was not methylated (Figure 80).  
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Figure 80. Scheme showing the synthesis of compound 69. 
 
  The structure of this compound, which was analyzed by single crystal X-ray 
crystallography, revealed that the methyl group attached to the nitrogen atom in the five-
membered ring instead of the nitrogen atom in the dimethyl amino moiety (Figure 81). 
These results are consistent with photophysical properties that this compound is non-
fluorescence because of the effect of the remaining lone-pair electrons on the NMe2 
group. 
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Figure 81. Crystal structure of 69. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 69: B1-F1 1.371(3), B1-F2 1.367(3), B1-N1 1.596(3), 
B1-N3 1.561(3), N1-N2 1.402(2), N2-C1 1.350(3), N3-C1 1.354(3), N2-C6 1.450(3); 
F1-B1-F2 111.9(2), N1-B1-N3 96.45(17), B1-N1-N2 108.89(17), B1-N3-C1 111.65(18), 
N1-N2-C1 110.71(18), N2-C1-N3 111.90(19). 
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  Previously, we reported that activated BODIPY dyes with a labile hydroxide 
group as well as DMAP bound to a boron centre were successfully prepared. Presently, 
we question whether our new HPY dyes can be activated using the same approaches. To 
prove our hypothesis, we decided to synthesize the HPY-DMAP adducts via the reaction 
of BF2-HPY dyes (65, 66, 67, and 68) with TMSOTf in CH3CN followed by the addition 
of DMAP at room temperature. Unfortunately, only the 5-DMAP adduct (70) was 
successfully isolated as a red solid in a 57 % yield (Figure 82).  
    
 
Figure 82. Scheme showing the synthesis of compound 70. 
 
 
  This boron-DMAP adduct 70 was fully characterized by NMR spectroscopy and 
single crystal X-ray crystallography. The 
11
B NMR spectrum presents a doublet signal at 
4.12 ppm (JB-F = 39.35 Hz), indicating that one of the B-F bonds has been activated. The 
19
F NMR spectrum displays a singlet resonance at -78.12 ppm and a quartet resonance at 
-161.0 ppm (JB-F = 40.60 Hz) corresponding to the triflate and BF units, respectively. 
The short B(1)–N(4) separation of 1.560(3) Å in the crystal structure (Figure 83) 
suggests a strong coordination of DMAP ligand. 
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Figure 83. Crystal structure of 70. Displacement ellipsoids are scaled to the 50% 
probability level and hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (deg) for 70: B1-F1 1.377(3), B1-N4 1.560(3), B1-N1 1.531(3), 
B1-N3 1.557(3), N1-N2 1.401(3), N2-C1 1.333(3), N3-C1 1.374(3); F1-B1-N4 108.6(2), 
N1-B1-N3 97.08(19), B1-N1-N2 112.81(19), B1-N3-C1 108.4(2), N1-N2-C1 
105.13(19), N2-C1-N3 116.5(2). 
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  As we have already examined that the HPY dye 67 with a nitro substituent gives 
the highest quantum yield among our newly synthesized HPY dyes, we decided to use 
this organic backbone (64) to synthesize an activated HPY dye with a labile hydroxide 
group bound to a boron atom. This new derivative was prepared by the reaction of 64 
with PhBCl2 in the presence of DBU base at 90 °C in toluene (Figure 84). After column 
purification, the red powder of 71 was obtained in a 35 % yield. The presence of the B-
OH moiety was confirmed by the detection of a broad singlet 
11
B NMR resonance at 
7.22 ppm. The 
1
H NMR spectrum shows the expected pyridyl and phenyl backbone 
resonances in the aromatic region (6 – 8 ppm). The photophysical properties of this 
derivative have also been determined. The compound 71 displays strong absorption 
maxima at 500 nm and emission maxima at 649 nm and possesses a large stoke shift of 
149 nm. In addition, it exhibits a high quantum yield with Φf = 50 %, which is greater 
than the BF2 analogue (67).    
 
 
Figure 84. Scheme showing the synthesis of HPY dye 71. 
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5.3 Fluorination and aqueous stability of the dyes 
  In 2008, Gabbai and coworkers reported that the BODIPY-DMAP adduct reacted 
with fluoride anions to form the corresponding difluoride species.
16
 This protocol is 
significant because it can be used for fluorescent ‘turn-on’ sensing of fluoride ions. 
Moreover, it is the first example to demonstrate F
—
incorporation into a BODIPY dye. 
Thus, this approach can be used as a model for the synthesis of PET/Fluorescence dual 
modality imaging agents. Subsequently, Mazitschek and coworkers investigated the 
18
F-
incorporation reaction of our reported BODIPY-DMAP adduct. They discovered that 
[
18
F]-BODIPY can be efficiently prepared at high temperature (100 °C) in DMF. 
Inspired by these results, we decided to investigate whether our new HPY-DMAP adduct 
(70) could be implemented by similar approach. We were very pleased to find that 70 
can indeed be transformed to the corresponding difluoride species (66) by the addition of 
KHF2 (excess) at 60 °C (Figure 85). As monitored by 
11
B NMR spectroscopy, 37 % of 
70 was transformed to 66 in 20 min (Figure 86). This result is noteworthy because we 
have shown that the fluorination of an HPY-dye can be achieved in a short reaction time, 
which is suitable for 
18
F-incorporation. Finally, 66 was produced in 80 % yield 
(calculated by integration of 
11
B NMR signal) at elevated temperature for 5 h. 
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Figure 85. Scheme showing the fluorination of compound 70. 
 
 
 
Figure 86. 
11
B NMR spectra of the fluorination reaction of 70 at different reaction times. 
 
  Likewise, Gabbai and coworkers also showed that 
18
F fluoride anions can be 
incorporated into the novel ammonium BODIPY-phenylboron hydroxide in aqueous 
solution.
18
 Moreover, they demonstrated that this new [
18
F]-BODIPY dye is stable in 
vivo. Encouraged by this research, we decided to examine whether our new HPY-
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phenylboron hydroxide dye could undergo fluorination to form the corresponding HPY-
phenylboron fluoride dye. To achieve this goal, 71 was reacted with an excess of KHF2 
in THF at 60 °C (Figure 87), and the reaction was monitored by 
19
F NMR spectroscopy. 
Gratifyingly, the 
19
F NMR signal of the corresponding HPY-phenylboron fluoride (72) 
was observed at -166 ppm after 20 min. The new HPY-phenylboron fluoride dye was 
isolated after continuing the reaction overnight to ensure that the fluorination was 
complete. The photophysical properties of this new dye are typical of HPY dyes. It 
features a board absorption band centered at 500 nm and an emission band centered at 
654 nm with a quantum yield of 55 %. Based on the results of the fluorination of 70 and 
71, we can conclude that these HYP dyes are the new candidates for the design of an 
alternative PET/Fluorescence dual modality imaging agents. 
   
 
Figure 87. Scheme showing the fluorination of compound 71. 
 
  In addition, we decided to investigate the rate of hydrolysis of our new HPY dyes 
in aqueous solution. To complete this objective, 65, 66, 67, and 68 were dissolved in 
10% w/v triton X-100 in H2O/ DMSO (7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 
mM, [BF2-dye] = 20 mM with BF2-dye = HPY dyes). The hydrolysis reactions of the 
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HPY dyes (65, 66, 67, and 68) were monitored periodically by 
19
F NMR spectroscopy. 
Based on the kinetic data shown in Figure 88, the first order hydrolysis rate constants 
(kobs) of the HPY dyes were calculated to be 7.3 x 10
-4
 min
-1
 for 65, 2.1 x 10
-4
 min
-1
 for 
66, 4.8 x 10
-4
 min
-1
 for 67, and 3.0 x 10
-4
 min
-1
 for 68, which are comparatively less 
stable than our reported ortho-phosphonium aryltrifluoroborate
79,80
 and ortho-
ammonium aryltrifluoroborate.
80
 However, these HPY dyes are slightly more stable than 
ortho-sulfonium aryltrifluoroborate
80
. Although these results suggest that the HPY dyes 
are less stable than the reported zwitterionic aryltrifluoroborates and conventional 
BODIPY dyes, they confirm that subtle structural changes have an impact on the 
stability of the complexes.             
 
 
Figure 88. Kinetic plots for the hydrolysis of 65, 66, 67, and 68. The data were obtained 
at room temperature in 10% w/v triton X-100 in H2O/ DMSO (7/3 vol) at pH = 7.5. 
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5.4 Conclusion 
  In this study, we have demonstrated that novel triazaborolopyridinium HPY dyes 
can be easily prepared from hydrazone precursors. The photophysical properties of these 
dyes are varied based on the nature of the substituent. HPY dyes with an electron-
withdrawing nitro group feature high quantum yields and large stoke shifts, which are 
suitable characteristics for imaging applications. We have also successfully prepared 
activated HPY dyes, a DMAP-HPY adduct (70) and a boron-hydroxide HPY dye (71) 
for the fluorination test. Gratifyingly, the activated dyes 70 and 71 can be fluorinated in 
a short reaction time, which makes them viable for the 
18
F-fluorination reaction. 
Although the HPY dyes have been shown to be potential candidates for application in a 
PET/Fluorescence dual modality, the low stability of these dyes in aqueous solution 
might create a major problem for in vivo imaging studies because of 
18
F-defluorination. 
Therefore, the stability of these dyes must be optimized before the further development 
of PET imaging applications. 
 
5.5 Experimental 
General Consideration 
Boron trifluoride diethyl etherate (BF3OEt2), dichlorophenylborane (BPhCl2), 4-
dimethylaminopyridine (DMAP), methyl trifluoromethanesulfonate (MeOTf), and 10% 
palladium on carbon (Pd/C) were purchased from Alfar Aesar; 4-(dimethylamino) 
benzaldehyde and 4-nitrobenzaldehyde were purchased from Sigma Aldrich; 2-
hydrazinylpyridine was purchased from Ark Pharm, Inc; 1,8-Diazabicyclo[5.4.0]undec-
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7-ene (DBU) was purchased from TCI America; pyridine was purchased from EMD 
chemicals, Inc; trimethylsilyl trifluoromethanesulfonate (TMSOTf) was purchased from 
Oakwood Products, Inc. All chemicals were used without further purification except for 
BF3OEt2. BF3OEt2 was dried over CaH2. Solvents were dried by passing through an 
alumina column (CH2Cl2 and toluene), refluxing under N2 over Na (Et2O and THF), 
refluxing under N2 over CaH2 (CH3CN).     Electrospray mass spectra were acquired 
from a MDS Sciex API QStar Pulsar. NMR spectra were recorded on a Varian Unity 
Inova 400 NMR and an Inova 500B spectrometer at ambient temperature. Chemical 
shifts are given in ppm, and are referenced to residual 
1
H and 
13
C solvent signals as well 
as external BF3-Et2O (
11
B NMR and 
19
F NMR). 
 
Synthesis of 2-(2-benzylidenehydrazinyl)pyridine (62) 
A solution of 2-hydrazinylpyridine (0.4285 g, 3.924 mmol) and benzaldehyde 
(0.40 mL, 3.920 mmol) in pyridine (20 mL) was stirred at 80 °C for 18 h. Next, the 
solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate 
(50 mL) and washed with saturated NaHCO3 solution (50 mL) followed by water (2 x 50 
mL). The organic layer was dried over anhydrous MgSO4 and removed in vacuo 
affording 62 as a pale yellow solid (0.6705 g, 87 %). 
1
H NMR (399.5 MHz, DMSO -d6): 
 6.72 (ddd, 1H, J = 7.59, 5.19, and 0.92 Hz), 7.20 (d, 1H, J = 8.79), 7.28 (m, 1H), 7.36 
(m, 2H), 7.60 (m, 3H), 7.97 (s, 1H, =CH-), 8.05 (ddd, 1H, J = 4.79, 1.76, and 0.72 Hz), 
10.76 (s, 1H, NH). 
13
C NMR (125.6 MHz, DMSO-d6):  106.74, 115.41, 126.37, 
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128.93, 129.16, 135.83, 138.36, 139.16, 148.22, 157.50. MS (ESI
+
) calcd for [M+H]
+
: 
198.1031, found: 198.0995. 
 
Synthesis of N,N-dimethyl-4-((2-(pyridin-2-yl)hydrazono)methyl)aniline (63) 
A solution of 2-hydrazinylpyridine (0.5645 g, 5.173 mmol) and 4-
(dimethylamino) benzaldehyde (0.6559 g, 4.396 mmol) in pyridine (20 mL) was stirred 
at 80 °C for 18 h. Next, the solvent was removed under reduced pressure. The residue 
was dissolved in ethyl acetate (50 mL) and washed with saturated NaHCO3 solution (50 
mL) followed by water (2 x 50 mL). The organic layer was dried over anhydrous MgSO4 
and removed in vacuo affording 63 as a pale yellow solid (0.9660 g, 91 %). 
1
H NMR 
(399.5 MHz, DMSO-d6):  2.90 (s, 6H, -CH3), 6.65 (ddd, 1H, pyridinium-CH, J = 7.19, 
4.79, and 1.04 Hz), 6.69 (d, 2H, phenyl-CH, J = 8.79 Hz), 7.13 (d, 1H, pyridinium-CH, J 
= 8.39 Hz), 7.44 (d, 2H, phenyl-CH, J = 8.79 Hz), 7.55 (ddd, 1H, pyridinium-CH, J = 
8.79, 6.79, and 1.76 Hz), 7.88 (s, 1H, =CH-), 8.03 (ddd, 1H, pyridinium-CH, J = 5.19, 
1.84, and 1.24 Hz), 10.48 (s, 1H, NH).
13
C NMR (100.5 MHz, DMSO-d6):  40.33, 
106.39, 112.45, 114.56, 123.53, 127.58, 138.15, 140.36, 148.14, 151.00, 157.78. MS 
(ESI
+
) calcd for [M+H]
+
: 241.1453, found: 241.1494.  
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Synthesis of 2-(2-(4-nitrobenzylidene)hydrazinyl)pyridine (64) 
A solution of 2-hydrazinylpyridine (0.6239 g, 5.718 mmol) and 4-
nitrobenzaldehyde (0.8640g, 5.718 mmol) in pyridine (20 mL) was stirred at 80 °C for 
18 h. Then, the solvent was removed under reduced pressure. The solid residue was 
suspended in CH2Cl2 (50 mL) and the suspension was filtered. The resulting powder was 
washed by CH2Cl2 (2 x 50 mL) yielding 64 as a yellow solid (1.0347 g, 75 %). 
1
H NMR 
(499.4 MHz, DMSO-d6):  6.83, (dd, 1H, pyridinium-CH, J = 7.99, 5.99 Hz), 7.32 (d, 
1H, pyridinium-CH, J = 8.49 Hz), 7.68 (dd, 1H, pyridinium-CH, J = 8.99, 7.49 Hz), 7.89 
(d, 2H, phenyl-CH, J = 8.49 Hz), 8.09 (s, 1H, =CH-), 8.15 (d, 1H, pyridinium-CH, J = 
4.64 Hz), 8.22 (d, 2H, phenyl-CH, J = 8.49 Hz), 11.30 (s, 1H, NH). 
13
C NMR (100.5 
MHz, DMSO-d6):  107.20, 116.40, 124.50, 126.95, 136.45, 138.59, 142.40, 146.94, 
148.31, 156.91. MS (ESI
+
) calcd for [M+H]
+
: 243.0882, found: 243.0945. 
 
Synthesis of 2-benzylidene-3,3-difluoro-2,3-dihydro-[1,2,4,3]triazaborolo[4,5-a]pyridin-
2-ium-3-uide (65) 
BF3OEt2 (0.60 mL, 4.862 mmol) was added dropwise to a solution of 62 (0.2006 
g, 1.018 mmol) and 1,8-diazabicycloundec-7-ene (DBU) (0.45 mL, 3.015 mmol) in 
anhydrous toluene (15 mL) at room temperature. The mixture was heated at 90 °C for 12 
h. Then, the reaction mixture was quenched with water (5 mL) and the product was 
extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were washed with 
water (3 x 50 mL), dried over anhydrous MgSO4, and removed under reduced pressure, 
respectively. The solid residue was purified by silica gel column chromatography using 
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CH2Cl2 as an eluent. The purified product (0.1383 g) was obtained as 65 in a 56 % yield. 
1
H NMR (399.5 MHz, CDCl3):  6.35 (dd, 1H, pyridinium-CH, J = 7.19, 6.79 Hz), 6.79 
(d, 1H, pyridinium-CH, J = 9.19 Hz), 7.38 – 7.47 (m, 5H), 7.52 (d, 1H, pyridinium-CH, 
J = 6.39 Hz), 8.34 (m, 2H). 
13
C NMR (100.5 MHz, CDCl3):  109.21, 112.11, 127.80, 
131.06, 131.53, 134.67, 138.65, 140.29. 
11
B NMR (128.2 MHz, CDCl3):  3.43 (t, JB-F = 
30.51 Hz). 
19
F NMR (375.9 MHz, CDCl3):  -149.0 (q, JB-F = 31.58 Hz). MS (ESI
+
) 
calcd for [M+H]
+
: 246.1014, found: 246.0999. 
 
Synthesis of 2-(4-(dimethylamino)benzylidene)-3,3-difluoro-2,3 dihydro[1,2,4,3] 
triazaborolo [4,5-a]pyridin-2-ium-3-uide (66) 
BF3OEt2 (1.00 mL, 8.103 mmol) was added dropwise to a solution of 63 (0.4142 
g, 1.726 mmol) and 1,8-diazabicycloundec-7-ene (DBU) (0.77 mL, 5.159 mmol) in 
anhydrous toluene (15 mL) at room temperature. The mixture was heated at 90 °C for 12 
h. Then, the reaction mixture was quenched with water (5 mL) and the product was 
extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were washed with 
water (3 x 50 mL), dried over anhydrous MgSO4, and removed under reduced pressure, 
respectively. The solid residue was purified by silica gel column chromatography using 
CH2Cl2 as an eluent. The purified product (0.1590 g) was obtained as 66 in a 32 % yield. 
1
H NMR (399.5 MHz, CDCl3):  3.02 (s, 6H, -CH3), 6.17 (dd, 1H, pyridinium-CH, J = 
7.19, 6.39 Hz), 6.65 (d, 2H, phenyl-CH, J = 9.19 Hz), 6.66 (dd, 1H, pyridinium-CH, J = 
9.59, 7.19 Hz), 7.24 (ddd, 1H, pyridinium-CH, J = 9.59, 6.39, and 1.60 Hz), 7.31 (s, 1H, 
=CH-), 7.41 (d, 1H, pyridinium-CH, J = 6.39 Hz), 8.22 (d, 2H, phenyl-CH, J = 9.19 Hz). 
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13
C NMR (125.6 MHz, CDCl3):  29.72, 40.00, 108.52, 111.29, 113.01, 118.08, 135.13, 
135.38, 139.78, 141.54, 152.65, 161.21. 
11
B NMR (128.2 MHz, CDCl3):  3.28 (t, JB-F = 
30.77 Hz). 
19
F NMR (375.9 MHz, CDCl3):  -148.4 (q, JB-F = 31.20 Hz). MS (ESI
+
) 
calcd for [M+H]
+
: 289.1436, found: 289.1351. 
 
Synthesis of 3,3-difluoro-2-(4-nitrobenzylidene)-2,3-dihydro-[1,2,4,3]triazaborolo[4,5-
a]pyridin-2-ium-3-uide (67) 
BF3OEt2 (1.00 mL, 8.103 mmol) was added dropwise to a suspension of 64 
(0.3754 g, 1.550 mmol) and 1,8-diazabicycloundec-7-ene (DBU) (0.70 g, 4.690 mmol) 
in anhydrous toluene (15 mL) at room temperature. After being stirred at 90 °C for 2 h, 
all precursors are completely dissolved. The red solution was stirred at elevated 
temperature for 12 h. Then, the reaction mixture was quenched with water (5 mL) and 
the product was extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were 
washed with water (3 x 50 mL), dried over anhydrous MgSO4, and removed under 
reduced pressure, respectively. The solid residue was purified by silica gel column 
chromatography using CH2Cl2 as an eluent. The purified product (0.2855 g) was 
obtained as 67 in a 63 % yield. 
1
H NMR (499.4 MHz, CDCl3):  6.53 (dd, 1H, 
pyridinium-CH, J = 6.99, 6.49 Hz), 6.91 (d, 1H, pyridinium-CH, J = 8.99 Hz), 7.41 (s, 
1H, =CH-), 7.55 (dd, 1H, pyridinium-CH, J = 8.99, 7.49 Hz), 7.63 (d, 1H, pyridinium-
CH, J = 5.99 Hz), 8.27 (d, 2H, phenyl-CH, J = 8.49 Hz), 8.52 (d, 2H, phenyl-CH, J = 
8.99 Hz). 
13
C NMR (100.5 MHz, CDCl3):  111.06, 112.55, 122.81, 123.30, 129.47, 
131.65, 133.66, 134.69, 135.21, 141.55. 
11
B NMR (128.2 MHz, CDCl3):  3.52 (t, JB-F = 
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29.87 Hz). 
19
F NMR (469.9 MHz, CDCl3):  -149.5 (q, JB-F = 30.07 Hz). MS (ESI
+
) 
calcd for [M+H]
+
: 291.0865, found: 291.0973. 
 
Synthesis of 2-(4-aminobenzylidene)-3,3-difluoro-2,3-dihydro-[1,2,4,3]triazaborolo[4,5-
a] pyridine-2-ium-3-uide (68) 
10% palladium on carbon (0.0410 g, 0.0385 mmol Pd) was added to a solution of 
67 (0.1118 g, 0.0385 mmol) in CH2Cl2 (20 mL). Hydrogen gas was bubbled through the 
solution for 30 min. The mixture was stirred under hydrogen atmosphere overnight at 
room temperature. Then, it was filtered over celite and the solvent was removed under 
vacuum yielding 68 (0.0726 g, 72 %) as a yellow solid. 
1
H NMR (399.5 MHz, CDCl3): 
 6.24 (dd, 1H, pyridinium-CH, J = 7.19, 5.99 Hz), 6.66 (d, 2H, phenyl-CH, J = 8.79 
Hz), 6.73 (d, 1H, pyridinium-CH, J = 8.79 Hz), 7.30 (ddd, 1H, pyridinium-CH, J = 9.19, 
6.79, and 1.64 Hz), 7.31 (s, br, 1H, =CH-), 7.45 (d, 2H, phenyl-CH, J = 5.99 Hz), 8.17 
(d, 2H, phenyl-CH, J = 8.79 Hz). 
13
C NMR (100.5 MHz, CDCl3):  108.87, 112.94, 
114.27, 135.31, 135.41, 140.16, 141.01, 150.46. 
11
B NMR (128.2 MHz, CDCl3):  3.36 
(t, JB-F = 31.02 Hz). 
19
F NMR (469.9 MHz, CDCl3):  -148.7 (q, JB-F = 31.01 Hz). MS 
(ESI
+
) calcd for [M+H]
+
: 261.1123, found: 261.1173. 
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Synthesis of 2-(4-(dimethylamino)benzylidene)-3,3-difluoro-1-methyl-2,3-dihydro-
[1,2,4,3] triazaborolo[4,5-a]pyridine-1,2-diium-3-uide 2,2,2-trifluoroacetate (69) 
MeOTf (0.036 mL, 0.328 mmol) was added to a solution of 66 (0.0473 g, 0.164 
mmol) in Et2O (5 mL). The reaction mixture was stirred at room temperature. After 
being stirred overnight, the pale yellow solid precipitated. The solid was collected by 
filtration affording 69 (0.0411 g) in a 60 % yield. 
1
H NMR (399.5 MHz, CD3CN):  
3.19 (s, 6H, -CH3), 3.69 (s, 3H, -CH3), 6.92 (d, 2H, phenyl-CH, J = 9.19 Hz), 7.23 (dd, 
1H, pyridinium-CH, J = 7.59, 6.79 Hz), 7.31 (d, 1H, pyridinium-CH, J = 9.19 Hz), 7.99 
(d, 2H, phenyl-CH, J = 9.19 Hz), 8.18 (d, 1H, pyridinium-CH, J = 6.39 Hz), 8.20 (ddd, 
1H, pyridinium-CH, J = 9.59, 7.19, and 1.52 Hz), 8.23 (s, br, 1H, =CH-). 
13
C NMR 
(100.5 MHz, CD3CN):  33.32, 39.91, 57.29, 108.98, 112.16, 112.75, 117.19, 136.24, 
137.15, 146.42, 151.72, 156.06. 
11
B NMR (128.2 MHz, CD3CN):  3.73 (t, JB-F = 23.72 
Hz). 
19
F NMR (375.9 MHz, CD3CN):  -78.41 (trifluoroacetate salt), -145.7 (q, JB-F = 
25.56 Hz). MS (ESI
+
) calcd for [M]
+
: 303.1492, found: 303.1659. 
 
Synthesis of 2-(4-(dimethylamino)benzylidene)-3-(4-(dimethylamino)pyridin-1-ium-1-
yl)-3-fluoro-2,3-dihydro-[1,2,4,3]triazaborolo[4,5-a]pyridin-2-ium-3-uide 2,2,2-
trifluoro acetate (70) 
Compound 66 (0.0557 g, 0.193 mmol) in CH3CN (3 mL) was treated with 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) (0.035 mL, 0.193 mmol) and 4-
dimethylaminopyridine (DMAP) (0.0243 g, 0.193 mmol), respectively. The reaction 
mixture was stirred at room temperature for 10 h. Then, the solution was concentrated in 
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vacuo to a volume of 1 mL. To the concentrated solution, was added Et2O (10 mL) 
which resulted in the precipitation of a red solid. The red solid was washed by Et2O (3 x 
10 mL) yielding 70 (0.0555 g) in a 57 % yield. 
1
H NMR (499.4 MHz, CDCl3):  3.12 (s, 
6H, -CH3), 3.24 (s, 6H, -CH3), 6.25 (dd, 1H, pyridinium-CH, J = 7.99, 6.49 Hz), 6.71 (d, 
2H, phenyl-CH, J = 9.49 Hz), 6.80 (d, 2H, phenyl-CH, J = 9.49 Hz), 6.88 (d, 2H, 
phenyl-CH, J = 7.49 Hz), 7.18 (d, 1H, pyridinium-CH, J = 6.49 Hz), 7.29 (s, 1H, =CH-), 
7.34 (ddd, 1H, pyridinium-CH, J = 9.49, 6.99, and 1.05 Hz), 7.90 (d, 2H, phenyl-CH, J = 
6.99 Hz), 8.04 (s, br, 1H, pyridinium-CH). 
13
C NMR (125.6 MHz, CDCl3):  40.03, 
40.19, 107.02, 108.26, 109.64, 111.43, 113.39, 117.05, 119.49, 122.05, 134.13, 136.65, 
139.12, 140.21, 140.85, 140.89, 145.09, 153.78, 157.21, 160.98. 
11
B NMR (128.2 MHz, 
CDCl3):  4.12 (d, JB-F = 39.35 Hz). 
19
F NMR (375.9 MHz, CDCl3):  -78.12 
(trifluoroacetate salt), -161.0 (q, JB-F = 40.60 Hz). MS (ESI
+
) calcd for [M]
+
: 391.2218, 
found: 391.2358. 
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Synthesis of 3-hydroxy-2-(4-nitrobenzylidene)-3-phenyl-2,3-dihydro-[1,2,4,3]triaza- 
borolo[4,5-a]pyridin-2-ium-3-uide (71) 
PhBCl2 (0.20 mL, 1.544 mmol) was added dropwise to a suspension of 64 
(0.1805 g, 0.745 mmol) and 1,8-diazabicycloundec-7-ene (DBU) (0.35 mL, 2.345 mmol) 
in anhydrous toluene (15 mL) at room temperature. The mixture was heated at 90 °C for 
12 h. Then, the reaction mixture was quenched with water (5 mL) and the solvent was 
removed under reduced pressure. The product was extracted with CH2Cl2 (2 x 50 mL). 
The combined organic layers were washed with water (3 x 50 mL), dried over anhydrous 
MgSO4, and removed under reduced pressure, respectively. The solid residue was 
purified by silica gel column chromatography using CH2Cl2 as an eluent. The purified 
product (0.0921g) was obtained as 71 in a 35 % yield. 
1
H NMR (399.5 MHz, CDCl3):  
6.48 (dd, 1H, pyridinium-CH, J = 7.59, 6.79 Hz), 6.98 (d, 1H, pyridinium-CH, J = 9.19 
Hz), 7.28 (m, 4H), 7.47 (m 3H), 7.52 (ddd, 1H, pyridinium-CH, J = 9.19, 6.79, and 1.28 
Hz), 8.22 (d, 2H, phenyl-CH, J = 8.79 Hz), 8.45 (d, 2H, phenyl-CH, J = 9.19 Hz). 
13
C 
NMR (100.5 MHz, CDCl3):  112.51, 112.56, 123.67, 128.06, 128.66, 131.94, 132.09, 
135.86, 136.11, 137.42, 141.70, 147.88, 161.73. 
11
B NMR (128.2 MHz, CDCl3):  7.22. 
MS (ESI
+
) calcd for [M+H]
+
: 347.1315, found: 347.1408. 
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Synthesis of 3-fluoro-2-(4-nitrobenzylidene)-3-phenyl-2,3-dihydro-[1,2,4,3]triaza- 
borolo[4,5-a]pyridin-2-ium-3-uide (72) 
A solution of 71 (0.0832 g, 0.240 mmol) in THF (10 mL) was treated with KHF2 
(0.0938 g, 1.202 mmol) and stirred at 60 °C for 12 h. The reaction mixture was then 
quenched with water (10 mL) and extracted with CH2Cl2 (3 x 30 mL). The combined 
organic layers were dried over anhydrous MgSO4 and removed under reduced pressure. 
The solid residue was purified by silica gel column chromatography using CH2Cl2 as an 
eluent. The purified product (0.0685 g) was obtained as 72 in a 82 % yield. 
1
H NMR 
(399.5 MHz, CDCl3):  6.45 (dd, 1H, pyridinium-CH, J = 7.19, 6.39 Hz), 6.99 (d, 1H, 
pyridinium-CH, J = 8.79 Hz), 7.14 (d, 1H, J = 2.24 Hz), 7.28 (m 3H), 7.39 (m 2H), 7.45 
(d, 1H, pyridinium-CH, J = 5.99 Hz), 7.54 (dd, 1H, pyridinium-CH, J = 9.59, 7.59 Hz), 
8.22 (d, 2H, phenyl-CH, J = 8.79 Hz), 8.46 (d, 2H, phenyl-CH, J = 9.19 Hz). 
13
C NMR 
(100.5 MHz, CDCl3):  111.04, 111.83, 122.69, 126.99, 127.63, 130.44, 130.49, 131.07, 
133.77, 135.29, 136.64, 140.89, 146.80, 161.74. 
11
B NMR (128.2 MHz, CDCl3):  7.66. 
19
F NMR (469.9 MHz, CDCl3):  -166.0. MS (ESI
+
) calcd for [M+H]
+
: 349.1272, 
found: 349.1349. 
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Figure 89. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 65 in CDCl3. 
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Figure 90. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 66 in CDCl3. 
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Figure 91. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 67 in CDCl3. 
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Figure 92. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 68 in CDCl3. 
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Figure 93. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 69 in CD3CN. 
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Figure 94. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 70 in CDCl3. 
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Figure 95. 
1
H, 
13
C, and 
11
B NMR spectra of 71 in CDCl3. 
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Figure 96. 
1
H, 
13
C, 
11
B, and 
19
F NMR spectra of 72 in CDCl3. 
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Crystallographic Measurements  
  Single crystals of 69 were obtained by slow diffusion of Et2O into a CH3CN 
solution of 69. Single crystals of 70 were obtained by slow diffusion of Et2O into a 
CH2Cl2 solution of 70. The crystallographic measurement of 69 and 70 were performed 
using a Bruker APEX-II CCD area detector diffractometer, with graphite-
monochromated Mo-Kα radiation (λ = 0.71069 Å). A specimen of suitable size and 
quality was selected and mounted onto a nylon loop. The semi-empirical method 
SADABS was applied for absorption correction. The structure was solved by direct 
methods, and refined by the full-matrix least-square method against F
2
 with the 
anisotropic temperature parameters for all non-hydrogen atoms.  All H atoms were 
geometrically placed and refined using the riding model approximations. Data reduction 
and further calculations were performed using the Bruker SAINT+ and SHELXTL NT 
program packages. The crystal data are included in Table 18 and 19. 
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Table 18. Crystal data, data collections, and structure refinements of 69. 
Crystal data 69 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C17H18BF5N4O2 
434.07 
0.10 x 0.15 x 0.06 
110(2) K 
0.71073 Å 
Triclinic 
P-1 
a = 7.778(5) Å            α = 104.721(7)° 
b = 11.445(7) Å  β = 96.536(7)° 
c = 11.847(8) Å  γ = 105.629(7)° 
963.3(11) Å
3
 
2 
1.559 g cm
-3
 
0.242 mm
-1 
464.0 
ω, φ 
-10 → +10 
-15 → +15 
-15 → +15 
12126 
4819 (0.0522) 
4819 
271 
1.597 
0.0911, 0.1612 
0.92, -0.58 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.0743 and b = 0.7221. 
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Table 19. Crystal data, data collections, and structure refinements of 70. 
Crystal data 70 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C23H25BF4N6O2 
515.15 
0.30 x 0.25 x 0.10 
110(2) K 
0.71073 Å 
Triclinic 
P-1 
a = 10.532(7) Å            α = 112.408(7)° 
b = 11.026(7) Å  β = 93.202(8)° 
c = 11.582(7) Å  γ = 92.399(8)° 
1238.6(14) Å
3
 
2 
1.449 g cm
-3
 
0.198 mm
-1 
560.0 
ω, φ 
-14 → +14 
-14 → +14 
-15 → +15 
15447 
6119 [0.0332] 
6119 
334 
1.664 
0.0754, 0.1736 
0.86, -0.43 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.077 and b = 1.089. 
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Kinetic studies 
A sample of 65, 66, 67, and 68 was dissolved in 0.3 mL DMSO-d6 and 0.7 mL of 
10% w/v triton X-100 in D2O phosphate buffer (pH 7.5, 500 mM) for the stability test. 
The 
19
F NMR spectra were collected periodically. The decomposition of BF2-HPY dyes 
were monitored by integration of the decreasing BF2-HPY dye signal in conjunction 
with the increasing signal corresponding to free F
-
. All spectra were processed using the 
VNMRJ Version 2.2 NMR software. The rate constant, kobs, was calculated using a well-
established NMR method reported in the literature.
4 
 This method is based on the fact 
that the concentration in BF2-HPY dye is proportional to the 
19
F NMR integration of 
BF2-HPY dye signal divided by the sum of the integration of BF2-HPY dye signal and 
the free fluoride signal.  For convenience, the value of the BF2-HPY dye integration is 
arbitrarily set at 100 and the free fluoride integration determined. The resulting data is 
provided in Table 20, 21, and 22.  
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Table 20. Kinetic data for the hydrolysis of 65 in 10% w/v triton X-100 in H2O/ DMSO 
(7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 mM).  The values provided for F
-
 and 
ArBF3 correspond to the integration of the corresponding NMR signal. 
    Data for 65 kobs = 7.3E-4 
Time 
(min) [F
-
] [BF2] [BF2]/([BF2]+[F
-
] [BF2]/([BF2]+[F
-
] 
      exp. Ratio calc. ratio 
0 0 100 1.00 1.00 
1066 115.28 100 0.46 0.46 
1496 205.55 100 0.33 0.34 
2495 476.28 100 0.17 0.16 
2927 691.42 100 0.13 0.12 
3834 1939 100 0.05 0.06 
4200       0.05 
4500       0.04 
4800       0.03 
 
Table 21. Kinetic data for the hydrolysis of 66 in 10% w/v triton X-100 in H2O/ DMSO 
(7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 mM).  The values provided for F
-
 and 
ArBF3 correspond to the integration of the corresponding NMR signal. 
    Data for 66 kobs = 2.1E-4 
Time 
(min) [F
-
] [BF2] [BF2]/([BF2]+[F
-
] [BF2]/([BF2]+[F
-
] 
      exp calc 
0 0 100 1.00 1.00 
1081 30.36 100 0.77 0.80 
1509 38.52 100 0.72 0.73 
2512 62.3 100 0.62 0.59 
2943 75.18 100 0.57 0.54 
3346 84.26 100 0.54 0.50 
4200       0.41 
4500       0.39 
4800       0.36 
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Table 22. Kinetic data for the hydrolysis of 67 in 10% w/v triton X-100 in H2O/ DMSO 
(7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 mM).  The values provided for F
-
 and 
ArBF3 correspond to the integration of the corresponding NMR signal. 
    Data for 67 kobs = 4.8E-4 
Time 
(min) [F
-
] [BF2] [BF2]/([BF2]+[F
-
] [BF2]/([BF2]+[F
-
] 
      exp calc 
0 0 100 1.00 1.00 
1058 88.58 100 0.53 0.60 
1482 120.56 100 0.45 0.49 
2480 186.78 100 0.35 0.30 
2912 245.46 100 0.29 0.25 
3915 322.60 100 0.24 0.15 
4200       0.13 
4500       0.12 
4800       0.10 
 
Table 23. Kinetic data for the hydrolysis of 68 in 10% w/v triton X-100 in H2O/ DMSO 
(7/3 vol) at pH = 7.5 ([phosphate buffer] = 500 mM).  The values provided for F
-
 and 
ArBF3 correspond to the integration of the corresponding NMR signal. 
    Data for 68 kobs = 3.0E-4 
Time (min) [F
-
] [BF2] [BF2]/([BF2]+[F
-
] [BF2]/([BF2]+[F
-
] 
      exp calc 
0 0 100 1.00 1.00 
1025 44.66 100 0.69 0.74 
1452 60.88 100 0.62 0.65 
2459 95.02 100 0.51 0.48 
2892 118.89 100 0.46 0.42 
3894 162.75 100 0.38 0.31 
4200       0.28 
4500       0.26 
4800       0.24 
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UV-vis and fluorescence measurements  
UV-vis spectra were recorded on an Ocean Optics USB4000 spectrometer with 
an Ocean Optics ISS light source. Steady state emission spectra were collected at room 
temperature using a PTI QuantaMaster 4 fluorescence spectrophotometer equipped with 
a Model 810 PMT detector. The spectra were measured in CH2Cl2. Quantum yields were 
measured using fluorescein as a standard in 0.1 M NaOH solution. All absorption and 
emission spectra were demonstrated in Figure 97-102. 
 
 
Figure 97. Absorption (blue) and emission (red) spectra of 65 in CH2Cl2. 
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Figure 98. Absorption (blue) and emission (red) spectra of 66 in CH2Cl2. 
 
 
Figure 99. Absorption (blue) and emission (red) spectra of 67 in CH2Cl2. 
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Figure 100. Absorption (blue) and emission (red) spectra of 68 in CH2Cl2. 
 
 
Figure 101. Absorption (blue) and emission (red) spectra of 71 in CH2Cl2. 
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Figure 102. Absorption (blue) and emission (red) spectra of 72 in CH2Cl2. 
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CHAPTER VI  
SYNTHESIS, STRUCTURE, AND ISOMERIZATION OF PHOSPHINO-
METHYLIUM COMPOUNDS 
 
6.1 Introduction 
  The discovery of frustrated Lewis pairs (FLPs) and the exploration of their 
potential for the activation of small molecules have led to the development of metal–free 
approaches to catalytic reactions.
92-95
 One of the first examples of an FLP was the 
combination of perfluorotriphenylborane and tri-tert-butylphosphine, which can activate 
dihydrogen at room temperature.
96
 In addition to intermolecular FLPs, the decoration of 
a molecular backbone with bulky Lewis acids and Lewis bases in proximity to one 
another gives rise to intramolecular FLPs, which have found applications in catalysis
97,98
 
and transition metal complexation.
99-101
 Erker and coworkers developed the 
intramolecular P/B frustrated Lewis pair I (Figure 103) for use in heterolytic dihydrogen 
splitting.
98
 They also demonstrated that the resultant borohydride is capable of acting as 
a reducing agent for organic substrates. These results are noteworthy as they describe 
useful steps toward the metal-free utilization of dihydrogen in organic syntheses. In 
addition to catalytic applications, Bourissou and coworkers investigated the use of ortho-
phenylene phosphino-borane IIa (Figure 103) as an ambiphilic ligand for the 
coordination of gold and palladium.
101
 This work provided the first evidence of M → B 
interactions supported by single donor buttresses. Later, they successfully coordinated 
both Rh and Cu metal centers with the P/B ambiphilic ligands IIa and IIb.
99,100
 These 
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studies further substantiated the versatile coordination properties of ortho-phenylene 
phosphino-boranes. Apart from the P/B FLP system, Bourissou and Gabbai synthesized 
the new ortho-phenylene phosphino-stannane derivatives IIIa and IIIb, and studied the 
intramolecular P-Sn interactions presenting in the compounds. They found the phosphine 
and stannane groups to be engaged in an intramolecular P→Sn dative interaction. The 
interaction in IIIb is stronger than that in IIIa because of the intense donicity of the 
di(iso-propyl)phosphine moiety of IIIb.           
. 
 
Figure 103. Illustration of intramolecular frustrated Lewis pair systems. 
 
  The utilities of I, IIa and IIb in catalytic reactions and the interesting interaction 
in IIIa and IIIb prompted us to investigate whether a carbocation, a strong Lewis acid, 
and a phosphine, a Lewis base, might be incorporated into the ortho positions of the 
same phenylene backbone to furnish intramolecular FLPs (Figure 104). Gabbai and 
Wang discovered that a carbocation can be easily generated on a naphthalene backbone 
through the treatment of 1,8-bis[bis(p-methoxy-phenyl)hydroxymethyl]naphthalene with 
trifluoroacetic anhydride (TFAA) and fluoroboric acid (HBF4).
102
 With this objective 
and promising preliminary results in mind, we endeavored to synthesize novel ortho-
phenylene phosphino-methylium compounds (Figure 104) and to investigate their 
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properties and reactivities with small molecules.  
     
 
Figure 104. Illustration of the intramolecular P/C
+ 
frustrated Lewis pairs synthesized in 
this work. 
 
6.2 Synthesis and characterizations  
  Inspired by reports from Wang and Gabbai,
102-104
 we first prepared the (2-
(phosphino)phenyl)diphenylmethanol compounds a and b by the metalation of (2-
bromophenyl)diphenylphosphine or (2-bromophenyl)di-iso-propylphosphine with n-
butyllithium (nBuLi), followed by the addition of benzophenone (Figure 105). The 
ortho-phenylene phosphino-methylium compounds 73 and 74 were then synthesized by 
the addition of aqueous HBF4 to suspensions of a and b in trifluoroacetic anhydride. 
After precipitation from Et2O, compounds 73 and 74 were obtained as white powders in 
70% and 72% yield, respectively. Surprisingly, compounds 73 and 74 were stable in air. 
Each was fully characterized by NMR spectroscopy. The presence of the phosphonium 
moiety was confirmed by the detection of a 
31
P NMR resonance at 54.4 ppm for 73 and 
82.3 ppm for 74. The low-field 
31
P NMR signal observed for 74 suggested strong 
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donation from di-iso-propylphosphine to carbon center. The 
1
H NMR spectra of 73 and 
74 showed the expected phenyl backbone resonances in the aromatic region (6 – 8 ppm). 
The 
13
C NMR signal of the CPh2 center appears as a doublet at 74.7 ppm (
1
JC-P = 50.01 
Hz) for 73 and 70.4 ppm (
1
JC-P = 43.5 Hz) for 74. 
 
 
Figure 105. Scheme depicting the synthesis of phosphino-methylium 73 and 74. 
 
  The structures of these compounds, which were confirmed by single-crystal X-
ray crystallography, show the formation of strained four-membered rings (Figures 106 
and 107). The P(1)-C(1) separations of 1.871(4) Å in 73 and 1.913(2) Å in 74 are 
slightly longer than typical P-C bonds because of the strain of the four member ring and 
the bulk of the substituents on the phosphorous and carbon centers. The C(1)-P(1)-C(3) 
angles of 73 (80.33(18)°) and 74 (74.28(8)°) are smaller than the ideal tetrahedral angle 
(109.5°), indicating distorted tetrahedral geometries for the P atoms of 73 and 74.  
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Figure 106. Crystal structure of 73. Displacement ellipsoids are scaled to the 50% 
probability level. Tetrafluoroborate counter anion and hydrogen atoms were omitted for 
clarity. Selected bond lengths (Å) and angles (deg) for 73: P1-C1 1.871(4), C1-C2 
1.597(5), C2-C3 1.401(5), P1-C3 1.735(4); C1-P1-C3 80.33(18), P1-C1-C2 83.4(2), C1-
C2-C3 101.7(3), C2-C3-P1 94.6(3). 
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Figure 107. Crystal structure of 74. Displacement ellipsoids are scaled to the 50% 
probability level. Tetrafluoroborate counter anion and hydrogen atoms were omitted for 
clarity. Selected bond lengths (Å) and angles (deg) for 74: P1-C1 1.9129(18), C1-C2 
1.542(2), C2-C3 1.395(3), P1-C3 1.7727(19); C1-P1-C3 74.28(8), P1-C1-C2 83.63(10), 
C1-C2-C3 104.74(15), C2-C3-P1 93.39(12). 
 
 
 
 198 
 
  Although the four-membered-ring-containing diphenylphosphino-methylium 
derivative 73 is air-stable in when stored as a solid, it undergoes an unexpected 
isomerization when dissolved in polar organic solvent (chloroform and acetonitrile), 
forming the cyclic diphenylphosphino-methylium derivative 75 (Figure 108). This 
isomerization was monitored by 
31
P NMR spectroscopy. The 
31
P NMR signal shifted 
from 54.4 ppm to 3.18 ppm over 72 h, suggesting the formation of the new phosphonium 
salt containing a six-membered ring (75). The presence of a methine unit ( ) in 75 was 
confirmed by detection of a doublet at 5.08 ppm (
4
JH-P = 1.62 Hz) in the 
1
H NMR 
spectrum, as well as doublet at 52.9 ppm (
3
JC-P = 9.07 Hz) in the 
13
C NMR spectrum. 
Nonetheless, under ambient conditions, the highly strained di-iso-propylphosphino-
methylium derivative 74 is stable in both the solid and solution phases. To examine 
whether 74 isomerizes at elevated temperatures, 74 was heated to 80 °C in acetonitrile. 
Upon heating, the 
31
P NMR signal of 74 shifted from 82.3 ppm to 17.1 ppm, indicating 
formation of the isomerized six-membered ring product (76). The existence of the 
methine unit ( ) in 76 was also suggested by the detection of doublet at 5.93 ppm (
4
JH-
P = 3.76 Hz) in the 
1
H NMR spectrum and a doublet at 50.7 ppm (
3
JC-P = 8.58 Hz) in the 
13
C NMR spectrum.  
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Figure 108. Scheme depicting the isomerization of phosphino-methylium 73 and 74. 
 
  The structure of the isomerized products, confirmed by single crystal X-ray 
crystallography, confirms formation a six-membered phosphonium ring species (Figure 
109 and 110). The P(1)-C(1) distances of 1.7848(18) Å in 75 and 1.773(5) in 76 are 
shorter than those in the four-membered ring species 73 (1.871(4) Å) and 74 (1.913(2) 
Å), suggesting the formation of more stable P-C bonds. The C(1)-P(1)-C(5) angles of 75 
(109.54(8)°) and 76 (106.65(18)°) are closer to the ideal tetrahedral angle (109.5°), 
indicating a less strained bonding environment at phosphorus. These structural results 
indicate that the isomerizations of 73 and 74 are driven by the strain in the four-
membered ring species. 
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Figure 109. Crystal structure of 75. Displacement ellipsoids are scaled to the 50% 
probability level. Tetrafluoroborate counter anion and hydrogen atoms were omitted for 
clarity. Selected bond lengths (Å) and angles (deg) for 75: P1-C1 1.7848(18), C1-C2 
1.400(2), C2-C3 1.517(2), C3-C4 1.524(2), C4-C5 1.399(2), P1-C5 1.7838; C1-P1-C5 
109.54(8), P1-C1-C2 118.56(12), C1-C2-C3 123.38(14), C2-C3-C4 114.87(13), C3-C4-
C5 122.25(14), C4-C5-P1 119.09(12). 
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Figure 110. Crystal structure of 76. Displacement ellipsoids are scaled to the 50% 
probability level. Tetrafluoroborate counter anion and hydrogen atoms were omitted for 
clarity. Selected bond lengths (Å) and angles (deg) for 76: P1-C1 1.773(5), C1-C2 
1.405(5), C2-C3 1.513(5), C3-C4 1.529(5), C4-C5 1.406(5), P1-C5 1.779(5); C1-P1-C5 
106.65(18), P1-C1-C2 121.8(3), C1-C2-C3 125.5(3), C2-C3-C4 118.8(3), C3-C4-C5 
125.1(4), C4-C5-P1 121.8(3). 
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  The four-membered-ring-containing diphenylphosphino-methylium compound 
(73) is easier to isomerize than its di-iso-propyl analogue (74) due to the weak donicity 
of the diphenylphosphine moiety. This argument is strengthened by the observation that 
73 underwent isomerization upon dissolving in CDCl3 at ambient temperature, whereas 
74 showed no reaction. Through periodic monitoring by 
31
P NMR, we discovered that 
the room temperature isomerization of 73 could be fit to a first-order rate equation with a 
rate constant of 0.0011 min
-1
 (Figure 111). 
       
 
Figure 111. Kinetic plot of the isomerization process of 73. 
 
  Finally, we tested the reactivity of the four-membered-ring-containing 
phosphino-methylium derivertives 73 and 74 with small molecules, including H2, CO2, 
and N2O, as well as with late transition metal complexes such as (tht)AuCl and 
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Pd(PPh3)4. Unfortunately, neither 73 nor 74 successfully activated the small molecules, 
nor did they act as ambiphilic ligands with transition metal complexes.  
 
6.3 Conclusion 
  The phosphine methylium derivatives 73 and 74 have been successfully prepared 
and fully characterized.  These compounds features short intramolecular PC+ bonds 
indicating that they are not truly frustrated Lewis pairs as originally envisaged.  This is 
especially true for the di-isopropyl derivative 74 which is remarkably inert.  
Interestingly, 73 undergoes an isomerization reaction when dissolved in organic solvents 
at room temperature, whereas 74 is stable under the same conditions. The difference 
observed in the isomerization processes derives from the dissimilarity of the electron 
donating ability of the phosphine ligand.   
 
6.4 Experimental 
General Consideration 
  (2-bromophenyl) diphenylphosphine
105
, and (2-bromophenyl) diisopropyl 
phosphine
105
 were synthesized according to the published procedure. Fluoroboric acid 
(HBF4) and n-butyllithium (n-BuLi) were purchased from Alfar Aesar; trifluoroacetic 
anhydride (TFAA) was purchased from Oakwood product, Inc; benzophenone was 
purchased from Baker Analyzed. All chemicals were used without further purification. 
Solvents were dried by passing through an alumina column (CH2Cl2) or refluxing under 
N2 over Na/K (Et2O and THF). Electrospray mass spectra were acquired from a MDS 
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Sciex API QStar Pulsar. NMR spectra were recorded on Inova 300, Inova 400, and an 
Inova 500B NMR spectrometer at ambient temperature. Chemical shifts are given in 
ppm, and are referenced to residual 
1
H and 
13
C solvent signals as well as external H3PO4 
(
31
P NMR) and BF3-Et2O (
11
B NMR and 
19
F NMR). 
 
Preparation of 7,7,8,8-tetraphenyl-7-phosphabicyclo[4.2.0]octa-1(6),2,4-trien-7-ium 
tetrafluoroborate (73) 
  (2-bromophenyl)diphenylphosphine (0.561 g, 1.65 mmol) was lithiated at 0 °C in 
diethyl ether (10 mL) using a 2.60 M n-BuLi in hexane (0.62 mL, 1.65 mmol). The 
solution mixture was stirred at 0 °C for 15 min leading to formation of the lithium salt as 
white powder. The suspension was allowed to warm up to room temperature. Then, 
benzophenone (0.300, 1.65 mmol) was added to the suspension of the lithium salt. The 
solution mixture was stirred overnight. The solvent was removed in vacuo.  The residue 
was suspended in CH2Cl2 (15 mL) and treated with as saturated NH4F aqueous solution 
(10 mL). The mixture was rigorously stirred for 1 h until all white powder dissolved. 
The organic layer was collected and dried over MgSO4. The mixture was filtered to 
remove MgSO4 and the solvent was removed under reduced pressure yielding a as a 
white powder (0.483 g, 68% yield). 
1
H NMR (299.9 MHz, CDCl3):  6.30 (d,1H, 
3
JH-P = 
18.64 Hz), 6.71 (m, 1H), 7.02 – 7.09 (m, 4H), 7.12 – 7.26 (m, 17H), 7.36 (m, 1H). 13C 
NMR (100.5 MHz, CDCl3):  83.90 (d, JC-P = 2.88 Hz), 127.14, 127.51, 127.78, 128.29, 
128.36, 128.42, 128.61, 128.66, 130.17 (d, JC-P = 8.81 Hz), 133.31, 133.49, 135.25 (d, 
JC-P = 14.02 Hz), 135.68 (d, JC-P = 5.39 Hz), 138.12 (d, JC-P = 2.31), 147.18, 154.48 (d, 
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JC-P = 23.30 Hz). 
31
P
31
 NMR (121.4 MHz, CDCl3):  -16.00. Mass (ESI
+
): calcd for 
C31H25OP (M+H)
+
, 445.1721; found 445.1732. a was used without further purification. 
To a suspension of a (0.483 g, 1.09 mmol) in trifluoroacetic anhydride (TFAA) (7 mL) 
was added 48% HBF4 (0.5 mL, 3.85 mmol). After being stirred for 10 min, all the white 
powder dissolved and the mixture turned red. The red solution was stirred for 1.5 h and 
quenched by diethyl ether (20 mL). After addition of diethyl ether, a white powder 
precipitated. The reaction mixture was filtered yielding 73 as a white solid (0.392 g , 
70% yield). 
1
H NMR (399.59 MHz, CDCl3):  6.98 – 7.01 (m, 4H), 7.16 – 7.22 (m, 5H), 
7.36 – 7.49 (m, 8H), 7.61 – 7.66 (m, 2H), 7.71 (d, 1H, 3JH-H = 7.99 Hz), 8.04 (q, 1H, 
3
JH-
H = 7.59 Hz), 8.15 (t, 1H, 
3
JH-H = 8.39 Hz), 8.41 (dd, 1H, 
3
JH-H = 7.99 Hz, 
3
JH-P = 11.59  
Hz). 
13
C NMR (100.5 MHz, CDCl3):  74.81 (d, 
1
JC-P = 48.24 Hz), 116.85, 117.57, 
123.82, 124.60, 127.41, 127.66, 128.83, 128.85, 129.53, 129.60, 130.03, 130.15, 131.99, 
133.67, 133.77, 133.83, 134.16, 134.23, 135.31 (d, JC-P = 5.03 Hz), 138.73 (d, JC-P = 5.03 
Hz), 153.75 ((d, JC-P = 8.04 Hz),) 
31
P
31
 NMR (121.4 MHz,CDCl3):   54.43. Anal. Calcd 
for C31H24PBF4: C, 72.52; H, 4.67. Found: C, 72.30; H, 4.59. 
 
Preparation of 7,7-diisopropyl-8,8-diphenyl-7-phosphabicyclo[4.2.0]octa-1(6),2,4-trien-
7-ium tetrafluoroborate (74) 
  Ortho-bromo-diisopropylphosphinobenzene (1-Br-2-(PiPr2)C6H4) (1.095 g, 4.01 
mmol) was lithiated at -78 °C in diethyl ether (15 mL) using a 2.60 M n-BuLi in hexane 
(1.70 mL, 4.42 mmol). The solution mixture was stirred at -78 °C for 1 h leading to 
formation of the lithium salt as white powder. Then, benzophenone (0.730, 4.01 mmol) 
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was added to the suspension of the lithium salt. The solution mixture was allowed to 
warm to room temperature and stirred overnight. The solvent was removed in vacuo.  
The residue was suspended in CH2Cl2 (15 mL) and treated with as saturated NH4F 
aqueous solution (10 mL). The mixture was rigorously stirred for 1 h until all white 
powder dissolved. The dichloromethane layer was separated and  dried with MgSO4. 
The mixture was filtered to remove MgSO4 and the solvent was removed under reduced 
pressure yielding b as a white powder (1.09 g, 72% yield). 
1
H NMR (399.5 MHz, 
CDCl3):  1.09 (dd, 6H, isopropyl-CH3, 
3
JH-P = 19.12 Hz, 
3
JH-H = 7.14 Hz), 1.21 (dd, 
6H, isopropyl-CH3, 
3
JH-P = 18.62 Hz, 
3
JH-H = 7.14 Hz), 3.10 (m, 2H, isopropyl-CH), 7.32 
– 7.49 (m, 10H), 7.77 (dd, 1H, 3JH-P = 7.96 Hz, 
3
JH-H = 1.11 Hz ) 7.87 (m, 1H), 8.06 (m, 
1H), 8.15 (m, 1H). 
13
C NMR (100.5 MHz, CDCl3):  16.65 (d, JC-P = 3.04 Hz), 16.99 
(d, JC-P = 3.04 Hz), 26.54 (d, JC-P = 21.52 Hz), 69.95, 126.03, 127.51, 127.72, 128.16, 
128.54, 128.61, 128.95, 129.37 (d, JC-P = 2.18 Hz), 129.70 (d, JC-P = 1.75 Hz), 129.87, 
129.98, 131.82, 132.78, 132.88, 135.76 (d, JC-P = 5.41 Hz), 137.55 (d, JC-P = 2.38 H    z), 
151.17 (d, JC-P = 6.28 Hz). 
31
P{
1
H} NMR (161.4 MHz, CDCl3):  -2.60. Mass (ESI
+
): 
calcd for C25H29OP (M+H)
+
, 377.2034; found 377.2100. . To a suspension of b (0.683 g, 
1.82 mmol) in trifluoroacetic anhydride (TFAA) (7 mL) was added 48% HBF4 (0.5 mL, 
3.85 mmol). After being stirred for 10 min, all the white powder dissolved and the 
mixture turned red. The red solution was stirred for 1.5 h and quenched by diethyl ether 
(20 mL). After addition of diethyl ether, a white powder precipitated. The mixture was 
filtered to get 74 as a white powder (0.584 g, 72% yield). 
1
H NMR (299.9 MHz, 
CDCl3):  1.11 (dd, 6H, isopropyl-CH3, 
3
JH-P = 17.99 Hz, 
3
JH-H = 7.20 Hz), 1.20 (dd, 6H, 
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isopropyl-CH3, 
3
JH-P = 18.89 Hz, 
3
JH-H = 7.20 Hz), 3.16 (m, 2H, isopropyl-CH), 7.32 – 
7.37 (m, 4H), 7.40 – 7.51 (m, 6H), 7.75 (d, 1H, 3JH-H = 6.00 Hz), 7.87 (m, 1H), 8.05 (t, 
1H, 
3
JH-H = 6.00 Hz), 8.20 (dd, 1H, 
3
JH-H = 7.50 Hz, 
3
JH-P = 9.80 Hz). 
13
C NMR (75.4 
MHz, CD3CN):  16.47 (d, 
2
JC-P = 2.94 Hz), 16.64 (d, 
2
JC-P = 3.62 Hz), 26.43 (d,
1
JC-P = 
21.04 Hz), 70.35 (d, 
1
JC-P = 43.51 Hz), 128.71, 128.98, 129.17, 129.26, 129.69, 129.72, 
130.11, 131.66, 133.03, 133.18, 136.59 (d, JC-P = 5.26 Hz), 138.39 (d, JC-P = 2.74 Hz), 
151.65 (d, JC-P = 7.22 Hz). 
31
P{
1
H} NMR (121.4 MHz, CDCl3):  82.28. Anal. Calcd for 
CH24PBF4: C, 67.30; H, 6.28. Found: C, 66.12; H, 6.27. 
 
Synthesis of 5,5,10-triphenyl-5,10-dihydroacridophosphin-5-ium tetrafluoroborate (75) 
  Compound 73 (0.022 g, 0.043 mmol) was dissolved in CD3CN (5 mL). The 
solution was stirred at room temperature for 72 h. The solvent was removed in vacuo 
affording 75 as a white powder (0.021) in a 95 % yield. 
1
H NMR (299.9 MHz, CD3CN): 
 5.08 (d, 1H, 4JH-P = 1.62 Hz), 5.6 – 5.65 (m, 2H), 5.88 – 6.01 (m, 3H), 6.43 – 6.59 (m, 
7H), 6.71 – 6.80 (m, 7H), 6.96 – 7.00 (m, 5H). 13C NMR (75.4 MHz, CD3CN):  52.91 
(d, 
3
JC-P = 9.07 Hz), 127.84, 128.74, 129.33, 129.81, 129.97, 130.97, 131.14, 131.21, 
131.39, 132.61, 132.74, 134.24, 134.39, 135.18, 135.31, 135.70 (d, JC-P = 3.38 Hz), 
135.87, 136.03, 136.23, 136.26, 136.67 (d, JC-P = 3.38 Hz), 147.91 (d, JC-P = 6.69 Hz). 
31
P{
1
H} NMR (121.4 MHz,CD3CN):  3.18. Mass (ESI
+
): calcd for [C31H24P]
+
 (M)
+
, 
427.1615; found 427.1368.        
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Synthesis of 7,7-diisopropyl-8,8-diphenyl-7-phosphabicyclo[4.2.0]octa-1,3,5-trien-7-ium 
tetrafluoroborate (76)  
  Compound 74 (0.018 g, 0.040 mmol) was dissolved in CD3CN (5 mL). The 
solution was stirred at 80 °C for 5 h. The solvent was removed in vacuo affording 76 as a 
white powder (0.017) in a 94 % yield. 
1
H NMR (299.9 MHz, CD3CN):  1.16 (dd, 6H, 
isopropyl-CH3, 
3
JH-P = 18.76 Hz, 
3
JH-H = 7.20 Hz), 1.46 (dd, 6H, isopropyl-CH3, 
3
JH-P = 
17.99 Hz, 
3
JH-H = 6.94 Hz), 3.21 (m, 1H, isopropyl-CH), 3.39 (m, 1H, isopropyl-CH), 
5.93 (d, 1H, 
4
JH-P = 3.76 Hz), 7.14 – 7.20 (m, 2H), 7.28 – 7.42 (m, 4H), 7.46 – 7.56 (m, 
3H), 7.64 – 7.72 (m, 2H), 7.75 – 7.82 (m, 2H), 7.94 – 8.03 (m, 2H). 13C NMR (75.4 
MHz, CD3CN):  16.00 (d, 
2
JC-P = 2.69 Hz), 16.74 (d, 
2
JC-P = 2.17 Hz), 24.98 (
1
JC-P = 
45.63 Hz), 26.76 (
1
JC-P = 46.83 Hz), 50.67 (
3
JC-P = 8.58 Hz), 109.69, 110.74, 128.35, 
129.36, 129.51, 129.80, 130.23 (d, JC-P = 3.27 Hz), 132.13, 132.5, 133.67, 133.78, 
135.62 (d, JC-P = 2.32 Hz), 146.19 (d, JC-P = 1.69 Hz), 147.86 (d, JC-P = 3.87 Hz)  
31
P{
1
H} NMR (202.2 MHz, CD3CN):  17.13. Mass (ESI
+
): calcd for [C25H28P]
+
 (M)
+
, 
359.1928; found 359.1636. 
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Figure 112. 
1
H, 
13
C, and 
31
P NMR spectra of 73. 
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1
H, 
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C, and 
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P NMR spectra of 74. 
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Figure 114. 
1
H, 
13
C, and 
31
P NMR spectra of 75. 
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Figure 115. 
1
H, 
13
C, and 
31
P NMR spectra of 76. 
 
 213 
 
Crystallographic Measurements  
  Single crystals of 73 and 74 were obtained by slow diffusion of Et2O into a 
CH2Cl2 solution of 73 and 74, respectively.  In addition, single crystals of 75 and 76 
were obtained by slow diffusion of pentane into a CH2Cl2 solution of 75 and 76. The 
crystallographic measurement of 73, 74, 75, and 76 were performed using a Bruker 
APEX-II CCD area detector diffractometer, with graphite-monochromated Mo-Kα 
radiation (λ = 0.71069 Å). A specimen of suitable size and quality was selected and 
mounted onto a nylon loop. The semi-empirical method SADABS was applied for 
absorption correction. The structure was solved by direct methods, and refined by the 
full-matrix least-square method against F
2
 with the anisotropic temperature parameters 
for all non-hydrogen atoms.  All H atoms were geometrically placed and refined using 
the riding model approximations.
4
 Data reduction and further calculations were 
performed using the Bruker SAINT+ and SHELXTL NT program packages. The crystal 
data are included in Table 24-27. 
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Table 24. Crystal data, data collections, and structure refinements of 73. 
Crystal data 73 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C31H24BF4P 
514.28 
0.5 x 0.25 x 0.3 
110(2) K 
0.71073 Å 
Monoclinic 
P21 
a = 8.858(4) Å             α = 90° 
b = 16.639(7) Å  β = 115.031(4)° 
c = 9.682(4) Å             γ = 90° 
1293.0(9) Å
3 
2 
1.321 g cm
-3
 
0.154 mm
-1 
532.0 
ω, φ 
-10 → +10 
-20 → +20 
-11 → +10 
12767 
5868 [0.035] 
5868 
149 
1.053 
0.0704, 0.1620 
1.22, -0.45 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.0798 and b = 1.0925. 
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Table 25. Crystal data, data collections, and structure refinements of 74. 
Crystal data 74 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C25H28BF4P 
446.25 
0.7 x 0.45 x 0.2 
110(2) K 
0.71073 Å 
Monoclinic 
P 21/c 
a = 8.1220(8) Å  α = 90° 
b = 13.5733(14) Å  β = 91.8340(10)° 
c = 20.319(2) Å  γ = 90° 
2238.9(4) Å
3
 
4 
1.324 g cm
-3
  
0.166 mm
-1 
936.0 
ω, φ 
-10 → +10 
-18 → +18 
-27 → +26 
26228 
5390 [0.0277] 
5390 
125 
1.045 
0.0624, 0.1618 
1.17, -0.54 e.Å
-3
   
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.0911 and b = 1.8858. 
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Table 26. Crystal data, data collections, and structure refinements of 75. 
Crystal data 75 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C31H24BF4P 
514.28 
0.65 x 0.35 x 0.22 
110(2) K 
0.71073 Å 
Monoclinic 
P 21/n 
a = 10.748(7) Å  α = 90° 
b = 17.213(11) Å  β = 94.818(8)° 
c = 13.441(9) Å  γ = 90° 
2478(3) Å
3
 
4 
1.378 g cm
-3
 
0.160 mm
-1
  
1064.0 
ω, φ 
-14 → +14 
-22 → +23 
-17 → +17 
30020 
6165 [0.0603] 
6165 
334 
1.026 
0.0640, 0.1069 
0.31, -0.35 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.0414 and b = 0.6928. 
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Table 27. Crystal data, data collections, and structure refinements of 76. 
Crystal data 76 
Empirical formula 
Formula weight 
Crystal size/mm 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
 
 
Volume 
Z 
Density (calculated) 
μ 
F(000)  
Scan mode 
hkl ranges 
 
 
Reflections collected 
Unique reflections [Rint] 
Reflection used for refinement 
Refined parameters 
GooF 
R1,
a
 wR2
b
 (all data) 
Largest diff. peak and hole  
C25H28BF4P 
446.25 
0.3 x 0.3 x 0.12 
110(2) K 
0.71073 Å 
Monoclinic 
P 21/c 
a = 9.807(5) Å             α = 90° 
b = 15.502(11) Å  β = 101.83(6)° 
c = 14.979(7) Å  γ = 90° 
2229(2) Å
3
 
4 
1.330 g cm
-3
 
0.166 mm
-1
  
936.0 
ω, φ 
-13 → +12 
-20 → +20 
-19 → +20 
54606 
5760 [0.1069] 
5760 
280 
1.071 
0.0866, 0.2669 
0.59, -0.65 e.Å
-3
 
 
a
R1 = Σ||Fo| - |Fc||/ Σ|Fo|. 
b
wR2 ([w(Fo
2
 – Fc
2
)
2]/[Σw(Fo
2
)
2
])
1/2
; w = 1/[σ2(Fo
2
) + (ap)
2
 + 
bp]; p = (Fo
2
 + 2Fc
2
)/3 with a = 0.1136 and b = 0.5971. 
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Kinetic studies 
  A sample of 73 (10 mg) was dissolved in 0.5 mL CD3CN in NMR tube. The 
31
P 
NMR spectrum of 73 was collected periodically. The isomerization process of the 4-
membered ring ortho-phenylene phosphine-methylium 73 was monitored by integration 
of the decreasing 
31
P NMR signal of 73 in conjunction with the increasing 
31
P NMR 
signal of 75 corresponding to the isomerized product. All spectra were processed using 
the VNMRJ Version 2.2 NMR software. The rate constant was calculated using a well-
established NMR method reported in the literature.
4 
 This method is based on the fact 
that the concentration of 73 is proportional to the integration of the 
31
P NMR signal of 
73 divided by the sum of the integration of the 
31
P NMR signal of 73 and 75.  For 
convenience, the value of the 73 integration is arbitrarily set at 100 and the 75 
integration determined. The kinetic data of the isomerization process was shown in 
Table 28. 
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Table 28. Kinetic data for the isomerization of 73.   
  
Isomerization of 73 k=0.0011 min
-1
 
Time (min) [73] [75] [73]/([73]+[75]) [73]/([73]+[75]) 
   
exp calc 
0 100 0 1.00 1.00 
15 100 1.22 0.99 0.98 
64 100 11.94 0.89 0.93 
210 100 29.31 0.77 0.79 
272 100 34.26 0.74 0.74 
330 100 47.47 0.68 0.70 
390 100 54.56 0.65 0.65 
492 100 72.77 0.58 0.58 
660 100 113.29 0.47 0.48 
721 100 129.44 0.44 0.45 
1443 100 357.16 0.22 0.20 
1530 100 379.05 0.21 0.19 
1700 
   
0.15 
1900 
   
0.12 
2100 
   
0.10 
2300 
   
0.08 
2500 
   
0.06 
2700 
   
0.05 
2900 
   
0.04 
3000 
   
0.04 
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CHAPTER VII  
SUMMARY 
 
7.1 Zwitterionic arytrifluoroborate for 
18
F fluoride anion capture  
  As part of our research in the chemistry of cationic boranes as fluoride anion 
sensors, we have found that fluoroborate moieties are efficiently stabilized by 
neighboring onium ions. Capitalizing on this knowledge, the ortho-phenylene 
phosphino-borane derivatives 30, 35, 36, 37 have been synthesized, and kinetic stability 
experiments have been performed. Based on the amount of ArBF3 in solution as 
determined by 
19
F NMR vs times, we found that the first order hydrolysis rate constants 
of 30, 35, 36, and 37 were shown to be 3.4 x 10
-6
 min
-1
, 3.9 x 10
-5
 min
-1
, 1.5 x 10
-5
 min
-1
, 
and 5.2 x 10
-5
 min
-1
, respectively. These kinetic results indicate that the presence of iso-
propyl substituents decreases the kinetic stability of the complexes. Moreover, 
comparisons between the hydrolysis rate constants of 30 and 36 as well as 35 and 37 
also demonstrate that the pendent carboxylic acid functionality plays a labilizing role in 
aqueous environment. 
  The radiolabeled products [
18
F]30 and [
18
F]35 were prepared by a simple 
18
F-
19
F 
isotopic exchange process in aqueous solution in high yield (>87%). Gratifyingly, 
[
18
F]30 and [
18
F]35 are shown to be stable in vivo thus illustrating the stabilization of the 
BF3 units provided by the neighboring ortho-phosphonium group. Encouraged by these 
results, these zwitterionic fluoroborates are a good candidate for the construction of 
disease specific 
18
F PET imaging agents. 
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Figure 116. Illustration of zwitterionic aryltrifluoroborate 30, 35, 36, and 37. 
  
7.2 [
18
F]-Zwitterionic aryltrifluoroborate/indomethacin conjugates for potential PET 
probes 
  Indomethacin is a nonsteroidal anti-inflammatory drug that selectively binds and 
inhibits cyclooxygenase (COX) enzymes, especially, COX-2 enzyme which is highly 
upregulated in inflamed tissues as well as tumor tissues. Inspired by these results, the 
zwitterionic aryltrifluoroborate/indomethacin conjugates 45 and 46 have been 
synthesized to evaluate their potential as tumor imaging probe. These conjugates were 
simply radiolabeled by 
18
F-
19
F isotopic exchange in aqueous solutions and injected into a 
tumor bearing murine model. The PET images showed that the [
18
F]45 which gave a 
distinct skeletal signal due to defluorination in vivo is the only probe that accumulated 
into the tumour. These results suggested that the nature of the phosphorus substituents 
influences both the stability and binding property of the radiotracers. 
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Figure 117. Illustration of zwitterionic aryltrifluoroborate/indomethacin conjugates 45 
and 46. 
 
7.3 [
18
F]-Carbene-borane adducts as a novel radio-prosthetic group for PET imaging 
  In addition to phosphonium aryltrifluoroborates, we were drawn by the 
remarkable stability of a carbene-BF3 adduct (34). This compound can be recrystallized 
from boiling water suggesting that it is highly resistant to hydrolysis. Encouraged by 
these properties, novel carbene-BF3 adducts have been synthesized to use as a potential 
radio-prosthetic group. Favourably, the [
18
F]-radiolabeled carbene-borane adducts can be 
easily constructed by SnCl4 assisted 
18
F-
19
F isotopic exchange. The in vivo stability of 
these derivatives was evaluated by injecting the [
18
F]-carbene-borane (56) / H-Cys-Phe-
OH peptide conjugate into normal nude mice. The PET-CT images showed that no 
obvious bone uptake signal at 4 h post-injection indicating that minimal free [
18
F]-
fluoride anions coming off from the radiotracer during the imaging process. Thus, we 
can conclude that these new [
18
F]-carbene-borane derivatives have a good B-F stability 
in vivo. 
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Figure 118. Illustration of carbene-borane adducts 34 and 56/H-Cys-Phe-OH conjugate. 
 
7.4 Triazaborolopyridinium dyes for PET/Fluorescence dual modality imaging agents 
  Although PET imaging is a powerful technique for medical diagnosis, the spatial 
resolution provided by this technique is relatively low. Therefore, combining PET 
imaging with a second imaging technique such as fluorescence gives much higher spatial 
and temporal resolution. This protocol necessitates the incorporation of a fluorophore 
into a radiolabeled component. With the goal of developing new boron-based 
PET/Fluorescence imaging agent, a series of triazaborolopyridinium dyes has been 
synthesized and studied. We found that the triazaborolopyridinium dye (71) with nitro 
substituent features high quantum yields and large stoke shifts, which are suitable 
characteristics for imaging applications. 71 can also be easily fluorinated by KHF2 which 
is viable for 
18
F-radiofluorination process. 
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Figure 119. Illustration of Triazaborolopyridinium dyes 71. 
 
7.5 Synthesis, structure, and isomerization of phosphino-methylium compounds 
  The utilities of intramolecular P/B frustrated Lewis pairs (FLPs) in catalytic 
reactions and transition metal complexation prompted us to investigate whether a 
carbocation and a phosphine could be incorporated at the ortho positions of the same 
phenylene backbone to furnish novel intramolecular FLPs. With this in mind, we 
endeavored to synthesize novel ortho-phenylene phosphino-methylium compounds (73 
and 74) and to investigate their properties. Surprisingly, 73 underwent an isomerization 
upon dissolving in organic solvent at ambient temperature, whereas 74 showed no 
reaction. The difference observed in the isomerization processes derives from the 
dissimilarity of the electron donating ability of the phosphine ligand. 
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Figure 120. Illustration of phosphino-methylium compounds 73 and 74. 
 
7.6 Conclusion 
  This dissertation illustrates how the introduction of cationic moiety impacts the 
B-F bond stability against hydrolysis and its application for the construction of boron-
based radiotracers. Firstly, we demonstrated that the proximal ortho-phosphonium group 
can retard the rate of trifluoroborate hydrolysis. These results lead to the construction of 
the [
18
F]ortho-phenylene phosphino-boranes and the [
18
F]ortho-phenylene phosphino-
borane/ indomethacin conjugates that showed good stability in vivo. Exploiting this 
concept, the new carbene-borane adducts as well as the triazaborolopyridinium dyes 
were also developed to use as potential probes for PET applications.     
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